Anti-PDL1, IL-15 and TGF-β receptor combination molecule
By developing multispecific protein complexes containing IL-15 and TGFβRII domains, the problem of limited effectiveness of anti-PD-1/PD-L1 therapy has been solved, and the immune cell activity and attack on tumor cells has been enhanced, and the treatment has been improved. Effective and reduce side effects.
Patent Information
- Application Number
- CN201980016096.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-21
- Filing Date
- 2019-03-26
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-06-10
AI Technical Summary
The existing anti-PD-1/PD-L1 monotherapy has limited effect in the treatment of malignant tumors and has side effects, and most patients fail to achieve objective responses, and there is a need to improve treatment efficacy and reduce side effects.
Developing multispecific protein complexes based on IL-15, including IL-15 or its variant, TGFβRII domain and binding domains specifically targeting disease antigens or immune checkpoints, enhance the activity of immune cells and promote targeting disease cells The attack can achieve therapeutic effects through ADCC and CDC mechanisms.
It enhances the activity and binding ability of immune cells to target disease cells, reduces or prevents diseases, improves therapeutic efficacy and reduces side effects, and significantly improves the therapeutic effect on various tumor types.
Smart Images

Figure CN111867612B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority under 35 USC §119(e) to U.S. Provisional Application No. 62 / 648,373, filed on March 26, 2018, and U.S. Provisional Application No. 62 / 734,994, filed on September 21, 2018. The entire contents of these applications are incorporated herein by reference in their entirety. Technical Field
[0003] The present invention relates generally to the field of multimeric fusion molecules. Background Art
[0004] Cancer immunotherapy studies have now demonstrated promising clinical response rates in patients with melanoma and in subsets of patients with other solid tumors. Those studies have involved monoclonal antibody (MAb) checkpoint inhibitors (e.g., anti-CTLA4), anti-programmed cell death-1 (PD-1), and anti-programmed cell death protein-1 ligand (PD-L1), as well as cytokines (e.g., IL-2 and IL-15). 1-5
[0005] Most antibodies against PD-1 / PD-L1 are of the IgG4 isotype, or are engineered with Fc domain mutations that impair antibody-dependent cellular cytotoxicity (ADCC) activity. Various anticancer MAbs, such as anti-CTLA4 (ipilimumab), anti-CD20 (rituximab), anti-HER2 (trastuzumab, pertuzumab), and anti-EGFR (cetuximab), however, are of the IgG1 isotype and therefore have the potential to mediate ADCC. The ADCC mechanism has been implicated in contributing to clinical efficacy, 9-11 Although other studies do not support this finding. Genentech) and avelumab ( EMD Serono) is a fully human anti-PD-L1 therapy of the IgG1 isotype that has been approved by the FDA for the treatment of non-small cell lung cancer (NSCLC), bladder cancer, urothelial carcinoma, and metastatic Merkel cell carcinoma. 12-15
[0006] Because PD-L1 is expressed on some immune cells, studies were performed to evaluate ADCC mediated by avelumab using whole peripheral blood mononuclear cells (PBMCs) as targets. Substantial lysis of a range of human tumor cell types was observed using natural killer (NK) cells from healthy donors and cancer patients, with little or no lysis occurring when human PBMC subsets were used as targets. Similar results were seen in the analysis of 123 immune cell subsets from PBMCs of patients treated with nine doses of avelumab. 13,16 Furthermore, although clinical benefit has been observed with avelumab across a range of human tumors, no adverse events exceeding those seen with other anti-PD1 / PD-L1 MAbs have been observed. 3,14,17,18
[0007] Despite these promising results, only 10%-30% of patients with most malignancies achieve an objective response when treated with anti-PD-1 / PD-L1 monotherapy, even in trials that enrolled only those patients whose pretreatment tumor samples expressed PD-L1. 19
[0008] Prior to the invention described herein, there was a pressing need to develop new strategies for targeting different effector molecules to disease sites to provide therapeutic benefit without the side effects associated with nonspecific immune activity. Summary of the invention
[0009] The present invention is based at least in part on the surprising discovery that multi-specific protein complexes based on IL-15 enhance the stimulation of immune cells and promote their activity against disease cells, thereby reducing or preventing diseases. These IL-15-based protein complexes also show increased binding to diseases and target antigens. Provided herein are multi-specific protein complexes having at least one domain comprising IL-15 or a functional variant, a transforming growth factor-β receptor type 2 (TGFβRII) domain, and a binding domain specific for a disease antigen, an immune checkpoint, or a signaling molecule. In particular, these complexes include an IL-15N72D:IL-15RαSu / Fc scaffold fused to an antibody or antibody binding fragment, and a TGFβRII domain that binds to transforming growth factor-β (TGFβ). Specifically, protein complexes are described herein, which contain: binding domains that specifically bind programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), cluster of differentiation 47 (CD47), T cell immunoglobulin mucin domain molecule-3 (TIM-3, TIM3) or glucocorticoid-induced tumor necrosis factor receptor (TNFR) family-related genes (GITR). By providing immunostimulatory cytokines to immune cells, these complexes enhance immune activity. Such cytokines are known in the art and can be used alone or in combination with other cytokines or agents. These complexes further enhance the immune response by blocking immune checkpoints via anti-PD-L1, PD-1, CTLA-4, CD47, TIM3 or GITR binding domains. Finally, these complexes can bind to TGFβ and block its immunosuppressive activity that promotes tumor growth and metastasis and other diseases.
[0010] In some cases, these complexes also recognize antigens expressed on disease cells, such as PD-L1, single-stranded deoxyribonucleic acid (ssDNA), CD20, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), CD19, CD38, CD52, disiaganglioside (GD2), CD33, Notch1, intercellular adhesion molecule 1 (ICAM-1), tissue factor, or HIV envelope, and stimulate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against disease cells via the Fc binding domain.
[0011] A soluble fusion protein complex of separation is provided, the complex comprising at least two soluble proteins.For example, the first protein comprises interleukin-15 (IL-15) polypeptide, for example, a variant IL-15 polypeptide (IL-15N72D) comprising N72D mutations. The second protein comprises a soluble IL-15 receptor αsushi-binding domain (IL-15RαSu) (IL-15RαSu / Fc) fused to an immunoglobulin Fc domain. The third component of the soluble fusion protein complex of separation comprises a binding domain for identifying disease antigens, immune checkpoint molecules or signaling molecules (eg, PD-L1, PD-1, CTLA-4, CD47, TIM3 or GITR), wherein the binding domain is fused to IL-15N72D or IL-15RαSu / Fc protein. The fourth component of the soluble fusion immune complex comprises a cytokine receptor, such as TGFβRII or a cytokine. In some aspects, the binding domain is fused to both IL-15N72D and IL-15RαSu / Fc proteins. In other aspects, one of these domains is fused to IL-15N72D or IL-15RαSu / Fc proteins, and the second binding domain (i.e., specific for immune checkpoints or signaling molecules or disease antigens) is fused to the same or other proteins. In some aspects, cytokine receptors (such as TGFβRII) are fused to IL-15N72D and / or IL-15RαSu / Fc proteins. In some aspects, cytokine receptors (such as TGFβRII) are fused to or connected to IgG1 Fc via a linker molecule. On the other hand, cytokine receptors (such as TGFβRII) are fused to dimers of IL-15N72D and IL-15RαSu / Fc proteins. In one aspect, disease antigens are associated with neoplasia, infectious diseases, or autoimmune diseases. In some cases, the first and / or second soluble protein further comprises a binding domain that recognizes a disease antigen expressed on disease cells (e.g., PD-L1, ssDNA, CD20, HER2, EGFR, CD19, CD38, CD52, GD2, CD33, Notch1, intercellular adhesion molecule 1 (ICAM-1), tissue factor, or HIV envelope). Alternatively, IL-15N72D or IL-15RαSu / Fc protein comprises a binding domain specific for a disease antigen, an immune checkpoint, or a signaling molecule, and the other protein (IL-15RαSu / Fc or IL-15N72D protein, respectively) does not comprise an additional fusion binding domain. The IL-15N72D domain of the first protein binds to the soluble IL-15RαSu domain of the second protein to form a soluble fusion protein complex. An exemplary fusion protein complex comprises an anti-PD-L1 antibody covalently linked to an IL-15N72D and / or IL-15RαSu / Fc fusion protein.In other aspects, a cytokine receptor (e.g., TGFβRII) and / or a binding domain is covalently linked to a soluble IL-15 receptor αsushi-binding domain (IL-15RαSu), which is fused to an immunoglobulin Fc domain; and a second protein comprises a binding domain that recognizes a covalently linked disease antigen and a variant interleukin-15 (IL-15) polypeptide (IL-15N72D) comprising an N72D mutation. In another aspect, the second protein comprises a cytokine receptor, such as TGFβRII.
[0012] In certain embodiments, the isolated soluble fusion protein complex comprises at least two soluble proteins, wherein the first soluble protein comprises an interleukin-15 (IL-15) polypeptide domain, and the second soluble protein comprises a soluble IL-15 receptor αsushi-binding domain (IL-15RαSu) fused to an immunoglobulin Fc domain, wherein the immunoglobulin Fc (IgG Fc) domain is fused to or connected to a glycosylated or unglycosylated transforming growth factor-β receptor type 2 (TGFβRII) domain; the first and / or second soluble protein further comprises a binding domain that specifically binds to a disease antigen, an immune checkpoint molecule, or an immune signaling molecule, and the IL-15 domain of the first soluble protein binds to the IL-15RαSu domain of the second soluble protein, thereby forming a soluble fusion protein complex. An example of an unglycosylated TGFβRII amino acid sequence is as follows: IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM Q NCPITSICEKPQEVCVAVWRK Q DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEY Q TSNPD (SEQ ID NO: 35).
[0013] In this and other embodiments, the immunoglobulin Fc domain is linked to a transforming growth factor-β receptor type 2 (TGFβRII) domain via a linker molecule. In these and other embodiments, the immunoglobulin Fc domain is an IgG Fc variant comprising a hinge region lacking a free cysteine at residue position 70. In certain embodiments, at residue position 70, the cysteine is substituted with serine (IgGFcC70S). An example of a Δ free cysteine IL15RαSuFc amino acid sequence is as follows: ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKS S DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:36).
[0014] In certain embodiments, the immunoglobulin Fc domain is an IgG-Fc variant lacking a hinge region. For example, IL15RαSuFc lacks amino acid residues EPKSC at positions 66 to 70. An example of a Δ hinge IL15RαSuFc amino acid sequence is as follows:
[0015] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIR DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:37)
[0016] In these and other embodiments, one of the first and second soluble proteins further comprises a second binding domain that specifically binds to a disease antigen, an immune checkpoint molecule, or an immune signaling molecule. In these and other embodiments, the IL-15 polypeptide is an IL-15 variant comprising the following: N72D mutation (IL-15N72D), IL-15K41Q mutation, IL-15L45S mutation, IL-15I67T mutation, IL-15N79Y mutation, IL-15E93A mutation, or a combination thereof. Examples of IL-15-K41Q, L45S, I67T, N79Y, E93A amino acid sequences are as follows:
[0017] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAM Q CFL S ELQVISLESGDASIHDTVENL T ILANDSLSSNG Y VTESGCKECEELE A KNIKEFLQSFVHIVQMFINTS (SEQ ID NO: 38).
[0018] In certain embodiments, the IL-15 polypeptide is an IL-15 variant comprising a L45S mutation. An example of an IL15-L45S amino acid sequence is as follows:
[0019] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFL S ELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS (SEQ ID NO: 39).
[0020] In certain embodiments, the binding domain comprises an immunoglobulin light chain variable domain covalently linked to an immunoglobulin heavy chain variable domain via a polypeptide linker sequence. In these and other embodiments, the binding domain specifically binds to one or more molecules comprising: programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), cluster of differentiation 33 (CD33), cluster of differentiation 47 (CD47), glucocorticoid-induced tumor necrosis factor receptor (TNFR) family-related gene (GITR), lymphocyte function-associated antigen 1 (LFA-1), tissue factor (TF), delta-like protein 4 (DLL4), single-stranded DNA or T cell immunoglobulin mucin domain molecule-3 (Tim-3). In certain embodiments, the binding domain specifically binds to one or more molecules comprising: programmed death ligand 1 (PD-L1). In these and other embodiments, the TGFβRII domain binds to transforming factor β (TGFβ). In these and other embodiments, the first fusion protein complex is covalently linked to the second fusion protein complex via a disulfide bond that links the Fc domain of the first soluble fusion protein complex to the Fc domain of the second soluble fusion protein complex.
[0021] In certain embodiments, the isolated soluble fusion protein complex comprises at least two soluble proteins, wherein the first soluble protein comprises an interleukin-15 (IL-15) polypeptide domain, and the second soluble protein comprises a soluble IL-15 receptor αsushi-binding domain (IL-15RαSu) fused to an immunoglobulin Fc domain, the first and / or second soluble proteins further comprise a binding domain that specifically binds to a disease antigen, an immune checkpoint molecule, or an immune signaling molecule, and the IL-15 domain of the first soluble protein binds to the IL-15RαSu domain of the second soluble protein, thereby forming a soluble protein complex. In certain embodiments, the immunoglobulin Fc (IgG Fc) domain further comprises a glycosylated or unglycosylated transforming growth factor-β receptor type 2 (TGFβRII) domain fused to or connected to the IgG Fc domain via a linker molecule. In certain embodiments, the immunoglobulin Fc (IgG Fc) domain lacks a TGFβRII domain. In these and other embodiments, the immunoglobulin Fc domain is an IgG Fc variant comprising a hinge region lacking a free cysteine at residue position 70. In these and other embodiments, at residue position 70, cysteine is substituted by serine (IgG-FcC70S). In these and other embodiments, the immunoglobulin Fc domain is an IgG-Fc variant lacking a hinge region. In these and other embodiments, one of the first and second soluble proteins further comprises a second binding domain that specifically binds to a disease antigen, an immune checkpoint molecule, or an immune signaling molecule. In these and other embodiments, the IL-15 polypeptide is an IL-15 variant comprising the following: N72D mutation (IL-15N72D), IL-15K41Q mutation, IL-15L45S mutation, IL-15I67T mutation, IL-15N79Y mutation, IL-15E93A mutation, or a combination thereof. In these and other embodiments, the binding domain comprises an immunoglobulin light chain variable domain covalently linked to an immunoglobulin heavy chain variable domain via a polypeptide linker sequence. In these and other embodiments, the binding domain specifically binds to one or more molecules comprising: programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), cluster of differentiation 33 (CD33), cluster of differentiation 47 (CD47), glucocorticoid-induced tumor necrosis factor receptor (TNFR) family-related gene (GITR), lymphocyte function-associated antigen 1 (LFA-1), tissue factor (TF), delta-like protein 4 (DLL4), single-stranded DNA, or T-cell immunoglobulin mucin domain molecule-3 (Tim-3).In certain embodiments, the binding domain specifically binds to one or more molecules comprising: programmed death ligand 1 (PD-L1). In certain embodiments, the first fusion protein complex is covalently linked to the second fusion protein complex via a disulfide bond, which links the Fc domain of the first soluble fusion protein complex to the Fc domain of the second soluble fusion protein complex.
[0022] In certain embodiments, the binding domain comprises a single-chain antibody (scAb or scFv), wherein the immunoglobulin light chain variable domain is covalently linked to the immunoglobulin heavy chain variable domain by a polypeptide linker sequence. Alternatively, the binding domain comprises a soluble or extracellular ligand or receptor domain that can act as an immune checkpoint inhibitor or an immune agonist.
[0023] Exemplary polynucleotide molecules include: nucleic acid sequences comprising SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 16, 17, 18, 19, or a combination thereof. In one aspect, the one or more nucleic acid sequences further include a promoter, a translation initiation signal, and a leader sequence operably linked to a sequence encoding a fusion protein. In certain embodiments, the expression vector includes: nucleic acid sequences comprising SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 16, 17, 18, 19, or a combination thereof.
[0024] Exemplary polypeptide molecules include: an amino acid sequence comprising SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or a combination thereof.
[0025] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1.
[0026] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:3.
[0027] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:5.
[0028] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:7.
[0029] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:9.
[0030] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:11.
[0031] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:13.
[0032] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:15.
[0033] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:16.
[0034] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:17.
[0035] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:18.
[0036] In some embodiments, the isolated soluble fusion protein complex is encoded by a nucleic acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:19.
[0037] Also provided are one or more expression vectors comprising the nucleic acid sequences described herein. For example, the nucleic acid sequence is used in the vector for replication, expression, or both.
[0038] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:2.
[0039] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:4.
[0040] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:6.
[0041] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:8.
[0042] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:10.
[0043] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:12.
[0044] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:14.
[0045] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:20.
[0046] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:21.
[0047] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:22.
[0048] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:23.
[0049] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:24.
[0050] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:25.
[0051] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:26.
[0052] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:27.
[0053] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:28.
[0054] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:29.
[0055] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:30.
[0056] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:31.
[0057] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:32.
[0058] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:33.
[0059] In some embodiments, the isolated soluble fusion protein complex comprises an amino acid sequence having at least about 70% (e.g., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater) sequence identity to SEQ ID NO:34.
[0060] Soluble fusion protein complex is also provided, the complex comprises a first soluble fusion protein complex covalently linked to a second soluble fusion protein complex. For example, the soluble fusion protein complex of the present invention is multimerized, for example, dimerized, trimerized, or other multimerized (for example, 4 complexes, 5 complexes, etc.). For example, the polymer is a homopolymer or a heteropolymer. The soluble fusion protein complex is connected by a covalent bond (for example, a disulfide bond, a chemical cross-linking agent). In some cases, a soluble fusion protein is covalently linked to another soluble fusion protein by a disulfide bond, and the disulfide bond connects the Fc domain of the first soluble protein with the Fc domain of the second soluble protein.
[0061] The Fc domain or its functional fragment comprises an Fc domain selected from the group consisting of: an IgG Fc domain, a human IgG1 Fc domain, a human IgG2 Fc domain, a human IgG3 Fc domain, a human IgG4 Fc domain, an IgAFc domain, an IgD Fc domain, an IgE Fc domain, and an IgM Fc domain; a mouse IgG2A domain, or any combination thereof. Optionally, the Fc domain comprises amino acid changes that form an Fc domain with altered complement or Fc receptor binding properties or altered dimerization or glycosylation characteristics. Amino acid changes that produce Fc domains with altered complement or Fc receptor binding properties or altered dimerization or glycosylation characteristics are known in the art. For example, substitution of the leucine residues at positions 234 and 235 of IgG1 CH2 (i.e., ... PEL LG G ...) with alanine residues (i.e., ... PEAAGG ...) results in loss of Fcγ receptor binding, while substitution of the lysine residue at position 322 of IgG1 CH2 (i.e., ... KCKSL ...) with alanine residues (i.e., ... KC AS L ...) results in loss of complement activation. In some examples, such mutations are combined.
[0062] In some aspects, the binding domain and / or cytokine receptor domain is covalently linked to the IL-15 polypeptide (or its functional fragment) by a polypeptide linker sequence. Similarly, the binding domain and / or cytokine receptor domain is covalently linked to the IL-15Rα polypeptide (or its functional fragment) by a polypeptide linker sequence. Optionally, the IL-15Rα polypeptide (or its functional fragment) is covalently linked to the Fc domain (or its functional fragment) by a polypeptide linker sequence. Each polypeptide linker sequence can be selected independently. Optionally, these polypeptide linker sequences are the same. Alternatively, they are different.
[0063] Optionally, a soluble fusion protein complex of the invention is provided, wherein at least one of the soluble fusion proteins comprises a detectable label. Detectable labels include, but are not limited to, biotin, streptavidin, an enzyme or a catalytically active fragment thereof, a radionuclide, a nanoparticle, a paramagnetic metal ion, or a fluorescent, phosphorescent, or chemiluminescent molecule, or any combination thereof.
[0064] The present invention provides a method for preparing a soluble fusion protein complex of the present invention. The method comprises the following steps: a) introducing a DNA vector encoding a first protein with a suitable control sequence into a first host cell; b) culturing the first host cell in a culture medium under conditions sufficient to express the first protein in the cell or culture medium; c) purifying the first protein from these host cells or culture medium; d) introducing a DNA vector encoding a second protein with a suitable control sequence into a second host cell; e) culturing the second host cell in a culture medium under conditions sufficient to express the second protein in the cell or culture medium; and f) purifying the second protein from these host cells or culture medium; and g) mixing the first and second proteins under conditions sufficient to allow the IL-15 domain of the first protein and the soluble IL-15Rα domain of the second protein to form a soluble fusion protein complex.
[0065] In some cases, the method further comprises mixing the first and second proteins under conditions sufficient to allow disulfide bonds to form between the polypeptides expressed by the expression vector.
[0066] Alternatively, the method for preparing the soluble fusion protein complex of the present invention is carried out by: a) introducing into host cells a DNA vector encoding a first protein with suitable control sequences and a DNA vector encoding a second protein with suitable control sequences; b) culturing the host cells in a culture medium under conditions sufficient to express these proteins in the cells or culture medium and to allow association between the IL-15 domain of the first protein and the soluble IL-15Rα domain of the second protein to form a soluble fusion protein complex; and c) purifying the soluble fusion protein complex from these host cells or culture medium.
[0067] In one aspect, the method further comprises mixing the first and second proteins under conditions sufficient to allow disulfide bonds to form between the polypeptides expressed by the expression vector.
[0068] Also provided are methods for preparing soluble fusion protein complexes, comprising: a) introducing into host cells a DNA vector encoding a first and a second protein with suitable control sequences; b) culturing the host cells in culture medium under conditions sufficient to express the proteins in the cells or culture medium and to allow association between the IL-15 domain of the first protein and the soluble IL-15Rα domain of the second protein to form a soluble fusion protein complex, and under conditions that allow disulfide bonds to form between the polypeptides; and c) purifying the soluble fusion protein complex from the host cells or culture medium.
[0069] Optionally, the method further comprises mixing the first and second proteins under conditions sufficient to allow disulfide bonds to form between the polypeptides expressed by the expression vector.
[0070] A method for treating a neoplasia, infectious disease, or autoimmune disease in a subject in need thereof is performed by administering to the subject an effective amount of a pharmaceutical composition comprising a soluble fusion protein complex described herein (e.g., a soluble anti-PD-L1 scAb / IL-15N72D:TGFβRII / IL-15RαSu / Fc fusion protein complex), thereby treating a neoplasia, infectious disease, or autoimmune disease. For example, a method for treating a solid malignancy or a hematological malignancy in a subject in need thereof is performed by administering to the subject an effective amount of a pharmaceutical composition comprising a soluble TGFβRII dimer / huIL-15N72D:anti-human PD-L1 scAb / huIL-15RαSu / huIgG1 Fc fusion protein complex, thereby treating a malignancy.
[0071] Suitable neoplasias for treatment with the methods described herein include glioblastoma, prostate cancer, acute myeloid leukemia, B cell neoplasms, multiple myeloma, B cell lymphoma, B cell non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, cutaneous T cell lymphoma, T cell lymphoma, solid tumors, urothelial / bladder cancer, melanoma, lung cancer, renal cell carcinoma, breast cancer, gastric and esophageal cancer, head and neck cancer, prostate cancer, pancreatic cancer, colorectal cancer, ovarian cancer, non-small cell lung cancer, and squamous cell head and neck cancer.
[0072] The pharmaceutical composition comprising the fusion protein complex is administered in an effective amount. For example, the effective amount of the pharmaceutical composition is between about 1 μg / kg and 100 μg / kg, for example, 1 μg / kg, 5 μg / kg, 10 μg / kg, 15 μg / kg, 20 μg / kg, 25 μg / kg, 30 μg / kg, 35 μg / kg, 40 μg / kg, 45 μg / kg, 50 μg / kg, 55 μg / kg, 60 μg / kg, 65 μg / kg, 70 μg / kg, 75 μg / kg, 80 μg / kg, 85 μg / kg, 90 μg / kg, 95 μg / kg, or 100 μg / kg. Alternatively, the TxM complex is administered in a fixed dose or based on body surface area (i.e., per m 2 ) dose.
[0073] The pharmaceutical composition comprising the fusion protein complex is administered at least once a month, for example, twice a month, once a week, twice a week, once a day, twice a day, once every 8 hours, once every 4 hours, once every 2 hours, or once an hour. Suitable modes of administration for the pharmaceutical composition include systemic administration, intravenous administration, topical administration, subcutaneous administration, intramuscular administration, intratumoral administration, inhalation, and intraperitoneal administration.
[0074] Preferably, the fusion protein complex increases serum levels of interferon gamma (IFN-γ), and / or stimulates CD4 + and CD8 + T cells and NK cells kill disease cells or tumor cells in a subject.
[0075] In certain embodiments, methods of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cell-mediated phagocytosis (ADCP) in a subject in need thereof are provided, the method comprising administering to the subject in need thereof an effective amount of a soluble fusion protein complex embodied herein.
[0076] In certain embodiments, a method of inhibiting transforming growth factor β (TGFβ) activity in vitro or in vivo comprises contacting a TGFβ-responsive cell in vitro, or administering to a subject in need thereof, an effective amount of a soluble fusion protein complex embodied herein.
[0077] In certain embodiments, a method of reducing the amount of transforming growth factor beta (TGFβ) in vivo comprises administering to a subject in need thereof an effective amount of a soluble fusion protein complex embodied herein.
[0078] In certain embodiments, a method of inhibiting transforming growth factor β (TGFβ)-mediated phosphorylation and activation of a SMAD polypeptide in vivo comprises administering to a subject in need thereof a therapeutically effective amount of a soluble fusion protein complex embodied herein.
[0079] In certain aspects of the soluble fusion protein complex of the present invention, the IL-15 polypeptide is an IL-15 variant having an amino acid sequence different from that of the native IL-15 polypeptide. Human IL-15 polypeptides are referred to herein as huIL-15, hIL-15, huIL15, hIL15, IL-15 wild type (wt), and variants thereof refer to the use of natural amino acids, their positions in the mature sequence, and variant amino acids. For example, huIL15N72D refers to a human IL-15 comprising a substitution of N to D at position 72. In one aspect, the IL-15 variant acts as an IL-15 agonist, for example, by increasing IL-15 / IL-2βγ compared to the native IL-15 polypeptide. C Alternatively, the function of an IL-15 variant as an IL-15 antagonist may be demonstrated, for example, by reduced binding activity to IL-15R compared to the native IL-15 polypeptide.
[0080] A method for killing target cells by: a) contacting a plurality of cells with a soluble fusion protein complex of the present invention, wherein the plurality of cells further include immune cells with an IL-15R chain recognized by an IL-15 domain, or immune cells with checkpoints and / or cytokine receptors or signaling molecules regulated by a checkpoint inhibitor, a TGFβ molecule, or an immune agonist binding domain, and target disease cells; b) activating immune cells via IL-15R or signaling molecules, via inhibition of TGFβ immunosuppression, or via blocking of checkpoint molecules; and c) killing the target disease cells by activated immune cells. For example, the target disease cells are tumor cells, autoimmune cells, or virus-infected cells. In some cases, the binding domain comprises an anti-PD-L1 antibody.
[0081] The method for killing target cells further comprises: a) contacting a plurality of cells with a soluble fusion protein complex of the present invention, wherein the plurality of cells further comprises an immune cell with an Fc receptor chain recognized by an Fc domain, and a target disease cell with an antigen recognized by a binding domain (e.g., an antigen-specific scAb) and / or an immunostimulatory cytokine or its receptor; b) forming a specific binding complex (bridge) between an antigen on a target disease cell and an Fc receptor chain on an immune cell and an immunostimulatory cytokine or its receptor sufficient to bind and activate the immune cell; and c) killing the target disease cell by the bound activated immune cell. For example, the target disease cell is a tumor cell, an autoimmune cell, or a virus-infected cell. In some cases, the binding domain comprises an anti-PD-L1 antibody.
[0082] Also provided is a method for preventing or treating a disease in a patient, the method comprising the steps of: a) administering a soluble fusion protein complex of the present invention to the patient; b) activating immune cells in the patient; and c) destroying or killing disease cells via the activated immune cells sufficient to prevent or treat the disease in the patient.
[0083] The present invention also provides a method for preventing or treating a patient's disease, the method comprising the following steps: a) mixing immune cells with IL-15R chains, cytokine receptors and / or checkpoints or signaling molecules with the soluble fusion protein complex of the present invention; b) activating the immune cells; c) administering the activated immune cells to the patient; and d) destroying or killing disease cells via activated immune cells sufficient to prevent or treat the patient's disease. Immune cells can also be contacted with specific antigens to expand the number of activated immune cells.
[0084] Administration of the fusion protein complex of the present invention induces an immune response in a subject. For example, administration of the fusion protein complex of the present invention induces an immune response against cells associated with neoplasia, infectious diseases, or autoimmune diseases. In one aspect, the fusion protein complex of the present invention increases immune cell proliferation.
[0085] The present invention provides a method for stimulating the immune response of a mammal by administering an effective amount of the soluble fusion protein complex of the present invention to the mammal. The present invention also provides a method for inhibiting the immune response of a mammal by administering an effective amount of any soluble fusion protein complex of the present invention to the mammal.
[0086] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the invention belongs. The following references provide general definitions of many of the terms used in the present invention for those skilled in the art: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale and Marham, The Harper Collins Dictionary of Biology (1991). As used herein, unless otherwise indicated, the following terms have the meanings given below.
[0087] "Agent" refers to a peptide, nucleic acid molecule, or small chemical compound.
[0088] "TxM" refers to a complex comprising an IL-15N72D:IL-15RαSu / Fc scaffold linked to a binding domain. An exemplary TxM is an IL-15N72D:IL-15RαSu / Fc complex comprising a fusion with a binding domain that specifically recognizes PD-L1 (PD-L1 TxM).
[0089] "Improvement" means to reduce, suppress, attenuate, alleviate, prevent or stabilize the development or progression of a disease.
[0090] By "analog" is meant a molecule that is not identical but has similar functional or structural features. For example, a polypeptide analog retains the biological activity of the corresponding naturally occurring polypeptide while having certain biochemical modifications relative to the naturally occurring polypeptide that enhance the function of the analog. Such biochemical modifications may increase the protease resistance, membrane permeability, or half-life of the analog without altering, for example, ligand binding. Analogs may include non-natural amino acids.
[0091] The term "binding domain" is intended to cover antibodies, single chain antibodies, Fab, Fv, T cell receptor binding domains, ligand binding domains, receptor binding domains, or other antigen-specific polypeptides known in the art.
[0092] The present invention includes antibodies or fragments of such antibodies, as long as they show the desired biological activity. Also included in the present invention are chimeric antibodies, such as humanized antibodies. Typically, humanized antibodies have one or more amino acid residues introduced from a non-human source. For example, humanization can be performed by replacing the corresponding region of a human antibody with at least a portion of a rodent complementary determining region using methods described in the art.
[0093] The term "antibody" or "immunoglobulin" is intended to cover polyclonal and monoclonal antibodies. Preferred antibodies are monoclonal antibodies that react with antigens. The term "antibody" is also intended to cover a mixture of more than one antibody that reacts with an antigen (e.g., a mixture of different types of monoclonal antibodies that react with an antigen). The term "antibody" is further intended to cover complete antibodies, their biologically functional fragments, single-chain antibodies, and genetically altered antibodies (e.g., chimeric antibodies comprising parts from more than one species), bifunctional antibodies, antibody conjugates, humanized antibodies, and human antibodies. Biologically functional antibody fragments that can also be used are those peptide fragments derived from antibodies that are sufficient to bind to an antigen. "Antibody" as used herein is meant to include complete antibodies and any antibody fragment (e.g., F(ab')2, Fab', Fab, Fv) that can bind to an epitope, an antigen, or a target antigen fragment.
[0094] "Binding to a molecule" means having a physicochemical affinity for said molecule.
[0095] "Detection" refers to identifying the presence, absence or amount of an analyte to be detected.
[0096] By "disease" is meant any condition or disorder that damages or prevents the normal function of a cell, tissue, or organ. Examples of diseases include neoplasia, autoimmune disease, and viral infection.
[0097] The terms "effective amount" and "therapeutically effective amount" of a formulation or formulation component refer to a sufficient amount of a formulation or component, alone or in combination, to provide the desired effect. For example, an "effective amount" refers to the amount of the compound, alone or in combination, required to improve the symptoms of a disease relative to an untreated patient. The effective amount of one or more active compounds used to practice the present invention to therapeutically treat a disease varies with the mode of administration, the age, weight, and general health of the subject. Ultimately, the attending physician or veterinarian will determine the appropriate amount and dosing regimen. Such an amount is referred to as an "effective" amount.
[0098] By "fragment" is meant a portion of a polypeptide or nucleic acid molecule. This portion preferably comprises at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of a reference nucleic acid molecule or polypeptide. For example, a fragment may comprise 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids. However, the present invention also encompasses polypeptides and nucleic acid fragments as long as they exhibit the desired biological activity of the full-length polypeptide and nucleic acid, respectively. Nucleic acid fragments of almost any length are used. For example, illustrative polynucleotide segments having a total length of about 10,000, about 5,000, about 3,000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs in length (including all intermediate lengths) are included in many embodiments of the invention. Similarly, polypeptide fragments of almost any length are used. For example, illustrative polypeptide segments having a total length of about 10,000, about 5,000, about 3,000, about 2,000, about 1,000, about 5,000, about 1,000, about 500, about 200, about 100, or about 50 amino acids in length (including all intermediate lengths) are included in many embodiments of the invention.
[0099] The terms "isolated," "purified," or "biologically pure" refer to a material that is free to varying degrees from components that normally accompany it as found in nature. "Isolated" means the degree of separation from the original source or surrounding environment. "Purified" means a degree of separation greater than isolation.
[0100] A "purified" or "biologically pure" protein is sufficiently free of other substances that any impurities do not substantially affect the biological properties of the protein or cause other adverse consequences. In other words, a nucleic acid or peptide of the invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA technology, or substantially free of chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques (e.g., polyacrylamide gel electrophoresis or high performance liquid chromatography). The term "purified" can mean that a nucleic acid or protein produces essentially one band in an electrophoretic gel. For proteins that can be modified (e.g., phosphorylated or glycosylated), different modifications can produce different isolated proteins that can be purified individually.
[0101] Similarly, "substantially pure" means a nucleotide or polypeptide that has been separated from components that naturally accompany it. Typically, nucleotides and polypeptides are substantially pure when they are at least 60%, 70%, 80%, 90%, 95% or even 99% free by weight of proteins and naturally occurring organic molecules with which they are naturally associated.
[0102] "Isolated nucleic acid" refers to a nucleic acid that does not contain the genes that flank it in the naturally occurring genome of the organism from which it is derived. The term encompasses, for example: (a) DNA that is part of a naturally occurring genomic DNA molecule, but is not flanked by two nucleic acid sequences that flank the portion of the molecule in the genome of the organism in which the portion of the molecule is naturally present; (b) nucleic acid that is incorporated into a vector or into the genomic DNA of a prokaryotic or eukaryotic organism in a manner such that the resulting molecule is different from any naturally occurring vector or genomic DNA; (c) a separate molecule, such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene (i.e., a gene encoding a fusion protein). Nucleic acid molecules isolated according to the present invention further include synthetically produced molecules, as well as any nucleic acid that has been chemically altered and / or has a modified backbone. For example, an isolated nucleic acid is a purified cDNA or RNA polynucleotide. Isolated nucleic acid molecules also include messenger ribonucleic acid (mRNA) molecules.
[0103] By "isolated polypeptide" is meant a polypeptide of the present invention separated from the components that naturally accompany it. Typically, the polypeptide is separated from the proteins and naturally occurring organic molecules with which it is naturally associated when it is at least 60% by weight. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99% by weight of the polypeptide of the present invention. The isolated polypeptide of the present invention can be obtained, for example, by extraction from a natural source, by expressing a recombinant nucleic acid encoding such a polypeptide, or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.
[0104] "Marker" refers to any protein or polynucleotide having an alteration in expression level or activity that is associated with a disease or disorder.
[0105] "Neoplasia" refers to a disease or disorder characterized by excessive proliferation or decreased apoptosis. Exemplary tumors for which the present invention can be used include, but are not limited to, leukemias (e.g., acute leukemias, acute lymphocytic leukemias, acute myeloid leukemias, acute myeloblastic leukemias, acute promyelocytic leukemias, acute myelomonocytic leukemias, acute erythroleukemias, chronic leukemias, chronic myeloid leukemias, chronic lymphocytic leukemias), polycythemia vera, lymphomas (Hodgkin's lymphomas, non-Hodgkin's lymphomas), Waldenstrom's macroglobulinemia, heavy chain diseases, and solid tumors such as sarcomas and carcinomas (e.g., fibrosarcomas, myxosarcoma, liposarcoma, chondrosarcomas, osteogenic sarcomas, chordomas, angiosarcomas, endotheliosarcomas, lymphangiosarcomas, lymphangioendotheliosarcomas, synoviomas, mesotheliomas, In some embodiments, the neoplasia is a type of cancer. In some embodiments, the neoplasia is a type of cancer. In some embodiments, the neoplasia is a type of cancer. In some embodiments, the neoplasia is a type of cancer. As used herein, "obtaining" as in "obtaining an agent" includes synthesizing, purchasing or otherwise obtaining an agent.
[0106] "Decrease" refers to a negative change of at least 5%, 10%, 25%, 50%, 75%, or 100%.
[0107] By "reference" is meant a standard or control condition.
[0108] A "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence can be a subset or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or a complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will typically be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence is typically at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer near or between them.
[0109] "Specific binding" means that a compound or antibody recognizes and binds to the polypeptide of the present invention, but does not substantially recognize and bind to other molecules in a sample (eg, a biological sample that naturally contains the polypeptide of the present invention).
[0110] Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecules encoding polypeptides of the present invention or fragments thereof. Such nucleic acid molecules do not need to be 100% identical to endogenous nucleic acid sequences, but will typically show basic identity. Polynucleotides having "basic identity" to endogenous sequences are typically capable of hybridizing with at least one chain of a double-stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecules encoding polypeptides of the present invention or fragments thereof. Such nucleic acid molecules do not need to be 100% identical to endogenous nucleic acid sequences, but will typically show basic identity. Polynucleotides having "basic identity" to endogenous sequences are typically capable of hybridizing with at least one chain of a double-stranded nucleic acid molecule. So-called "hybridization" means pairing under different stringent conditions to form a double-stranded molecule between complementary polynucleotide sequences (e.g., genes described herein) or portions thereof. (See, eg, Wahl, GM and SL Berger (1987) Methods Enzymol. 152:399; Kimmel, AR (1987) Methods Enzymol. 152:507).
[0111] For example, stringent salt concentrations will typically be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of an organic solvent (e.g., formamide), while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide. Stringent temperature conditions will typically include a temperature of at least about 30° C., more preferably at least about 37° C., and most preferably at least about 42° C. Different additional parameters, such as hybridization time, detergent (e.g., sodium dodecyl sulfate (SDS)) concentration, and inclusion or exclusion of carrier DNA, are well known to those of ordinary skill in the art. Different stringency levels are achieved by combining these different conditions as needed. In a preferred embodiment, hybridization will occur at 30° C., in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37° C. in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 mu.g / ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42° C. in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg / ml ssDNA. Useful variations of these conditions should be readily apparent to those of ordinary skill in the art.
[0112] For most applications, the washing step after hybridization will also be different in stringency. Washing stringency conditions can be defined by salt concentration and temperature. As mentioned above, washing stringency can be increased by reducing salt concentration or by increasing temperature. For example, the stringent salt concentration for the washing step will be preferably less than about 30mM NaCl and 3mM trisodium citrate, and most preferably less than about 15mM NaCl and 1.5mM trisodium citrate. The stringent temperature conditions for the washing step will generally include a temperature of at least about 25°C, more preferably at least about 42°C and even more preferably at least about 68°C. In a preferred embodiment, the washing step will occur at 25°C, in 30mM NaCl, 3mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, the washing step will occur at 42°C, in 15mM NaCl, 1.5mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, the wash step will occur at 68° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions should be readily apparent to those of ordinary skill in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.
[0113] By "substantially identical" is meant a polypeptide or nucleic acid molecule that exhibits at least 50% identity relative to a reference amino acid sequence (e.g., any amino acid sequence described herein) or nucleic acid sequence (e.g., any nucleic acid sequence described herein). Preferably, such a sequence is at least 60%, more preferably 80% or 85%, and more preferably 90%, 95% or even 99% identical to the sequence used for comparison at the amino acid level or nucleic acid.
[0114] Sequence identity is typically measured using sequence analysis software (e.g., Sequencher, Gene Codes Corporation, 775 Technology Drive, Ann Arbor, Michigan; Vector NTI, Life Technologies, 3175 Staley Rd, Grand Island, New York). Such software can match identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary method for determining the degree of identity, the BLAST program can be used, wherein in e -3 With e -100 Probability scores between indicate closely related sequences.
[0115] "Subject" refers to a mammal, including but not limited to, a human or non-human mammal, such as a cow, horse, dog, sheep, or cat. The subject is preferably a mammal in need of such treatment, for example, a subject who has been diagnosed with B-cell lymphoma or a susceptibility thereof. The mammal is any mammal, such as a human, a primate, a mouse, a rat, a dog, a cat, a horse, and livestock or animals grown for food consumption, such as cows, sheep, pigs, chickens, and goats. In a preferred embodiment, the mammal is a human.
[0116] The ranges provided herein are understood to be shorthand for all values within the range. For example, a range of 1 to 50 should be understood to include any number, combination of numbers, or subrange from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0117] As used herein, the terms "treating" and "treatment" refer to the administration of an agent or formulation to a clinically symptomatic individual suffering from an undesirable condition, disorder, or disease in order to achieve a reduction in the severity and / or frequency of symptoms, eliminate symptoms and / or their underlying causes, and / or promote improvement or remediation of damage. It should be understood that treatment of a disorder or condition does not require, although it cannot be excluded, complete elimination of the disorder, condition, or symptoms associated therewith.
[0118] The terms "preventing" and "prevention" refer to the administration of an agent or composition to a clinically asymptomatic individual susceptible or susceptible to a particular undesirable condition, disorder or disease, and thus involve preventing the occurrence of symptoms and / or their underlying causes.
[0119] Unless expressly specified or obvious from the context, as used herein, the term "or" is understood to be inclusive. Unless expressly specified or obvious from the context, as used herein, the terms "a, an" and "the" are understood to be singular or plural.
[0120] Unless expressly specified or obvious from the context, as used herein, the term "about" is understood to be within the normal tolerance range in the art, for example, within 2 standard deviations of the mean. About can be understood to be within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the specified value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term about.
[0121] In any definition of a variable herein, the statement of a list of chemical groups includes the definition of the variable as any single group or combination of the listed groups. The statement of an embodiment for a variable or aspect herein includes the embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0122] Any composition or method provided herein can be combined with one or more of any other compositions and methods provided herein.
[0123] The transitional term "comprising," which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. In contrast, the transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps, "and those that do not materially affect one or more of the basic and novel characteristics of the claimed invention."
[0124] Other features and advantages of the present invention will be apparent from the following description of its preferred embodiments and from the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs, as generally understood. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All disclosed foreign patents and patent applications cited herein are incorporated herein by reference.
[0125] The Genbank and NCBI submissions indicated by the accession numbers cited herein are incorporated herein by reference. All other disclosed references, files, manuscripts and scientific literature cited herein are incorporated herein by reference. In the event of a conflict, the present specification including definitions shall prevail. In addition, these materials, methods and examples are illustrative only and are not intended to be limiting. BRIEF DESCRIPTION OF THE DRAWINGS
[0126] The patent or application file contains at least one drawing printed in color. Copies of this patent or patent application publication with one or more color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0127] Figure 1 is a schematic diagram illustrating an embodiment of the structure of the construct αPDL1 / TGFβRII / TXM.
[0128] Figure 2 Analytical size exclusion chromatography (SEC) of αPDL1 / TGFβRII / TXM after protein A purification.
[0129] Figure 3 It is a scan of a photograph showing the result of SDS PAGE of reduction of αPDL1 / TGFβRII / TXM.
[0130] Figure 4is a schematic diagram illustrating an embodiment of the structure of the construct TGFβRII / αPDL1 / TXM.
[0131] Figure 5 Analytical SEC of TGFβRII / αPDL1 / TXM after protein purification.
[0132] Figure 6 It is a scan of a photograph showing the result of SDS PAGE showing the reduction of TGFβRII / αPDL1 / TXM.
[0133] Figure 7 is a schematic diagram illustrating an embodiment of the structure of the construct αPDL1 / TxM / TGFβRII.
[0134] Figure 8 Shown are the SDS PAGE results of TGFβRII / αPDL1 / TxM and αPDL1 / TGFβRII / TxM reduction.
[0135] Fig. 9 is a table and schematic diagram of early protein characterization.
[0136] Fig.10 are graphs and tables depicting the results obtained using an IL-15 activity assay comparing αPDL1 / TxM / TGFβRII, αPDL1 / TGFβRII / TxM, TGFβRII / αPDL1 / TxM, and ALT-803.
[0137] Fig.11 are graphs and tables depicting the results obtained using a TGFβ activity blocking assay comparing αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TxM, and αPDL1 / TGFβRII / TxM.
[0138] Fig.12 are graphs and tables depicting the results obtained using a PDL1 binding assay comparing αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TxM, and αPDL1 / TGFβRII / TxM.
[0139] Fig.13 is a table showing an overall comparison between TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM.
[0140] Fig.14AFigures showing cell proliferation after stimulation with hTGFβRII / αPDL1 / TxM or ALT-803 are shown. IL-15-dependent 32Dβ cells were stimulated with hTGFβRII / αPDL1 / TxM or ALT-803 for 3 days, and cell proliferation was assessed using PrestoBlue. EC of IL-15 was performed by using ALT-803 as a positive control. 50 The results showed that hαPDL1 / TGFβRII / TxM had IL-15 activity with an EC50 of approximately 188 pM.
[0141] Fig. 14B is a graph showing cell proliferation after stimulation with hαPDL1 / TGFβRII / TxM or ALT-803. IL-15-dependent 32Dβ cells were stimulated with hαPDL1 / TGFβRII / TxM or ALT-803 for 3 days, and cell proliferation was assessed using PrestoBlue. EC of IL-15 was performed by using ALT-803 as a positive control. 50 The results showed that hαPDL1 / TGFβRII / TxM had IL-15 activity with an EC of approximately 376.5 pM. 50 .
[0142] Fig.15A The results obtained from the binding of TGFβRII / αPDL1 / TxM to human lung papillary adenocarcinoma cells are shown in Figure 1. The binding of TGFβRII / αPDL1 / TxM to PDL1 was analyzed by flow cytometry using an APC-labeled antibody specific for the Fc portion of hIgG. + The results showed that TGFβRII / αPDL1 / TxM has binding activity against PDL1.
[0143] Fig. 15B The results obtained from the binding of hαPDL1 / TGFβRII / TxM to human lung papillary adenocarcinoma cells are shown in Figure 1. The binding of hαPDL1 / TGFβRII / TxM to PDL1 was analyzed by flow cytometry using an APC-labeled antibody specific for the Fc portion of hIgG. + The results showed that hαPDL1 / TGFβRII / TxM has binding activity against PDL1.
[0144] Fig.16Ais a graph showing the results obtained by blocking TGFβ1-mediated Smad2 / 3 phosphorylation by hTGFβRII / αPDL1 / TxM. HEK293 cells (BPS Bioscience) containing the TGF / SMAD signaling pathway SBE reporter were used to evaluate the use of hTGFβRII / αPDL1 / TxM to block Smad2 / 3 phosphorylation induced by TGFβ1 (100 ng / mL). TGFβRII fused to IgG Fc was used as a control. The results show that hTGFβRII / αPDL1 / TxM can effectively block Smad phosphorylation mediated by TGFβ1 with an IC of approximately 2.35 nM 50 .
[0145] Fig. 16B is a graph showing the results obtained by blocking TGFβ1-mediated Smad2 / 3 phosphorylation by hαPDL1 / TGFβRII / TxM. HEK293 cells (BPS Bioscience) containing the TGF / SMAD signaling pathway SBE reporter were used to evaluate the use of hαPDL1 / TGFβRII / TxM to block Smad2 / 3 phosphorylation induced by TGFβ1 (100 ng / mL). TGFβRII fused to IgG Fc was used as a control. The results show that hαPDL1 / TGFβRII / TxM can effectively block Smad phosphorylation mediated by TGFβ1 with an IC of approximately 0.38 nM 50 .
[0146] Fig.17A is a graph showing the results obtained by blocking TGFβ3-mediated Smad2 / 3 phosphorylation by hTGFβRII / αPDL1 / TxM. HEK293 cells (BPS Bioscience) containing the TGF / SMAD signaling pathway SBE reporter were used to evaluate the use of hTGFβRII / αPDL1 / TxM to block Smad2 / 3 phosphorylation induced by TGFβ3 (100 ng / mL). TGFβRII fused to IgG Fc was used as a control. The results show that hTGFβRII / αPDL1 / TxM can effectively block Smad phosphorylation mediated by TGFβ3 with an IC of approximately 0.355 nM 50 .
[0147] Fig. 17Bis a graph showing the results obtained by blocking TGFβ3-mediated Smad2 / 3 phosphorylation by hαPDL1 / TGFβRII / TxM. HEK293 cells (BPS Bioscience) containing the TGF / SMAD signaling pathway SBE reporter were used to evaluate the use of hαPDL1 / TGFβRII / TxM to block Smad2 / 3 phosphorylation induced by TGFβ3 (100 ng / mL). TGFβRII fused to IgG Fc was used as a control. The results show that hαPDL1 / TGFβRII / TxM can effectively block Smad phosphorylation mediated by TGFβ3 with an IC of approximately 0.029 nM 50 .
[0148] Fig.18A is a graph showing the results obtained from the binding of hTGFβRII / αPDL1 / TXM to TGF-β1. ELISA was performed to evaluate the binding of hTGFβRII / αPDL1 / TXM to TGF-β1. The wells were first coated overnight with TGFβ1 (0.5 μg / ml) and then incubated with hTGFβRII / αPDL1 / TXM in serial dilutions. Protein binding was detected using anti-hIgG horseradish peroxidase (HRP). The results showed that hTGFβRII / αPDL1 / TXM could bind to plate-bound TGF-β1 with an EC50 of 1.28 nM.
[0149] Fig.18B is a graph showing the results obtained from the binding of hαPDL1 / TGFβRII / TXM to TGF-β1. ELISA was performed to evaluate the binding of hαPDL1 / TGFβRII / TXM to TGF-β1. The wells were first coated overnight with TGFβ1 (0.5ug / ml) and then incubated with hαPDL1 / TGFβRII / TXM in serial dilutions. Protein binding was detected using anti-hIgG horseradish peroxidase (HRP). The results showed that hαPDL1 / TGFβRII / TXM could bind to plate-bound TGF-β1 with an EC50 of 0.49nM.
[0150] Fig.19Ais a graph showing the results obtained from the binding of hTGFβRII / αPDL1 / TXM to TGF-β3. ELISA was performed to evaluate the binding of hTGFβRII / αPDL1 / TXM to TGF-β1. The wells were first coated overnight with TGFβ3 (0.5 μg / ml) and then incubated with hTGFβRII / αPDL1 / TXM in serial dilutions. Protein binding was detected using anti-hIgG horseradish peroxidase (HRP). The results showed that hTGFβRII / αPDL1 / TXM could bind to plate-bound TGFβ3 with an EC50 of 3.617 nM.
[0151] Fig.19B is a graph showing the results obtained from the binding of hαPDL1 / TGFβRII / TXM to TGF-β3. ELISA was performed to evaluate the binding of hαPDL1 / TGFβRII / TXM to TGF-β3. The wells were first coated overnight with TGFβ3 (0.5 μg / ml) and then incubated with hαPDL1 / TGFβRII / TXM in serial dilutions. Protein binding was detected using anti-hIgG horseradish peroxidase (HRP). The results showed that hαPDL1 / TGFβRII / TXM could bind to plate-bound TGFβ3 with an EC of 2.447 nM. 50 .
[0152] Fig. 20 is a graph of the results obtained from experiments evaluating the anti-tumor activity of hTGFβRII / αPDL1 / TXM. To evaluate the anti-tumor activity of hTGFβRII / αPDL1 / TXM protein, CellTrace labeled PD-L1 was incubated with 10:1 E:T ratio at 37°C in the presence of different proteins as indicated. + H441 lung tumor cells were incubated with human NK cells for 20 hours. The cells were then washed and resuspended in 2 μg / ml PI solution. PI death was determined by flow cytometry. + CellTrace + The percentage of H441 tumor cells and represents the NK cell-dependent killing of tumor cells mediated by different proteins. The results show that hTGFβRII / αPDL1 / TXM protein can induce ADCC against tumor cells.
[0153] Fig.21 is a graph of the results obtained from the experiment of anti-tumor activity of hαPDL1 / TGFβRII / TXM. To evaluate the anti-tumor activity of hαPDL1 / TGFβRII / TXM protein, CellTrace labeled PD-L1 was incubated with 10:1 E:T ratio at 37°C in the presence of different proteins as shown. +H441 lung tumor cells were incubated with human NK cells for 20 hours. The cells were then washed and resuspended in 2 μg / ml PI solution. PI death was determined by flow cytometry. + CellTrace + The percentage of H441 tumor cells and represents the NK cell-dependent killing of tumor cells mediated by different proteins. The results show that hαPDL1 / TGFβRII / TXM protein can induce ADCC against tumor cells.
[0154] Fig.22A is a schematic representation of the αPDL1 / TxM / TGFβRII construct. Fig. 22B : αPD-L1 / TxM, αPDL1 / TxM / TGFβRII, and control antibodies were run on SDS-PAGE under reducing (left) and non-reducing (right) conditions. Fig. 22C This is an SPR analysis of αPDL1 / TxM / TGFβRII and Rsbc6 (αPDL1 Ab). αPDL1 / TxM / TGFβRII and Rsbc6 were immobilized on the SPR sensor via Fc capture. Binding affinity to PD-L1 was determined by OneStep kinetic analysis on Pioneer FE (Fortebio). Fig.22D are the results from SEC-HPLC showing αPDL1 / TxM / TGFβRII with a purity of 93%. Fig.22E ADCC activity of αPD-L1 / TxM, Avelumab, Rsbc6 (Anti-PD-L1), αPDL1 / TxM / TGFβRIIR against PD-L1 positive tumor cells (MDA-MB-231 breast tumor cells) was demonstrated. αPD-L1 / TxM showed a maximum killing of about 85%, while αPDL1 / TxM / TGFβRII showed a maximum killing of about 30%.
[0155] Fig.23 A series of graphs showing surface plasmon resonance (SPR) analysis of TGFβ1, TGFβ2, and TGFβ3 binding on αPDL1 / TxM / TGFβRII. αPDL1 / TxM / TGFβRII was immobilized on an SPR sensor via Fc capture. Binding affinities to TGFβ1 (left), TGFβ2 (middle), and TGFβ3 (right) were determined by OneStep kinetic analysis on a Pioneer FE (Fortebio).
[0156] Fig.24 Schematic diagram of the standardized PD-L1 blockade assay used to assess the protein's immune checkpoint activity.
[0157] Fig.25A is a graph showing the results obtained from blocking PD-L1-mediated immune cell inhibition by hαPDL1 / TGFβRII / TxM and hTGFβRII / αPDL1 / TxM compared to αPDL1 Ab. Fig.25B is a graph showing the results obtained from blocking PD-L1-mediated immune cell inhibition by hαPDL1 / TxM / TGFβRII and hTGFβRII / αPDL1 / TxM compared to αPDL1 Ab. Increasing concentrations of hαPDL1 / TGFβRII / TxM, hTGFβRII / αPDL1 / TxM, and hαPDL1 / TxM / TGFβRII were added to a standardized cell-based PD-L1 blocking assay ( Fig.24 The ability of the complex to block immunosuppression was measured by T cell activation resulting in NFAT-RE mediated luminescence. Anti-PD-L1 antibody and PD-L1 / TxM protein complex (similar to TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM complexes, but lacking the TGFβRII domain) were used as positive controls.
[0158] Fig.26A and 26B It was demonstrated that the expression of αPDL1 / TxM in the parental control molecule (αPDL1 / TxM) Fig.26B ) were compared to the activity of each molecule (N-810, Fig.26A ), a graph of human TGFβ specific blocking activity. A stable cell-based luciferase reporter system (HEK-293T-luc2P / SBE) was used to assess specific TGFβ blocking activity. Cultured cells were stimulated with 0.0175 nM recombinant human TGFβ1 for 20 hours in the presence or absence of a blocker. The response to hTGFβ1 is expressed as relative luminescence units (RLU) ± SD.
[0159] Fig.27A and 27B It was demonstrated that the expression of αPDL1 / TxM in the parental control molecule (αPDL1 / TxM) Fig.27B ) were compared to the activity of each molecule (N-810Sorrento-Fc, Fig.27A ), a graph of specific hTGFβ1 blocking activity. A stable cell-based luciferase reporter system (HEK-293T-luc2P / SBE) was used to assess specific TGFβ blocking activity. Cultured cells were stimulated with 0.0175 nM recombinant human TGFβ1 for 20 hours in the presence or absence of a blocker. The response to hTGFβ1 is expressed as relative luminescence units (RLU) ± SD.
[0160] Fig.28A and28B It was demonstrated that the expression of αPDL1 / TxM in the parental control molecule (αPDL1 / TxM) Fig.28B ) were compared to the activity of each molecule (N-810ΔC, Fig.28A ), a graph of specific hTGFβ1 blocking activity. A stable cell-based luciferase reporter system (HEK-293T-luc2P / SBE) was used to assess specific TGFβ blocking activity. Cultured cells were stimulated with 0.0175 nM recombinant human TGFβ1 for 20 hours in the presence or absence of a blocker. The response to hTGFβ1 is expressed as relative luminescence units (RLU) ± SD.
[0161] Fig.29A and 29B It was demonstrated that the expression of αPDL1 / TxM in the parental control molecule (αPDL1 / TxM) Fig.29B ) were compared to the activity of each molecule (N-810D, Fig.29A ), a graph of specific hTGFβ1 blocking activity. A stable cell-based luciferase reporter system (HEK-293T-luc2P / SBE) was used to assess specific TGFβ blocking activity. Cultured cells were stimulated with 0.0175 nM recombinant human TGFβ1 for 20 hours in the presence or absence of a blocker. The response to hTGFβ1 is expressed as relative luminescence units (RLU) ± SD.
[0162] Fig.30 The antibody-dependent cellular cytotoxicity (ADCC) of TxM constructs was demonstrated in breast adenocarcinoma cells (MDA-MB-231). Antibody-dependent cellular cytotoxicity (ADCC) was used to determine specific αPD-L1 activity. Effector cells: haNK (NK-92 derivative).
[0163] Figures 31A-31H is a schematic representation showing different constructs. Fig.31A :N-810A. Fig.31B : Unglycosylated N-810A. Fig.31C : Unglycosylated N-810A, Δ free cysteine. Fig.31D :N-810AΔ Hinge. Fig.31E : N-810A (IL15-K41Q, L45S, I67T, N79Y, E93A). Mutations in IL15 enhance the solubility and expression of the molecule. Fig.31F : N-810A (IL15-L45S). Mutations in IL15 enhance the solubility and expression of the molecule. Figure 31G :N-810D. Fig.31H :N-810E.
[0164] Fig.32Table 2 demonstrates that IL15 mutations increase protein production and reduce aggregation. The N-810D mutation also increases production and reduces aggregation. DETAILED DESCRIPTION
[0165] The present invention is based at least in part on the surprising discovery that multi-specific protein complexes based on IL-15 enhance the activity of immune cells and promote their activity against disease cells, thereby reducing or preventing diseases. These protein complexes also show increased binding to diseases and target antigens. Provided herein are multi-specific protein complexes having a domain comprising IL-15 or a functional variant, a cytokine receptor or a cytokine ligand, and a binding domain comprising a disease-specific binding domain, an immune checkpoint inhibitor or an immune agonist. Such protein complexes have utility in methods for treating neoplasia, infectious diseases, or autoimmune diseases in subjects. Therefore, provided herein are compositions characterized by PD-L1 / TGFβRII / TxM, and methods for using such compositions to enhance immune responses against neoplasia (solid tumors and hematological tumors).
[0166] As described herein, the protein with the ability to target disease cells is used for host immune recognition and response, which is an effective strategy for treating cancer, infectious diseases, and autoimmune diseases. As described in U.S. Patent No. 8,507,222 (incorporated herein by reference), protein scaffolds comprising IL-15 and IL-15 receptor alpha domains have been used to produce multi-specific proteins capable of recognizing antigens on disease cells and receptors on immune cells. See U.S. Patent No. 8,507,222 in Example 15. The generation of IL-15 and IL-15 receptor alpha soluble multi-specific protein complexes comprising binding domains connected to one or more recognition immune checkpoints or signaling molecules is described herein. In some cases, these complexes also include binding domains that recognize antigens expressed on disease cells (e.g., PD-L1, ssDNA, CD20, HER2, EGFR, CD19, CD38, CD52, GD2, CD33, Notch1, intercellular adhesion molecule 1 (ICAM-1), tissue factor, HIV envelope or other tumor antigens).
[0167] In some cases, the binding domain comprises a single-chain antibody, wherein the immunoglobulin light chain variable domain is covalently connected to the immunoglobulin heavy chain variable domain by a polypeptide linker sequence. The single-chain antibody domain can be arranged in VH-linker-VL or VL-linker-VH format. Alternatively, the binding domain comprises a soluble or extracellular ligand or receptor domain that can serve as an immune checkpoint inhibitor or an immune agonist. As long as the binding activity is maintained, with or without another linker sequence, the binding domain identifying the immune checkpoint or signaling molecule is connected to the N or C-terminus of IL-15 or IL-15 receptor alpha protein. Preferably, the binding domain is connected to the N-terminus (huIL-15N72D) of human IL-15N72D superagonist protein. Alternatively, the binding domain is connected to the C-terminus of human IL-15N72D protein. Preferably, the binding domain is connected to the N-terminus (huIL-15RαSu) of human IL-15 receptor alphasushi domain. Alternatively, the binding domain is connected to the C-terminus of the huIL-15RαSuFc protein. In some cases, the multispecific protein complex of the present invention further comprises an IgG Fc domain for protein dimerization and recognition of CD16 receptors on immune cells. Such a domain mediates stimulation of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC) for target cells. In some instances, it is useful to use an Fc domain with enhanced or reduced CD16 binding activity. In one aspect, the Fc domain contains amino acid substitutions L234A and L235A (LALA) (based on the numbering of the Fc consensus sequence) that reduce ADCC activity but retain the ability to form disulfide dimers.
[0168] Therefore, in certain embodiments, the isolated soluble fusion protein complex comprises at least two soluble protein complexes, the first soluble protein complex comprises an interleukin-15 (IL-15) polypeptide domain, and the second soluble protein comprises a soluble IL-15 receptor αsushi-binding domain (IL-15RαSu) fused to an immunoglobulin Fc domain, wherein the immunoglobulin Fc domain is fused to or connected to a transforming growth factor-β receptor type 2 (TGFβRII) domain; the first and / or second soluble protein further comprises a binding domain that specifically binds to a disease antigen, an immune checkpoint molecule, or an immune signaling molecule, and the IL-15 domain of the first soluble protein binds to the IL-15RαSu domain of the second soluble protein, thereby forming a soluble fusion protein complex. In certain aspects, the immunoglobulin Fc domain is connected to the transforming growth factor-β receptor type 2 (TGFβRII) domain via a linker molecule.
[0169] In certain embodiments, the soluble fusion complex comprises at least two soluble proteins, a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a transforming growth factor-β receptor type 2 (TGFβRII) dimer, the TGFβRII dimer comprising a first TGFβRII domain connected to a second TGFβRII domain, wherein the TGFβRII dimer is fused to or connected to an interleukin-15 (IL-15) polypeptide domain; the second fusion protein comprises a soluble IL-15 receptor α sushi-binding domain (IL-15RαSu) fused to an immunoglobulin Fc domain; wherein the second fusion protein further comprises a binding domain that specifically binds to a disease antigen, an immune checkpoint molecule, or an immune signaling molecule, and wherein the IL-15 domain of the first fusion protein binds to the IL-15RαSu domain of the second fusion protein, thereby forming a soluble fusion protein complex.
[0170] In certain embodiments, the soluble fusion complex comprises at least two soluble proteins, a first fusion protein and a second fusion protein, wherein the first fusion protein comprises an interleukin-15 (IL-15) polypeptide domain, which is fused to a binding domain that specifically binds to a disease antigen, an immune checkpoint molecule, or an immune signaling molecule; the second fusion protein comprises a transforming growth factor-β receptor type 2 (TGFβRII) dimer, which TGFβRII dimer comprises a first TGFβRII domain connected to a second TGFβRII domain, wherein the TGFβRII dimer and a soluble IL-15 receptor αsushi-binding domain (IL-15RαSu) are fused to an immunoglobulin Fc domain; wherein the first or second TGFβRII domain is fused to an IL-15RαSu domain, wherein the IL-15 polypeptide domain of the first fusion protein binds to the IL-15RαSu domain of the second fusion protein, thereby forming a soluble fusion protein complex.
[0171] In certain embodiments, one of the first and second soluble proteins further comprises a second binding domain that specifically binds to a disease antigen, an immune checkpoint molecule, or an immune signaling molecule.
[0172] In certain embodiments, the IL-15 polypeptide is an IL-15 variant comprising an N72D mutation (IL-15N72D).
[0173] In certain embodiments, the binding domain comprises an immunoglobulin light chain variable domain covalently linked to an immunoglobulin heavy chain variable domain via a polypeptide linker sequence.
[0174] In certain embodiments, the binding domain specifically binds to one or more molecules comprising: programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), cluster of differentiation 33 (CD33), cluster of differentiation 47 (CD47), glucocorticoid-induced tumor necrosis factor receptor (TNFR) family-related gene (GITR), lymphocyte function-associated antigen 1 (LFA-1), tissue factor (TF), delta-like protein 4 (DLL4), single-stranded DNA, or T-cell immunoglobulin mucin domain molecule-3 (Tim-3).
[0175] In certain embodiments, the binding domain specifically binds one or more molecules comprising: programmed death-ligand 1 (PD-L1). In certain embodiments, the TGFβRII domain binds transforming factor beta (TGFβ).
[0176] In certain embodiments, a first fusion protein complex is covalently linked to a second fusion protein complex via a disulfide bond that links the Fc domain of the first soluble fusion protein complex to the Fc domain of the second soluble fusion protein complex.
[0177] Interleukin-15
[0178] Interleukin-15 (IL-15) is a protein that is used by effector NK cells and CD8 + An important cytokine for the development, proliferation, and activation of memory T cells. IL-15 binds to IL-15 receptor α (IL-15Rα) and presents it in trans to the IL-2 / IL-15 receptor β-covalent γ chain (IL-15Rβγ c ) complex. IL-15 and IL-2 share the IL-15Rβγ c However, unlike IL-2, IL-15 does not support CD4 + CD25 + FoxP3 + Maintenance or induction of activated CD8 regulatory T (Treg) cells + IL-15 is known to be an effector of CD8 T cells. +T cells to provide the only cytokine for anti-apoptotic signaling. IL-15, whether administered alone or as a complex with IL-15Rα, has shown potent antitumor activity against established solid tumors in experimental animal models and, therefore, has been identified as one of the most promising immunotherapeutic agents that can potentially cure cancer. The first human clinical trial found that patients administered recombinant human (rh) IL-15 showed an increase in γδ T cells, CD8 + There was a significant increase in T cells, and NK cells, but high doses resulted in toxicity and limited tumor response. 2 A shorter half-life of prokaryotic rhIL-15 was also observed. 23
[0179] To facilitate clinical development of IL-15-based cancer therapeutics, an IL-15 mutant (IL-15N72D) with increased bioactivity compared to IL-15 was identified (Zhu et al., J Immunol, 183:3598-3607, 2009). The pharmacokinetics and bioactivity of the IL-15 superagonist (IL-15N72D) were further improved by generating an IL-15N72D:IL-15Rα / Fc fusion complex (ALT-803), such that the superagonist complex has at least 25-fold the activity of the native cytokine in vivo (Han et al., Cytokine, 56:804-810, 2011).
[0180] Immune checkpoint inhibitor and immune agonist domains
[0181] In other embodiments, the binding domain is specific for an immune checkpoint or signaling molecule or its ligand and acts as an inhibitor of immune checkpoint inhibitory activity or as an agonist of immune stimulatory activity. Such immune checkpoint and signaling molecules and ligands include PD-1, PD-L1, PD-L2, CTLA-4, CD28, CD80, CD86, B7-H3, B7-H4, B7-H5, ICOS-L, ICOS, BTLA, CD137L, CD137, HVEM, KIR, 4-1BB, OX40L, CD70, CD27, CD47, CIS, OX40, GITR, IDO, TIM3, GAL9, VISTA, CD155, TIGIT, LIGHT, LAIR-1, Siglecs, and A2aR (Pardoll DM. 2012. Nature Rev Cancer 12:252-264, Thaventhiran T, et al. 2012. J Clin Cell Immunol S12:004). In addition, preferred antibody domains of the present invention may include ipilimumab and / or tremelimumab (anti-CTLA4), nivolumab, pembrolizumab, pidilizumab, TSR-042, ANB011, AMP-514 and AMP-224 (ligand-Fc fusion) (anti-PD1), atezolizumab (MPDL3280A), avelumab (MSB0010718C), durvalumab (MEDI4736), MEDI0680, and BMS-9365569 (anti-PDL1), MEDI6469 (anti-OX40 agonist), BMS-986016, IMP701, IMP731, IMP321 (anti-LAG3) and GITR ligands.
[0182] Cytokine Receptors and Cytokines
[0183] Cytokine receptors fused to or linked to the IL-15 embodied herein bind to immunostimulatory cytokines that result in enhanced immune activity. Examples of cytokines include, but are not limited to, the IL-2 family, interferon (IFN), IL-10, IL-1, IL-17, TGF and TNF cytokine families, and are not limited to IL-1 to IL-35, IFN-α, IFN-β, IFNγ, TGF-β, TNF-α, and TNFβ. An exemplary receptor is the transforming growth factor β receptor type II (TGFβRII) that binds TGFβ. The protein encoded by this gene is a transmembrane protein with a protein kinase domain that forms a heterodimeric complex with TGF-β receptor type 1 and binds TGF-β. This receptor / ligand complex phosphorylates the protein, which then enters the nucleus and regulates transcription of genes associated with: cell proliferation, cell cycle arrest, wound healing, immunosuppression, and tumorigenesis. Mutations in this gene have been associated with: Marfan syndrome, Lois-Detz aortic aneurysm syndrome, and the development of different types of tumors. The extracellular domain of TGFβRII can bind to TGF-β and block its activity. Within the tumor microenvironment, TGF-β acts to promote tumor progression through matrix modification, angiogenesis, and induction of epithelial-mesenchymal transition (EMT). TGF-β1 can directly inhibit T cell proliferation and response and natural killer (NK) cell activity. In addition, TGF-β signaling in myeloid cells is crucial in driving metastasis.
[0184] Antigen-specific binding domain
[0185] Antigen-specific binding domains consist of polypeptides that specifically bind to targets on disease cells. Alternatively, these domains can bind to targets on other cells that support the disease state, such as targets on stromal cells that support tumor growth or targets on immune cells that support disease-mediated immunosuppression. Antigen-specific binding domains include antibodies, single-chain antibodies, Fabs, Fvs, T cell receptor binding domains, ligand binding domains, receptor binding domains, domain antibodies, single domain antibodies, miniantibodies, nanoantibodies, peptibodies, or various other antibody mimetics known in the art (e.g., affimers, affitins, alpha bodies, atrimers, CTLA4-based molecules, adnectins, anticalins, Kunitz domain-based proteins, avimers, knottins, fynomers, designed ankyrin repeat proteins, affibodies, affilins, monomers, and armadillo repeat protein-based proteins (Weidle, UH, et al. 2013. Cancer Genomics & Proteomics 10: 155-168)).
[0186] In certain embodiments, the antigen for the antigen-specific binding domain comprises a cell surface receptor or ligand. In other embodiments, the antigen comprises a CD antigen, a cytokine or chemokine receptor or ligand, a growth factor receptor or ligand, a tissue factor, a cell adhesion molecule, an MHC / MHC-like molecule, an Fc receptor, a Toll-like receptor, a NK receptor, a TCR, a BCR, a positive / negative co-stimulatory receptor or ligand, a death receptor or ligand, a tumor-associated antigen, or a virus-encoded antigen. Preferably, the antigen-specific binding domain is capable of binding to an antigen on a tumor cell. The tumor-specific binding domain can be derived from antibodies approved for the treatment of cancer patients, including rituximab, ofatumumab, and obinutuzumab (anti-CD20 antibody); trastuzumab and pertuzumab (anti-HER2 antibody); cetuximab and panitumumab (anti-EGFR Ab); and alemtuzumab (anti-CD52 Ab). Similarly, binding domains from approved antibody-effector molecule conjugates specific for: CD20 ( 90 Y-labeled ibritumomab tiuxetan 131I-labeled tositumomab), HER2 (ado-trastuzumab emtansine), CD30 (brentuximab vedotin) and CD33 (gemtuzumab bozogamicin) (Sliwkowski MX, Mellman I. 2013 Science 341: 1192).
[0187] Additionally, preferred binding domains of the present invention may include various other tumor-specific antibody domains known in the art. Antibodies for treating cancer and their respective targets include, but are not limited to, nivolumab (anti-PD-1Ab), TA99 (anti-gp75), 3F8 (anti-GD2), 8H9 (anti-B7-H3), abavolumab (anti-CA-125 (copycat)), adelimumab (anti-EpCAM), afutuzumab (anti-CD20), alacizumab pegol (anti-VEGFR2), altumomab pentetate (anti-CEA), amatuximab (anti-mesothelin), AME-133 (anti-CD20), anatumomab mafenatox (anti-TAG-72), apolizumab (anti-HLA-DR), arcitumomab (anti-CEA), bavituximab (anti-phosphatidylserine), bectumomab (anti-CD22), belimumab (anti-BAFF), besilesomab (anti-CEA-related antigen), bevacizumab (anti-VEGF-A), bivatuzumab mertansine (anti-CD44 v6), blinatumomab (anti-CD19), BMS-663513 (anti-CD137), brentuximab (anti-CD30 (TNFRSF8)), cantuzumab mertansine (anti-mucin CanAg), cantuzumab ravtansine (anti-MUC1), capromab pendetide (anti-prostate cancer cell), carlumab (anti-MCP-1), catumaxomab (anti-EpCAM, CD3), cBR96-doxorubicin immunoconjugate (anti-Lewis Y antigen), CC49 (anti-TAG-72), cedelizumab (anti-CD4), Ch.14.18 (anti-GD2), ch-TNT (anti-DNA-associated antigen), citatuzumab bogatox (anti-EpCAM), cixutumumab (anti-IGF-1 receptor), titan-clivatuzumabtetraxetan (anti-MUC1), conatumumab (anti-TRAIL-R2), CP-870893 (anti-CD40), dacetuzumab (anti-CD40), daclizumab (anti-CD25), dalotuzumab (anti-insulin-like growth factor I receptor), daratumumab (anti-CD38 (cyclic ADP ribose hydrolase)), demcizumab (anti-DLL4), detumomab (anti-B-lymphoma cells), drozitumab (anti-DR5), duli duligotumab (anti-HER3), dusigitumab (anti-ILGF2), ecoromeximab (anti-GD3 ganglioside), edrecolomab (anti-EpCAM), elotuzumab (anti-SLAMF7), elsilimomab (anti-IL-6), enavatuzumab (anti-TWEAK receptor), enoticumab (anti-DLL4), ensituximab (anti-5AC), epitumomab (anti-EpCAM), and edrecolomab (anti-EpCAM).cituxetan (anti-epithelial sialoprotein), epratuzumab (anti-CD22), ertumaxomab (anti-HER2 / neu, CD3), etaracizumab (anti-integrin αvβ3), faralimomab (anti-interferon receptor), farletuzumab (anti-folate receptor 1), FBTA05 (anti-CD20), ficlatuzumab (anti-HGF), figitumumab (anti-IGF-1 receptor), flanvotumab (anti-TYRP1 (glycoprotein 75)), fresolimumab (anti-TGFβ), futuximab (anti-EGFR), galiximab (anti-CD80), ganitumab (anti-I GF-I), o-gemtuzumab (anti-CD33), girentuximab (anti-carbonic anhydrase 9 (CA-IX)), vetin-brentuximab (anti-GPNMB), guselkumab (anti-IL13), ibalizumab (anti-CD4), ibritumomab tiuxetan (anti-CD20), icrucumab (anti-VEGFR-1), igovolumab (anti-VEGFR-2). ab) (anti-CA-125), IMAB362 (anti-CLDN18.2), IMC-CS4 (anti-CSF1R), IMC-TR1 (TGFβRII), imgatuzumab (anti-EGFR), inclacumab (anti-selectin P), indatuximabravtansine (anti-SDC1), inotuzumab ozogamicin (anti-CD22), intetumumab (anti-CD51), ipilimumab (anti-CD152), iratumumab (anti-CD30 (TNFRSF8)), KM3065 (anti-CD20), KW-0761 (anti-CD194), LY2875358 (anti-MET), labetuzumab (anti-CEA), lambrolizumab (anti-PDCD1), lexatumumab (anti-TRAIL-R2), lintuzumab (anti-CD33), lirilumab (anti-KIR2D), lorvotuzumabmertansine (anti-CD56), lucatumumab (anti-CD40), lumiliximab (anti-CD23 (IgE receptor)), mapatumumab (anti-TRAIL-R1), margetuximab (anti-ch4D5), matuzumab (anti-EGFR), mavrilimumab (anti-GMCSF receptor α-chain), milatuzumab (anti-CD74), minretumomab (anti-TAG-72), mitumomab (anti-GD3 ganglioside), mogamulizumab (anti-CCR4), moxetumomab pasudotox (anti-CD22), tadalafil-nacolomab tafenatox (anti-C242 antigen), naptumomabestafenatox (anti-5T4), narnatumab (anti-RON), necitumumab (anti-EGFR), nesvacumab (anti-angiopoietin 2), nimotuzumab (anti-EGFR), nivolumab (anti-IgG4), nofetumomab merpentan, ocrelizumab (anti-CD20), ocaratuzumab (anti-CD20), olaratumab (anti-PDGF-Rα), onartuzumab (anti-c-MET), ontuxizumab (anti-TEM1), oportuzumabmonatox (anti-EpCAM), oregovomab (anti-CA-125), otlertuzumab (anti-CD37), pankomab (anti-tumor-specific glycosylation of MUC1), parsatuzumab (anti-EGFL7), pascolizumab (anti-IL-4), patritumab (anti-HER3), pemtumomab (anti-MUC1), pertuzumab (anti-HER2 / neu), pidilizumab (anti-PD-1), pinatuzumab vedotin (anti-CD22), pintumomab (anti-adenocarcinoma antigen), vedotin-polatuzumab vedotin (anti-CD79B), pritumumab (anti-vimentin), PRO131921 (anti-CD20), quilizumab (anti-IGHE), racotumomab (anti-N-glycolylneuraminic acid), radretumab (anti-fibronectin extracellular domain-B), ramucirumab (anti-VEGFR2), rilotumumab (anti-HGF), robatumumab (anti-IGF-1 receptor), roledumab (anti-RHD), rovelizumab (anti-CD11 & CD18), samalizumab (anti-CD200), satumomab pendetide (anti-TAG-72), seribantumab (anti-ERBB3), SGN-CD19A (anti-CD19), SGN-CD33A (anti-CD33), sibrotuzumab (anti-FAP), siltuximab (anti-IL-6), solitomab (anti-EpCAM), sontuzumab (anti-epithelial sialoprotein), tabalumab (anti-BAFF), tacatuzumabtetraxetan (anti-alpha-fetoprotein), taplitumomab paptox (anti-CD19), telimomabaritox), tenatumomab (anti-tenascin C), teneliximab (anti-CD40), teprotumumab (anti-CD221), TGN1412 (anti-CD28), ticilimumab (anti-CTLA-4), tigatuzumab (anti-TRAIL-R2), TNX-650 (anti-IL-13), tositumomab (anti-CS20), tovetumab (anti-CD140a), TRBS07 (anti-GD2), tregalizumab (anti-CD4), tremelimumab (anti-CTLA-4), TRU-016 (anti-CD37), tucotuzumab celmoleukin (anti-EpCAM), ublituximab (anti-CD20), urelumab (anti-4-1BB), vantictumab (anti-frizzled receptor), vapaliximab (anti-AOC3 (VAP-1)), vatelizumab (anti-ITGA2), veltuzumab (anti-CD20), vesencumab (anti-NRP1), visilizumab (anti-CD3), volociximab (anti-integrin α5β1), martin-vorsetuzumab mafodotin) (anti-CD70), votumumab (anti-tumor antigen CTAA16.88), zalutumumab (anti-EGFR), zanolimumab (anti-CD4), zatuximab (anti-HER1), ziralimumab (anti-CD147 (basal immunoglobulin)), RG7636 (anti-ETBR), RG7458 (anti-MUC16), RG7599 (anti-NaPi2b), MPDL3280A (anti-PD-L1), RG7450 (anti-STEAP1), and GDC-0199 (anti-Bcl-2).
[0188] Other antibody domains or tumor target binding proteins (e.g., TCR domains) that can be used in the present invention include, but are not limited to, those that bind to the following antigens (note that the cancer indications shown represent non-limiting examples): aminopeptidase N (CD13), annexin A1, B7-H3 (CD276, various cancers), CA125 (ovarian cancer), CA15-3 (cancer), CA19-9 (cancer), L6 (cancer), Lewis Y (cancer), Lewis X (cancer), alpha-fetoprotein (cancer), CA242 (colorectal cancer), placental alkaline phosphatase (cancer), prostate-specific antigen (prostate), prostatic acid phosphatase (prostate), epidermal growth factor (cancer), CD2 (Hodgkin's disease, NHL lymphoma, multiple myeloma), CD3ε (T-cell lymphoma, lung cancer, breast cancer, gastric cancer, ovarian cancer, autoimmune disease, malignant ascites), CD19 (B-cell malignancies), CD20 (non-Hodgkin's lymphoma, B-cell tumors, autoimmune disease), CD21 (B-cell lymphoma), CD22 (leukemia, lymphoma, multiple myeloma, SLE), CD30 (Hodgkin's lymphoma), CD33 (leukemia, autoimmune disease), CD38 (multiple myeloma), CD40 (lymphoma, multiple myeloma, leukemia (CLL)), CD51 (metastasis melanoma, sarcoma), CD52 (leukemia), CD56 (small cell lung cancer, ovarian cancer, Merkel cell carcinoma, and liquid tumors, multiple myeloma), CD66e (cancer), CD70 (metastatic renal cell carcinoma and non-Hodgkin's lymphoma), CD74 (multiple myeloma), CD80 (lymphoma), CD98 (cancer), CD123 (leukemia), mucin (cancer), CD221 (solid tumors), CD227 (breast cancer, ovarian cancer), CD262 (NSCLC and other cancers), CD309 (ovarian cancer), CD326 (solid tumors), CEACAM3 (colorectal cancer, gastric cancer), CEACAM5 (CEA, CD66e) (breast cancer, colorectal cancer, and lung cancer), DLL4 (A-like-4), EGFR (various cancers), CTLA4 (melanoma), CXCR4 (CD184, heme tumors, solid tumors), endothelin (CD105, solid tumors), EPCAM (epithelial cell adhesion molecule, bladder cancer, head cancer, neck cancer, colon cancer, NHL prostate cancer, and ovarian cancer), ERBB2 (lung cancer, breast cancer, prostate cancer), FCGR1 (autoimmune diseases), FOLR (folate receptor, ovarian cancer), FGFR (cancer), GD2 ganglioside (cancer), G-28 (cell surface antigen glycolipid, melanoma), GD3 idiotype (cancer), heat shock protein (cancer), HER1 (lung cancer, gastric cancer), HER2 (breast cancer, lung cancer, and ovarian cancer), HLA-DR10 (NHL), HLA-DRB (NHL, B-cell leukemia), human chorionic gonadotropin (cancer), IGF1R (solid tumors, blood cancer), IL-2 receptor (T-cell leukemia and lymphoma), IL-6R (multiple myeloma, RA, Castleman's disease disease), IL6-dependent tumors), integrins (ανβ3, α5β1, α6β4, α11β3, α5β5, ανβ5 for various cancers), MAGE-1 (cancer), MAGE-2 (cancer), MAGE-3 (cancer), MAGE 4 (cancer), anti-transferrin receptor (cancer), p97 (melanoma), MS4A1 (transmembrane 4-domain subfamily A member 1, non-Hodgkin's B-cell lymphoma, leukemia), MUC1 (breast cancer, ovarian cancer, cervical cancer, bronchial cancer and gastrointestinal cancer), MUC16 (CA125) (ovarian cancer), CEA (colorectal cancer), gp100 (melanoma), MARTI (melanoma), MPG (melanoma), MS4A1 (transmembrane 4-domain subfamily A, small cell lung cancer, NHL), nucleolin, Neu oncogene product (cancer), p21 (cancer), connexin-4 (cancer), paratope against -(N-glycolylneuraminic acid, breast cancer, melanoma cancer), PLAP-like testicular alkaline phosphatase (ovarian cancer, testicular cancer), PSMA (prostate tumor), PSA (prostate), ROB04, TAG 72 (tumor-associated glycoprotein 72, AML, gastric cancer, colorectal cancer, ovarian cancer), T-cell transmembrane protein (cancer), Tie (CD202b), tissue factor, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, cancer), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B, multiple myeloma, NHL, other cancers, RA and SLE), TPBG (trophoblast glycoprotein, renal cell carcinoma), TRAIL-R1 (tumor necrosis apoptosis-inducing ligand receptor 1, lymphoma, NHL, colorectal cancer, lung cancer), VCAM-1 (CD106, melanoma), VEGF, VEGF-A, VEGF-2 (CD309) (various cancers). Some other tumor-associated antigen targets have been reviewed (Gerber, et al., mAbs2009 1:247-253; Novellino et al., Cancer Immunol Immunother [Cancer Immunology, Immunotherapy]. 2005 54:187-207; Franke, et al., Cancer Biother Radiopharm [Cancer Biotherapy and Radiopharmaceuticals]. 2000, 15:459-76; Guo, et al., Adv Cancer Res. [Cancer Research Progress] 2013; 119:421-475; Parmiani et al. J Immunol. [Immunology Journal] 2007 178:1975-9). Examples of these antigens include clusters of differentiation (CD4, CD5, CD6, CD7, CD8, CD9, CD10, CD11a, CD11b, CD1 lc, CD12w, CD14, CD15, CD16, CDwl7, CD18, CD21, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD31, CD32, CD34, CD35, CD36, CD37, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD53, CD54, CD55, CD58, CD59, CD61, CD62E, CD62L, CD62P, CD63, CD68, CD69, CD71, C D72, CD79, CD81, CD82, CD83, CD86, CD87, CD88, CD89, CD90, CD91, CD95, CD96, CD100, CD103, CD105, CD106, CD109, CD117, CD120, CD127, CD133, CD134, CD135, CD138, CD141, CD142, CD1 43. CD144, CD147, CD151, CD152, CD154, CD156, CD158, CD163, CD166, .CD168, CD184, CDwl86 , CD195, CD202 (a, b), CD209, CD235a, CD271, CD303, CD304), annexin A1, nucleolin, endothelin (CD105), ROB04, amino-peptidase N,-like-4 (DLL4), VEGFR-2 (CD309), CXCR4 (CD184), Tie2, B7-H3, WT1, MUC1, LMP2, HPV E6 E7, EGFRvIII, HER-2 / neu, idiotype, MAGEA3, p53 non-mutant, NY-ESO-1, GD2, CEA, MelanA / MART1, Ras mutant, gp100, p53 mutant, proteinase 3 (PR1), bcr-abl, tyrosinase, survivin, hTERT, sarcoma translocation breakpoints, EphA2, PAP, ML-IAP, AFP, EpCAM, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, ALK, androgen receptor, cyclin B l, polysialic acid, MYCN, RhoC, TRP-2, GD3, fucosyl GM1, mesothelin, PSCA, MAGE Al, sLe(a), CYPIB I, PLACl, GM3, BORIS, Tn, GloboH, ETV6-AML, NY-BR-1, RGS5, SART3, STn, carbonic anhydrase IX, PAX5, OY-TES1, sperm protein 17, LCK, HMWMAA, AKAP-4, SSX2, XAGE 1, B7H3, legumin, Tie 2, Page4, VEGFR2, MAD-CT-1, FAP, PDGFR-β, MAD-CT-2, Notch1, ICAM1, and Fos-related antigen 1.
[0189] Additionally, preferred binding domains of the invention include binding domains specific for antigenic and epitope targets associated with infected cells known in the art. Such targets include, but are not limited to, those derived from the following infectious agents of interest: HIV virus (particularly antigens from HIV envelope spikes and / or gp120 and gp41 epitopes), human papillomavirus (HPV), Mycobacterium tuberculosis, Streptococcus agalactiae, methicillin-resistant Staphylococcus aureus, Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Cryptococcus neoformans, Histoplasma capsulatum, influenzae type B, B), Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, rabies virus, influenza virus virus), cytomegalovirus, herpes simplex virus I, herpes simplex virus II, human serum parvovirus, respiratory syncytial virus, varicella-zoster virus, hepatitis B virus, hepatitis C virus, measles virus, adenovirus, human T-cell leukemia virus, Epstein-Barr virus, murine leukemia virus, mumps virus, herpes stomatitis virus, sindbis virus, lymphocytic choriomeningitis virus, wart virus, blue tongue virus, Sendai virus, feline leukemia virus, reovirus, poliovirus, simian virus 40, mouse mammary tumor virus, dengue virus, rubella virus, West Nile virus, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondiigondii), Trypanosoma rangeli, Trypanosoma cruzi, Trypanosoma rhodesiensei, Trypanosoma brucei, Schistosoma mansoni, Schistosoma japonicum, Babesia bovis, Elmeria tenella, Onchocercavolvulus, Leishmania tropica, Trichinella spiralis, Theileria parva, Taenia hydatigena, Taenia ovis, Taenia saginata, Echinococcus granulosus granulosus), Mesocestoides corti, Mycoplasma arthritidis, M. hyorhinis, M. orale, M arginini, Acholeplasma laidlawii, M. salivarium, and M. pneumoniae.
[0190] T cell receptor (TCR)
[0191] T cell is a cell subgroup, and the cell constitutes the cellular component of the immune system together with other immune cell types (polymorphonuclear cells, eosinophils, basophils, mast cells, B cells, NK cells). Under physiological conditions, T cells play a role in immune surveillance and elimination of foreign antigens. However, under pathological conditions, there is convincing evidence that shows that T cells play a major role in the appearance and propagation of diseases. In these obstacles, the destruction of central or peripheral T cell immune tolerance is the basic process in the cause of autoimmune diseases.
[0192] The TCR complex is composed of at least seven transmembrane proteins. The (αβ or γδ) heterodimers connected by disulfide bonds form a single antigen recognition unit, and the invariant chain of CD3 composed of ε, γ, δ, ζ, and η chains is responsible for coupling ligand binding with signal transduction pathways (which lead to the development of T cell activation and cellular immune response). Although the TCR chain has genetic diversity, two structural features are common to all known subunits. First, they are transmembrane proteins with a single transmembrane domain (possibly α helix). Secondly, all TCR chains have the unusual feature of having charged amino acids in the predicted transmembrane domain. The invariant chain has a single negative charge, which is conserved between mice and humans, and the variant chain has one (TCR-β) or two (TCR-α) positive charges. The transmembrane sequence of TCR-α is highly conserved in many species, so it may play an important functional role in phylogeny. The octapeptide sequence containing hydrophilic amino acids arginine and lysine is the same between species.
[0193] T cell response is regulated by antigen binding to TCR. One type of TCR is a membrane-bound heterodimer, which is composed of α chains and β chains similar to immunoglobulin variable (V) and constant (C) regions. The TCR α chain includes covalently linked V-α and C-α chains, while the β chain includes a V-β chain covalently linked to the C-β chain. The V-α and V-β chains form a pocket or cleft that can bind superantigens or antigens in the context of the major histocompatibility complex (MHC) (referred to as the HLA complex in humans). See, Davis Ann.Rev.of Immunology [Annual Review of Immunology] 3:537 (1985); Fundamental Immunology [Basic Immunology] 3rd Edition, W.Paul edited Rsen Press LTD.New York [Rusen Press Limited, New York] (1993).
[0194] The extracellular domain (α β or γ δ) of TCR chain can also be engineered to be fused with heterologous transmembrane domain to express on cell surface.Such TCR can include fusion with CD3, CD28, CD8, 4-1BB and / or chimeric activation receptor (CAR) transmembrane or activation domain.TCR can also be one or more soluble proteins in the antigen binding domains comprising α β or γ δ chains.Such TCR can include TCR variable domains or its functional fragments (with or without TCR constant domains).Soluble TCR can be heterodimer molecule or single-chain molecule.
[0195] Fc domain
[0196] The protein complex of the present invention may include an Fc domain. For example, PD-L1 TxM includes an anti-PD-L1 scAb / huIL-15N72D: anti-PD-L1 scAb / huIL-15RαSu / huIgG1 Fc fusion complex. Fusion proteins combining the Fc region of IgG with the domain of another protein (e.g., various cytokines and soluble receptors) have been reported (see, e.g., Capon et al., Nature [Nature], 337:525-531, 1989; Chamow et al., Trends Biotechnol. [Biotechnology Trends], 14:52-60, 1996); U.S. Patent Nos. 5,116,964 and 5,541,087). The prototype fusion protein is a homodimeric protein connected by cysteine residues in the IgG Fc hinge region, producing a protein similar to that without heavy chain variable and C Hl The fusion protein of Fc domain is a kind of molecule of IgG molecule of light chain.The dimer property of fusion protein comprising Fc domain can be advantageous in providing higher-order interaction (i.e. bivalent or bispecific binding) with other molecules.Due to structural homology, Fc fusion protein shows in vivo pharmacokinetic characteristics comparable to human IgG with similar isotype.IgG class immunoglobulin is the most abundant protein in human blood, and its circulation half-life can be up to 21 days.In order to extend the circulation half-life of IL-15 or IL-15 fusion protein and / or increase its biological activity, the fusion protein complex containing IL-15 domain non-covalently bound to IL-15Rα is described herein, and the IL-15Rα is covalently connected to the Fc part of human heavy chain IgG protein.
[0197] The term "Fc" refers to a fragment crystallizable region, which is a constant region of an antibody, and the region interacts with some proteins of a cell surface receptor (referred to as an Fc receptor) and a complement system. Such "Fc" is in a dimer form. The original immunoglobulin source of natural Fc is preferably human-derived, and can be any immunoglobulin, although IgG1 and IgG2 are preferred. Natural Fc consists of monomeric polypeptides, which can be connected into dimer or polymeric forms by covalent (i.e., disulfide bonds) and non-covalent association. Depending on the class (e.g., IgG, IgA, IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, IgGA2), the number of intermolecular disulfide bonds between the monomer subunits of natural Fc molecules is in the range of from 1 to 4. An example of natural Fc is a disulfide-linked dimer produced by papain digestion of IgG (see Ellison et al. (1982), Nucleic Acids Res. [Nucleic Acids Research] 10: 4071-9). As used herein, the term "native Fc" is universal for monomeric, dimer and multimeric forms. The Fc domain contains binding sites for protein A, protein G, various Fc receptors and complement proteins. In some embodiments, the Fc domain of the complex can interact with Fc receptors to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and / or antibody-dependent cellular phagocytosis (ADCP). In other applications, the complex comprises an Fc domain (e.g., IgG4 Fc) that cannot effectively mediate ADCC or ADCP.
[0198] In some embodiments, the term "Fc variant" refers to a molecule or sequence modified from a native Fc, but still comprising a binding site for the salvage receptor FcRn. International applications WO 97 / 34631 and WO 96 / 32478 describe exemplary Fc variants, as well as interactions with salvage receptors, and are hereby incorporated by reference. Therefore, the term "Fc variant" comprises a molecule or sequence humanized from a non-human native Fc. In addition, the native Fc comprises sites that can be removed because they provide structural features or biological activities that are not required for the fusion molecules of the present invention. Thus, in certain embodiments, the term "Fc variant" encompasses molecules or sequences that alter one or more native Fc sites or residues that affect or participate in: (1) disulfide bond formation; (2) incompatibility with a selected host cell; (3) N-terminal heterogeneity after expression in a selected host cell; (4) glycosylation; (5) interaction with complement; (6) binding to Fc receptors other than salvage receptors; (7) antibody-dependent cellular cytotoxicity (ADCC); or (8) antibody-dependent cellular phagocytosis (ADCP). These changes may increase or decrease any one or more of these Fc properties. In certain embodiments, the Fc region is a human IgG Fc and comprises one or more amino acid substitutions, deletions, insertions or modifications (hydrocarbon chemical modifications) introduced at any position within the Fc region. In certain embodiments, the human IgG Fc variant comprises one or more amino acid residue mutants and has an increased binding affinity for FcRn compared to a wild-type Fc region that does not comprise one or more amino acid residue mutants. For hinged neonatal receptors, Fc binding interactions are necessary, but not limited to increasing the serum half-life of IgG. Therefore, in certain embodiments, relative to an unmodified Fc region having the same amino acid sequence but not comprising one or more amino acid substitutions, deletions, insertions or modifications (referred to herein as "comparable molecules"), such as, for example, containing naturally occurring amino acid residues at corresponding positions in the Fc region, human IgG Fc variants exhibit altered binding affinity for at least one or more Fc ligands (e.g., FcRns). Fc variants are described in further detail below.
[0199] The term "Fc domain" encompasses native Fc and Fc variant molecules and sequences as defined above. Like Fc variants and variants of native Fc, the term "Fc domain" includes molecules in monomeric or multimeric form, whether digested from intact antibodies or produced by recombinant gene expression or by other means.
[0200] Fusion protein complex
[0201] The present invention provides a fusion protein complex. In some cases, the first protein comprises a first biologically active polypeptide covalently linked to interleukin-15 (IL-15) or a functional fragment thereof; and the second protein comprises a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor α (IL-15Rα) polypeptide or a functional fragment thereof, wherein the IL-15 domain of the first protein binds to the soluble IL-15Rα domain of the second protein, thereby forming a soluble fusion protein complex. The fusion protein complex of the present invention also comprises an immunoglobulin Fc domain or a functional fragment thereof connected to one or both of the first and second proteins. Preferably, the Fc domains connected to the fusion protein interact to form a fusion protein complex. Such complexes can be stabilized by disulfide bond formation between immunoglobulin Fc domains. In one aspect, the soluble fusion protein complex of the present invention includes an IL-15 polypeptide, an IL-15 variant or a functional fragment thereof and a soluble IL-15Rα polypeptide or a functional fragment thereof, wherein one or both of the IL-15 and IL-15Rα polypeptides further include an immunoglobulin Fc domain or a functional fragment thereof.
[0202] In certain embodiments, one or both of the first and second proteins comprise an antibody or a functional fragment thereof. For example, one of the binding domains comprises a soluble anti-PD-L1 single-chain antibody or a functional fragment thereof. In another embodiment, the other or second binding domain comprises an anti-CTLA4 single-chain antibody or a disease antigen-specific antibody or a functional fragment thereof. In one embodiment, the present invention provides a PD-L1 TxM comprising a soluble anti-PD-L1 scAb / huIL-15N72D: anti-PD-L1 scAb / huIL-15RαSu / huIgG1 Fc fusion protein complex. In this embodiment, the huIL-15N72D and huIL-15RαSu domains on the two anti-PD-L1 scAb / huIL-15RαSu / huIgG1 Fc fusion proteins interact with the huIgG1 domain to form a multi-chain fusion protein complex.
[0203] As used herein, the term "biologically active polypeptide" or "effector molecule" means an amino acid sequence, such as a protein, polypeptide, or peptide; a sugar or polysaccharide; a lipid or glycolipid, glycoprotein, or lipoprotein, which can produce a desired effect as discussed herein. Effector molecules also include chemical agents. Effector molecule nucleic acids encoding biologically active or effector proteins, polypeptides, or peptides are also contemplated. Thus, suitable molecules include regulatory factors, enzymes, antibodies, or drugs as well as DNA, RNA, and oligonucleotides. The biologically active polypeptide or effector molecule can be naturally occurring or can be synthesized from known components, for example, by recombinant or chemical synthesis, and can include heterologous components. As judged by standard molecular quantitative techniques (e.g., centrifugation or SDS-polyacrylamide gel electrophoresis), biologically active polypeptides or effector molecules are generally between about 0.1KD and 100KD or higher to about 1000KD, preferably between about 0.1KD, 0.2KD, 0.5KD, 1KD, 2KD, 5KD, 10KD, 20KD, 30KD and 50KD. The desired effects of the present invention include, but are not limited to, for example, forming a fusion protein complex of the present invention with increased binding activity, killing target cells, such as inducing cell proliferation or cell death, triggering an immune response, preventing or treating a disease, or as a detection molecule for diagnostic purposes. For such detection, the following assay can be used, such as an assay comprising the following consecutive steps: culturing cells to proliferate, and contacting these cells with the fusion complex of the present invention, and then evaluating whether the fusion complex inhibits the further development of these cells.
[0204] According to the present invention, covalently linking an effector molecule to a fusion protein complex of the present invention provides many significant advantages. A fusion protein complex of the present invention comprising a single effector molecule (including peptides of known structure) can be produced. In addition, a variety of effector molecules can be produced in similar DNA vectors. In other words, a library of different effector molecules can be connected to a fusion protein complex for identifying infected cells or diseased cells. In addition, for therapeutic applications, instead of administering the fusion protein complex of the present invention to a subject, a DNA expression vector encoding the fusion protein complex can be administered for in vivo expression of the fusion protein complex. This method avoids the expensive purification steps typically associated with the preparation of recombinant proteins, and avoids the complexity of antigen uptake and processing associated with conventional methods.
[0205] As indicated, the components of the fusion proteins disclosed herein (e.g., effector molecules, such as cytokines, chemokines, growth factors, protein toxins, immunoglobulin domains or other biologically active molecules and any peptide linkers) can be organized in almost any manner (provided that the fusion protein has the intended function). In particular, if desired, each component of the fusion protein can be separated from another group by at least one suitable peptide linker sequence. In addition, the fusion protein can include a tag, for example, to facilitate modification, identification and / or purification of the fusion protein. More specific fusion proteins are in the embodiments described below.
[0206] Connectors
[0207] In certain embodiments, the fusion protein complex of the present invention further comprises a flexible linker sequence inserted between the IL-15 or IL-15Rα domain and the biologically active polypeptide. The linker sequence should allow for efficient positioning of the biologically active polypeptide with respect to the IL-15 or IL-15Rα domain to allow for functional activity of the two domains.
[0208] In some cases, the soluble fusion protein complex has a linker, wherein the first biologically active polypeptide is covalently linked to IL-15 (or a functional fragment thereof) via a polypeptide linker sequence. In other aspects, the soluble fusion protein complex as described herein has a linker, wherein the second biologically active polypeptide is covalently linked to the IL-15Rα polypeptide (or a functional fragment thereof) via a polypeptide linker sequence.
[0209] The linker sequence is preferably encoded by a nucleotide sequence that produces a peptide that can effectively position the binding groove of the binding domain of the TCR molecule for recognizing the presenting antigen or the antibody molecule for recognizing the antigen. As used herein, the phrase "effective positioning of the biologically active polypeptide with respect to the IL-15 or IL-15Rα domain" or other similar phrases is intended to indicate that the biologically active polypeptide connected to the IL-15 or IL-15Rα domain is positioned so that the IL-15 or IL-15Rα domains can interact with each other to form a protein complex. For example, the IL-15 or IL-15Rα domain is effectively positioned to allow interaction with immune cells to initiate or inhibit an immune response, or to inhibit or stimulate cell development.
[0210] The fusion complex of the present invention preferably also includes a flexible linker sequence inserted between the IL-15 or IL-15Rα domain and the immunoglobulin Fc domain. The linker sequence should allow the effective positioning of the Fc domain, the biologically active polypeptide, and the IL-15 or IL-15Rα domain to allow the functional activity of each domain. For example, the Fc domain is effectively positioned to allow the formation of an appropriate fusion protein complex and / or interact with Fc receptors on immune cells or proteins of the complement system to stimulate Fc-mediated effects, including opsonization, cell lysis, degranulation of mast cells, basophils, and eosinophils, and other Fc receptor-dependent processes; activation of the complement pathway; and enhanced in vivo half-life of the fusion protein complex.
[0211] Linker sequences can also be used to join two or more biologically active polypeptides to produce a single-chain molecule with the desired functional activity.
[0212] Preferably, the linker sequence comprises from about 7 to 20 amino acids, more preferably from about 10 to 20 amino acids. The linker sequence is preferably flexible so that the biologically active polypeptide or effector molecule is not maintained in a single undesirable conformation. The linker sequence can be used, for example, to separate the recognition site from the fused molecule. Specifically, the peptide linker sequence can be positioned between the biologically active polypeptide and the effector molecule, for example, to chemically crosslink it and provide molecular flexibility. The linker preferably mainly comprises amino acids with small side chains, such as glycine, alanine and serine, to provide flexibility. Preferably, about 80% or 90% or more of the linker sequence comprises glycine, alanine or serine residues (particularly glycine and serine residues).
[0213] Various linker sequences can be used, including any of a number of flexible linker designs that have been successfully used to link antibody variable regions together (see, Whitlow, M. et al., (1991) Methods: A Companion to Methods in Enzymology, 2:97-105).
[0214] Pharmacotherapeutic agents
[0215] The present invention provides pharmaceutical compositions comprising fusion protein complexes, which are used as therapeutic agents. In one aspect, the fusion protein complexes of the present invention are systemically administered, for example, formulated in a pharmaceutically acceptable buffer (such as saline). Preferred routes of administration include, for example, instillation into the bladder, subcutaneous, intravenous, intraperitoneal, intramuscular, intratumoral or intradermal injection, which provide continuous, sustained or effective levels of the composition in the patient. Treatment of human patients or other animals is performed using a therapeutically effective amount of the therapeutic agent identified herein in a physiologically acceptable carrier. Suitable carriers and their formulations are described, for example, in Remington's Pharmaceutical Sciences edited by EWMartin. The amount of the therapeutic agent to be administered varies according to the mode of administration, the age and weight of the patient, and the clinical symptoms of neoplasia. Typically, the amount will be within the range of the amount used of other agents, which are used in the treatment of other diseases associated with neoplasia, autoimmune diseases or infectious diseases, although in some cases a lower amount will be required due to the increased specificity of the compound. The compound is administered in an amount that enhances the subject's immune response, or reduces the proliferation, survival, or invasiveness of neoplastic cells, infected cells, or autoimmune cells, as determined by methods known to those skilled in the art.
[0216] Formulation of pharmaceutical compositions
[0217] The fusion protein complex of the present invention for treating neoplasia, infectious disease or autoimmune disease is administered by any suitable means, which results in a concentration of the therapeutic agent combined with other components that is effective in improving, reducing or stabilizing the neoplasia, infectious disease or autoimmune disease. The fusion protein complex of the present invention can be contained in any suitable carrier substance in any suitable amount, and is generally present in an amount of 1%-95% by weight of the total weight of the composition. The composition can be provided in a dosage form suitable for parenteral (e.g., subcutaneous, intravenous, intramuscular, intracapsular, intratumoral or intraperitoneal) administration. For example, pharmaceutical compositions are formulated in accordance with conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
[0218] Human dosages are initially determined by extrapolation from the amount of compound used in mice or non-human primates, as the skilled artisan recognizes that it is routine in the art to modify dosages in humans compared to animal models. For example, dosages may vary from about 1 μg of compound / kg body weight to about 5000 mg of compound / kg body weight; or from about 5 mg / kg body weight to about 4,000 mg / kg body weight; or from about 10 mg / kg body weight to about 3,000 mg / kg body weight; or from about 50 mg / kg body weight to about 2000 mg / kg body weight; or from about 100 mg / kg body weight to about 1000 mg / kg body weight; or from about 150 mg / kg body weight to about 500 mg / kg body weight. For example, the dosage is about 1, 5, 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, or 5,000 mg / kg body weight. Alternatively, the dosage is in the range of about 5 mg compound / Kg body weight to about 20 mg compound / kg body weight. In another example, the dosage is about 8, 10, 12, 14, 16 or 18 mg / kg body weight. Preferably, the fusion protein complex is administered at 0.5 mg / kg-about 10 mg / kg (e.g., 0.5, 1, 3, 5, 10 mg / kg). Of course, depending on the results of the initial clinical trial and the needs of the specific patient, the dosage may be adjusted upward or downward as routinely performed in such a treatment regimen.
[0219] The pharmaceutical composition is formulated with a suitable excipient into a pharmaceutical composition that releases the therapeutic agent in a controlled manner after administration. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, molecular complexes, nanoparticles, patches, and liposomes. Preferably, the fusion protein complex is formulated in an excipient suitable for parenteral administration.
[0220] Parenteral compositions
[0221] The pharmaceutical composition comprising the fusion protein complex of the present invention is administered parenterally by injection, infusion or implantation (subcutaneous, intravenous, intramuscular, intratumoral, intracapsular, intraperitoneal), in a dosage form, formulation or via a suitable delivery device or implant comprising a conventional non-toxic pharmaceutically acceptable carrier and adjuvant. Formulations and preparations of such compositions are well known to those skilled in the art of pharmaceutical formulations. Formulations can be found in Remington: The Science and Practice of Pharmacy, supra.
[0222] Compositions comprising the fusion protein complex of the present invention for parenteral use are provided in unit dosage form (e.g., in single-dose ampoules). Alternatively, the composition is provided in a vial containing several doses, and a suitable preservative (see below) may be added thereto. The composition is in the form of a solution, a suspension, an emulsion, an infusion device, or a delivery device for implantation, or is presented as a dry powder reconstituted with water or another suitable vehicle before use. In addition to the active agent that reduces or improves neoplasia, infectious diseases, or autoimmune diseases, the composition also includes a suitable parenteral acceptable carrier and / or excipient. One or more active therapeutic agents may be incorporated into microspheres, microcapsules, nanoparticles, liposomes for controlled release. In addition, the composition may include a suspending agent, a solubilizing agent, a stabilizer, a pH adjusting agent, a tension adjusting agent, and / or a dispersing agent.
[0223] As described above, the pharmaceutical composition comprising the fusion protein complex of the present invention can be in a form suitable for aseptic injection. In order to prepare such a composition, one or more suitable active therapeutic agents are dissolved or suspended in a liquid vehicle acceptable to the parenteral. Acceptable vehicles and solvents that can be used are water, water adjusted to a suitable pH by adding an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer's solution and isotonic sodium chloride solution and dextrose solution. Aqueous formulations may also contain one or more preservatives (e.g., methyl parahydroxybenzoate, ethyl parahydroxybenzoate or n-propyl parahydroxybenzoate). In the case where one of the compounds is only trace or slightly soluble in water, a dissolution enhancer or solubilizer may be added, or the solvent may include 10% w / w-60% w / w of propylene glycol.
[0224] The present invention provides a method for treating neoplasia, infectious disease or autoimmune disease or its symptoms, the method comprising administering to a subject (e.g., a mammal, such as a human) a therapeutically effective amount of a pharmaceutical composition comprising a compound of the general formula herein. Thus, one embodiment is a method for treating a subject suffering from or susceptible to neoplasia, infectious disease or autoimmune disease or its symptoms. The method comprises the following steps: administering to a mammal a therapeutic amount of a compound sufficient to treat the disease or disorder or its symptoms under conditions that treat the disease or disorder.
[0225] The methods herein include administering an effective amount of a compound described herein or a composition described herein to a subject (including a subject identified as needing such treatment) to produce such an effect. Identifying a subject in need of such treatment can be the judgment of the subject or a health care professional, and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or diagnostic method).
[0226] The treatment methods (including prophylactic treatments) of the present invention generally comprise administering a therapeutically effective amount of a compound herein (e.g., a compound of the formula herein) to a subject in need thereof (e.g., an animal, a human, including a mammal, particularly a human). Such treatment will be appropriately administered to a subject (particularly a human) suffering from, having, susceptible to, or at risk of developing a tumor, an infectious disease, an autoimmune disease, a disorder, or a symptom thereof. The determination of a subject "at risk" can be made by any objective or subjective determination made by a diagnostic test or the opinion of a subject or health care provider (e.g., genetic testing, enzyme or protein markers, markers (as defined herein), family history, etc.). The fusion protein complexes of the present invention can be used to treat any other disorder in which an increased immune response is desired.
[0227] The present invention also provides a method for monitoring treatment progress. The method comprises the following steps: in a subject suffering from or susceptible to a disorder or its symptoms associated with neoplasia, a diagnostic marker (marker) (e.g., any target, protein or its indicator described herein regulated by the compound herein, etc.) or a diagnostic measurement (e.g., screening, determination) level is determined, wherein the subject has been administered a therapeutic amount of the compound herein sufficient to treat the disease or its symptoms. The level of the marker determined in the method can be compared with the known level of the marker in a healthy normal control or other sick patient to determine the disease state of the subject. In some cases, a second level of the marker in the subject is determined at a later time point than the determination of the first level, and the two levels are compared to monitor the course of the disease or the efficacy of the treatment. In some aspects, the pre-treatment level of the marker in the subject is determined before treatment is started according to the present invention; then the pre-treatment level of the marker can be compared with the level of the marker in the subject after treatment starts to determine the efficacy of the treatment.
[0228] Combination therapy
[0229] Optionally, the fusion protein complexes of the invention are administered in combination with any other standard therapy; these methods are known to those skilled in the art and are described in Remington's Pharmaceutical Sciences by EW Martin. If desired, the fusion protein complexes of the invention are administered in combination with any conventional anti-tumor therapy, including but not limited to immunotherapy, therapeutic antibodies, targeted therapy, surgery, radiation therapy, or chemotherapy.
[0230] Kit or drug system
[0231] The pharmaceutical composition comprising the fusion protein complex of the present invention can be assembled into a kit or a pharmaceutical system for use in improving neoplasia, infectious diseases or autoimmune diseases. The kit or pharmaceutical system according to the aspects of the present invention includes a carrier means (e.g., a box, a carton, a tube) having one or more container devices (e.g., vials, tubes, ampoules, bottles, etc.) in a defined space therein. The kit or pharmaceutical system of the present invention may also include relevant instructions for using the fusion protein complex of the present invention.
[0232] Recombinant protein expression
[0233] Generally, preparation of the fusion protein complexes of the invention (eg, components of the TxM complex) can be accomplished by the methods disclosed herein and by recognized recombinant DNA techniques.
[0234] Generally, recombinant polypeptides are produced by transforming suitable host cells with all or part of the nucleic acid molecules encoding polypeptides or their fragments in suitable expression vectors. It will be appreciated by those skilled in the art of molecular biology that any of a variety of expression systems can be used to provide recombinant proteins. The clear host cells used are not important to the present invention. Recombinant polypeptides can be produced in almost any eukaryotic host (e.g., Saccharomyces cerevisiae; insect cells (e.g., Sf21 cells); or mammalian cells (e.g., NIH 3T3, HeLa, or preferably COS cells)). Such cells can be obtained from a variety of sources (e.g., American Type Culture Collection [U.S. Germplasm Preservation Center], Rockland, Maryland; see also, e.g., Ausubel et al., Current Protocol in Molecular Biology [Molecular Biology Modern Methods], New York: John Wiley and Sons [New York: John Wiley and Sons Publishing Company], 1997). The selection of transfection methods and expression vectors depends on the selected host system. Transformation methods are described in, e.g., Ausubel et al. (supra); expression vectors may be selected from those provided in, e.g., Cloning Vectors: A Laboratory Manual (Pouwels et al., 1985, Supplement 1987).
[0235] There are a variety of expression systems for producing recombinant polypeptides. Expression vectors that can be used to produce such polypeptides include, but are not limited to, chromosomal, episomal, and viral-derived vectors, such as vectors derived from bacterial plasmids, derived from bacteriophages, derived from transposons, derived from yeast episomes, derived from insertion elements, derived from yeast chromosomal elements; vectors derived from viruses such as baculovirus, papova virus (papova virus) (such as SV40), vaccinia virus, adenovirus, fowl pox virus, pseudorabies virus, and retrovirus, and vectors derived from combinations thereof.
[0236] Once after expressing the recombinant polypeptide, for example, affinity chromatography is used to separate. In one example, antibodies (for example, produced as described herein) produced for the polypeptide can be attached to a column and used to separate the recombinant polypeptide. Before affinity chromatography, the cracking and classification of the cell carrying the polypeptide can be carried out by standard methods (see, for example, Ausubel et al., the same). Once separated, if necessary, the recombinant protein can be further purified, for example, by high performance liquid chromatography (see, for example, Fisher, Laboratory Techniques in Biochemistry and Molecular Biology [biochemistry and molecular biology laboratory technology], editor, Work and Burdon, Elsevier Publishing Company (Elsevier), 1980).
[0237] As used herein, the biologically active polypeptides or effector molecules of the present invention may include factors such as cytokines, chemokines, growth factors, protein toxins, immunoglobulin domains, or other biologically active proteins (such as enzymes). Likewise, biologically active polypeptides may include conjugates with other compounds (such as non-protein toxins, cytotoxic agents, chemotherapeutic agents, detectable markers, radioactive substances, etc.).
[0238] The cytokines of the present invention are defined by any factor produced by a cell that affects other cells and is responsible for any of the many multiple effects of cellular immunity. Examples of cytokines include, but are not limited to, the IL-2 family, interferon (IFN), IL-10, IL-1, IL-17, TGF and TNF cytokine families, and are not limited to IL-1 to IL-35, IFN-α, IFN-β, IFNγ, TGF-β, TNF-α, and TNFβ.
[0239] In one aspect of the invention, the first protein comprises a first biologically active polypeptide covalently linked to an interleukin-15 (IL-15) domain or a functional fragment thereof. IL-15 is a cytokine that affects T cell activation and proliferation. The IL-15 activity that affects immune cell activation and proliferation is similar to IL-2 in some respects, although the basic differences have been well characterized (Waldmann, TA, 2006, Nature Rev. Immunol. [Natural Review Immunology] 6: 595-601).
[0240] In another aspect of the present invention, the first protein comprises an interleukin-15 (IL-15) domain, which is an IL-15 variant (also referred to herein as an IL-15 mutant). The IL-15 variant preferably comprises an amino acid sequence different from a natural (or wild-type) IL-15 protein. The IL-15 variant preferably binds to an IL-15Rα polypeptide and acts as an IL-15 agonist or antagonist. Preferably, an IL-15 variant with agonist activity has superagonist activity. The IL-15 variant can act as an IL-15 agonist or antagonist independently of its association with IL-15Rα. Compared with wild-type IL-15, an IL-15 agonist is exemplified by a comparable or increased biological activity. An IL-15 antagonist is exemplified by a reduced biological activity compared to wild-type IL-15 or by the ability to inhibit IL-15-mediated responses. In some examples, an IL-15 variant binds to an IL-15RβγC receptor with increased or decreased activity. In some cases, the sequence of the IL-15 variant has at least one amino acid change (e.g., substitution or deletion) compared to the native IL-2 sequence, and such changes result in IL-15 agonist or antagonist activity. Preferably, the amino acid substitution / deletion is in the domain of IL-15 that interacts with IL-15Rβ and / or γC. More preferably, the amino acid substitution / deletion does not affect the ability to bind to the IL-15Rα polypeptide or produce IL-15 variants. Suitable amino acid substitutions / deletions for producing IL-15 variants can be identified based on the putative or known IL-15 structure, by comparing IL-15 with homologous molecules (e.g., IL-2) with known structures as provided herein by rational or random mutagenesis and functional assays or other empirical methods. In addition, suitable amino acid substitutions can be conservative or non-conservative changes and insertions of additional amino acids. Preferably, the IL-15 variant of the present invention comprises one or more amino acid substitutions / deletions at positions 6, 8, 10, 61, 65, 72, 92, 101, 104, 105, 108, 109, 111, or 112 of the mature human IL-15 sequence; in particular, D8N ("D8" refers to the amino acid and residue position in the native mature human IL-15 sequence, and "N" refers to the substituted amino acid residue at the position in the IL-15 variant), I6S, D8A, D61A, N65A, N72R, V104P or Q108A substitutions form IL-15 variants with antagonist activity, and N72D substitutions form IL-15 variants with agonist activity.
[0241] Chemokines, similar to cytokines, are defined as any chemical factor or molecule that, when exposed to other cells, is responsible for any of the many multiple effects of cellular immunity. Suitable chemokines may include, but are not limited to, the CXC, CC, C, and CX3C chemokine families, and are not limited to CCL-1 to CCL-28, CXC-1 to CXC-17, XCL-1, XCL-2, CX3CL1, MIP-1b, IL-8, MCP-1, and Rantes.
[0242] Growth factors include any molecule that, when exposed to a particular cell, induces proliferation and / or differentiation of the affected cell. Growth factors include proteins and chemical molecules, some of which include: GM-CSF, G-CSF, human growth factor, and stem cell growth factor. Additional growth factors may also be suitable for the purposes described herein.
[0243] Toxin or cytotoxic agent include any substance, when it is exposed to cells, has lethal effect or inhibitory effect on growth. More specifically, effector molecule can be, for example, cytotoxin of plant or bacterial origin, for example diphtheria toxin (DT), Shiga toxin, abrin, cholera toxin, ricin, saporin, Pseudomonas exotoxin (PE), pokeweed antiviral protein, or gelonin. The biologically active fragments of this type of toxin are well known in the art, and include, for example, DT A chain and ricin A chain. In addition, toxin can be an agent active on the cell surface, for example, as phospholipase (e.g., phospholipase C).
[0244] Furthermore, the effector molecule may be a chemotherapeutic drug such as, for example, vindesine, vincristine, vinblastine, methotrexate, doxorubicin, bleomycin or cisplatin.
[0245] In addition, the effector molecule can be a detectably labeled molecule suitable for diagnostic or imaging studies. Such labels include biotin or streptavidin / avidin, detectable nanoparticles or crystals, enzymes or catalytically active fragments thereof, fluorescent labels (e.g., green fluorescent protein), FITC, phycoerythrin, cychome, Texas Red, or quantum dots; radionuclides (e.g., iodine-131, yttrium-90, rhenium-188, or bismuth-212); phosphorescent or chemiluminescent molecules or labels detectable by PET, ultrasound, or MRI (e.g., contrast agents based on Gd or paramagnetic metal ions). For disclosures on making and using proteins comprising effectors or tags, see, e.g., Moskaug, et al. J. Biol. Chem, 264, 15709 (1989); Pastan, I. et al. Cell, 47, 641, 1986; Pastan et al., Recombinant Toxins as Novel Therapeutic Agents, Ann. Rev. Biochem, 61, 331, (1992); "Chimeric Toxins" Olsnes and Phil, Pharmac. Ther., 25, 355 (1982); published PCT application No. WO 94 / 29350; published PCT application No. WO 94 / 04689; published PCT application No. WO 2005046449 and U.S. Patent No. 5,620,939.
[0246] Protein fusion or conjugated complexes comprising covalently linked IL-15 and IL-15Rα domains have several important uses. For example, a protein fusion or conjugated complex comprising an anti-PD-L1 scAb can be used to deliver the IL-15:IL-15Rα complex to certain cells, such as tumor cells expressing PD-L1. Therefore, the protein fusion or conjugated complex provides a way to selectively destroy or kill cells containing ligands. Examples of cells or tissues that can be destroyed or killed by protein fusion or conjugated complexes include tumors and viral or bacterially infected cells that express one or more ligands. Cells or tissues that are susceptible to damage or killing can be easily determined by the methods disclosed herein.
[0247] The IL-15 and IL-15Rα polypeptides of the present invention correspond appropriately in terms of amino acid sequence to naturally occurring IL-15 and IL-15Rα molecules, such as human, mouse or other rodent, or other mammalian IL-15 and IL-15Rα molecules. The sequences of these polypeptides and encoding nucleic acids are known in the literature, including human interleukin 15 (IL15) mRNA-GenBank: U14407.1 (incorporated herein by reference), Mus musculus interleukin 15 (IL15) mRNA-GenBank: U14332.1 (incorporated herein by reference), human interleukin-15 receptor alpha chain precursor (IL15RA) mRNA-GenBank: U31628.1 (incorporated herein by reference), Mus musculus interleukin 15 receptor alpha chain-GenBank: BC095982.1 (incorporated herein by reference).
[0248] In some cases, it is useful to multivalent the protein fusion or conjugate complex of the present invention, for example, to increase the valence of the sc-antibody. In particular, the interaction between the IL-15 and IL-15Rα domains of the fusion protein complex provides a way to produce a multivalent complex. In addition, multivalent fusion proteins can be prepared by covalent or non-covalent connection between one and four proteins (same or different) using, for example, standard biotin-streptavidin labeling techniques, or by conjugation with a suitable solid support (e.g., latex beads). Chemically cross-linked proteins (e.g., cross-linked with dendrimers) are also suitable multivalent substances. For example, proteins can be modified by including sequences encoding tag sequences that can be modified (e.g., biotinylated BirA tags) or amino acid residues (such as Cys or His) with chemically reactive side chains. Such amino acid tags or chemically reactive amino acids can be located in multiple positions of the fusion protein, preferably at the distal end of the active site of the biologically active polypeptide or effector molecule. For example, the C-terminus of a soluble fusion protein can be covalently linked to a tag or other fusion proteins comprising one or more such reactive amino acids. Suitable side chains can be included to connect two or more fusion protein chemistry to suitable dendrimers or other nanoparticles to produce multivalent molecules. Dendrimers are synthetic chemical polymers that can have any of many different functional groups on their surface (D. Tomalia, Aldrichimica Acta [Aldrich Chemical Company Magazine], 26: 91: 101 (1993)). Exemplary dendrimers used according to the present invention include, for example, E9 starburst polyamine dendrimers and E9 burning polyamine dendrimers, which polymers can be connected to cystine residues. Exemplary nanoparticles include liposomes, core-shell particles or particles based on PLGA.
[0249] In another aspect, one or both polypeptides of the fusion protein complex comprise an immunoglobulin domain. Alternatively, the protein binding domain-IL-15 fusion protein can be further linked to an immunoglobulin domain. Preferably, the immunoglobulin domain comprises a region that allows interaction with other immunoglobulin domains, thereby forming a multi-chain protein as provided above. For example, an immunoglobulin heavy chain region (e.g., IgG1 C H 2-C H 3) can stably interact to produce an Fc region. Preferred immunoglobulin domains including Fc domains also include regions with effector functions (including Fc receptor or complement protein binding activity) and / or with glycosylation sites. In some aspects, the immunoglobulin domain of the fusion protein complex includes mutations that reduce or enhance Fc receptor or complement binding activity or glycosylation or dimerization, thereby affecting the biological activity of the resulting protein. For example, an immunoglobulin domain containing a mutation that reduces binding to an Fc receptor can be used to produce a fusion protein complex of the present invention, and the complex has a lower binding activity to cells carrying Fc receptors, which may be advantageous for reagents designed to recognize or detect specific antigens.
[0250] Nucleic acids and vectors
[0251] The present invention further provides nucleic acid sequences, and in particular DNA sequences encoding fusion proteins of the present invention (e.g., components of TxM). Preferably, the DNA sequence is carried by a vector suitable for extrachromosomal replication (e.g., a phage, virus, plasmid, phagemid, cosmid, YAC or episome). In particular, a DNA vector encoding the desired fusion protein can be used to facilitate the preparation method described herein and obtain a significant amount of fusion protein. The DNA sequence can be inserted into a suitable expression vector, i.e., a vector containing the elements necessary for transcription and translation of the inserted protein-encoding sequence. A variety of host-vector systems can be used to express protein-encoding sequences. These include mammalian cell systems infected with viruses (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with viruses (e.g., baculovirus); microorganisms (e.g., yeast containing yeast vectors, or bacteria transformed with phage DNA, plasmid DNA or cosmid DNA). Depending on the host-vector system utilized, any of a number of suitable transcription and translation elements can be used. See, Sambrook et al., supra and Ausubel et al., supra.
[0252] The present invention includes a method for preparing a soluble fusion protein complex, the method comprising introducing into a host cell a DNA vector as described herein encoding a first and a second protein; culturing the host cell in a culture medium under conditions sufficient to express the fusion protein in the cell or culture medium and to allow association between the IL-15 domain of the first protein and the soluble IL-15Rα domain of the second protein to form a soluble fusion protein complex; and purifying the soluble fusion protein complex from these host cells or culture medium.
[0253] Typically, preferred DNA vectors according to the present invention comprise nucleotide sequences linked by phosphodiester bonds in 5' to 3' direction, wherein a first cloning site for introducing a first nucleotide sequence encoding a biologically active polypeptide is operably linked to a sequence encoding an effector molecule.
[0254] The fusion protein components encoded by the DNA vector can be provided in cassette form. The term "cassette" means that each component can easily replace another component by standard recombination methods. In particular, when the encoded fusion complex is to be used to combat pathogens that may have serotypes or have the ability to develop into serotypes, a DNA vector configured in cassette form is particularly desired.
[0255] In order for the vector to encode the fusion protein complex, the sequence encoding the biologically active polypeptide is linked to the sequence encoding the effector peptide by using a suitable ligase. The DNA encoding the presenting peptide can be obtained by isolating DNA from a natural source (e.g., from a suitable cell line) or by known synthetic methods (e.g., the phosphotriester method). See, for example, Oligonucleotide Synthesis, IRL Press (MJ Gait, ed., 1984). Synthetic oligonucleotides can also be prepared using commercially available automatic oligonucleotide synthesizers. Once isolated, the gene encoding the biologically active polypeptide can be amplified by polymerase chain reaction (PCR) or other methods known in the art. Suitable PCR primers for amplifying the biologically active polypeptide gene can add restriction sites to the PCR product. The PCR product preferably includes splice sites for the effector peptide and the leader sequence necessary for proper expression and secretion of the biologically active polypeptide-effector fusion complex. The PCR product also preferably includes a sequence encoding a linker sequence, or a restriction enzyme site for connecting such a sequence.
[0256] Fusion proteins described herein are preferably produced by standard recombinant DNA techniques. For example, once the DNA molecules encoding biologically active polypeptides are isolated, the sequence can be connected to another DNA molecule encoding effector polypeptides. The nucleotide sequence encoding biologically active polypeptides can be directly connected to the DNA sequence encoding effector peptides, or more typically, the DNA sequence encoding the linker sequence as described herein can be inserted between the sequence encoding biologically active polypeptides and the sequence encoding effector peptides, and connected using a suitable ligase. The resulting hybrid DNA molecule can be expressed in a suitable host cell to produce a fusion protein complex. The DNA molecules are connected to each other in a 5' to 3' direction so that after connection, the translation frame of the encoded polypeptide is not changed (that is, the DNA molecules are connected to each other in the frame). The resulting DNA molecule encodes the fusion protein in the frame.
[0257] Other nucleotide sequences may also be included in the gene construct. For example, a promoter sequence that controls the expression of a sequence encoding a biologically active polypeptide fused to an effector peptide, a leader sequence that directs the fusion protein to the cell surface or culture medium, may be included in the construct, or present in an expression vector inserted into the construct. Immunoglobulin or CMV promoters are particularly preferred.
[0258] In obtaining variant biologically active polypeptides, IL-15, IL-15Rα or Fc domain encoding sequences, one of ordinary skill in the art will recognize that the polypeptides can be modified by certain amino acid substitutions, additions, deletions and post-translational modifications without loss or reduction of biological activity. In particular, it is well known that conservative amino acid substitutions, i.e., substitution of one amino acid for another amino acid of similar size, charge, polarity and conformation, are unlikely to significantly alter protein function. The 20 standard amino acids that are components of proteins can be roughly classified into four groups of conservative amino acids as follows: the non-polar (hydrophobic) group includes alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine; the polar (uncharged, neutral) group includes asparagine, cysteine, glutamine, glycine, serine, threonine and tyrosine; the positively charged (basic) group includes arginine, histidine and lysine; and the negatively charged (acidic) group includes aspartic acid and glutamic acid. Replacing one amino acid in a protein with another amino acid in the same group is unlikely to have an adverse effect on the biological activity of the protein. In other cases, the amino acid position can be modified to reduce or enhance the biological activity of the protein. Such changes can be introduced randomly or via site-specific mutations based on known or assumed structural or functional properties of one or more target residues. After expressing the variant protein, changes in biological activity caused by the modification can be easily assessed using binding or functional assays.
[0259] Homology between nucleotide sequences can be determined by DNA hybridization analysis, wherein the stability of double-stranded DNA hybrids depends on the degree of base pairing that occurs. High temperature and / or low salt content conditions reduce the stability of the hybrid and can be changed to prevent annealing of sequences with less than the selected homology degree. For example, for sequences with about 55% GC content, hybridization and washing conditions of 40-50C, 6x SSC (sodium chloride / citrate buffer) and 0.1% SDS (sodium dodecyl sulfate) show about 60%-70% homology; hybridization and washing conditions of 50-65C, 1x SSC and 0.1% SDS show about 82%-97% homology; and hybridization and washing conditions of 52C, 0.1x SSC and 0.1% SDS show about 99%-100% homology. Various computer programs for comparing nucleotide and amino acid sequences (and measuring homology degrees) can also be obtained, and a list of commercially available and free software sources is found in the literature of Ausubel et al. (1999). Readily available algorithms for sequence comparison and multiple sequence alignment are the Basic Local Alignment Search Tool (BLAST) (Altschul et al., 1997) and the ClustalW program, respectively. BLAST is available on the World Wide Web at ncbi.nlm.nih.gov, and a version of ClustalW is available at 2.ebi.ac.uk.
[0260] The components of the fusion protein can be organized in almost any order, as long as each component is able to perform its intended function. For example, in one embodiment, the biologically active polypeptide is located at the C- or N-terminus of the effector molecule.
[0261] Preferred effector molecules of the present invention will have a size that contributes to the expected function of these domains. The effector molecules of the present invention can be prepared by a variety of methods (including well-known chemical cross-linking methods) and fused to biologically active polypeptides. See, for example, Means, GE and Feeney, RE (1974) in Chemical Modification of Proteins [Chemical Modification of Proteins], Holden-Day. See also, SS Wong (1991) in Chemistry of Protein Conjugation and Cross-Linking [Protein Conjugate and Cross-Linking Chemistry], CRC Press. However, it is generally preferred to use recombinant operations to prepare in-frame fusion proteins.
[0262] As described above, the fusion molecules or conjugate molecules according to the present invention can be organized in several ways. In an exemplary configuration, the C-terminus of the biologically active polypeptide is operably linked to the N-terminus of the effector molecule. If desired, the connection can be achieved by recombinant methods. However, in another configuration, the N-terminus of the biologically active polypeptide is linked to the C-terminus of the effector molecule.
[0263] Alternatively or additionally, one or more additional effector molecules may be inserted into the biologically active polypeptide or conjugate complex as desired.
[0264] Vectors and expression
[0265] Many strategies can be used to express the components of the fusion protein complex of the present invention (e.g., TxM). For example, a construct encoding one or more components of the fusion protein complex of the present invention can be incorporated into a suitable vector using restriction enzymes to form an incision in the vector for inserting the construct and then ligated. The vector containing the gene construct is then introduced into a suitable host for expressing the fusion protein. See generally, Sambrook et al., supra. The selection of a suitable vector can be made empirically based on factors related to the cloning scheme. For example, the vector should be compatible with the host being used and have an appropriate replicon for the host. The vector must be able to accommodate the DNA sequence encoding the fusion protein complex to be expressed. Suitable host cells include eukaryotic cells and prokaryotic cells, preferably those that are easy to transform and show rapid growth in culture medium. Specifically, preferred host cells include prokaryotes (such as Escherichia coli, Bacillus subtillus, etc.), and eukaryotes (such as animal cells and yeast strains, such as Saccharomyces cerevisiae). Mammalian cells are generally preferred, particularly J558, NSO, SP2-0 or CHO. Other suitable hosts include, for example, insect cells, such as Sf9. Conventional culture conditions are used. See, Sambrook, supra. Stably transformed or transfected cell lines can then be selected. Cells expressing the fusion protein complex of the present invention can be assayed by known methods. For example, the expression of the fusion protein complex linked to the immunoglobulin can be determined by ELISA specific for the linked immunoglobulin and / or by immunoblotting. Other methods for detecting the expression of fusion proteins comprising biologically active polypeptides linked to the IL-15 or IL-15Rα domains are disclosed in the Examples section below.
[0266] Generally, as described above, host cells can be used for preparation purposes to propagate nucleic acids encoding desired fusion proteins. Thus, host cells can include prokaryotic or eukaryotic cells in which fusion proteins are particularly expected to be produced. Thus, host cells particularly include yeast, flies, worms, plants, frogs, mammalian cells, and organs that can propagate nucleic acids encoding fusions. Non-limiting examples of mammalian cell lines that can be used include CHO dhfr cells (Urlaub and Chasm, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States], 77: 4216 (1980)), 293 cells [cells] (Graham et al., J Gen. Virol. [Journal of General Virology], 36: 59 (1977)) or myeloma cells (such as SP2 or NSO (Galfre and Milstein, Meth. Enzymol. [Enzymology Methods], 73 (B): 3 (1981)).
[0267] Host cells capable of propagating nucleic acids encoding the desired fusion protein complex encompass non-mammalian eukaryotic cells, and also include insects (e.g., S. frugiperda), yeast (e.g., S. cerevisiae, S. pombe, Pichia pastoris, K. lactis, H. polymorpha; as generally reviewed by Fleer, R., Current Opinion in Biotechnology, 3(5):486-496 (1992)), fungi, and plant cells. Certain prokaryotes (e.g., E. coli and Bacillus) are also contemplated.
[0268] The nucleic acid encoding the desired fusion protein can be introduced into the host cell by the standard techniques for transfecting cells. The term "transfection" ("transfecting" or "transfection") is intended to encompass all conventional techniques for introducing nucleic acid into host cells, including calcium phosphate coprecipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, microinjection, viral transduction and / or integration. The method suitable for transfecting host cells can be found in Sambrook et al., the same, and other laboratory teaching materials.
[0269] Various promoters (transcription initiation regulatory regions) can be used according to the present invention. The selection of a suitable promoter depends on the proposed expression host. Promoters from heterologous sources can be used as long as they function in the selected host.
[0270] The selection of promoter also depends on the desired efficiency and the level of peptide or protein production. Inducible promoters (such as tac) are usually used to significantly increase the level of protein expression in Escherichia coli. Overexpression of protein may be harmful to host cells. Therefore, host cell growth may be limited. The use of inducible promoter systems allows host cells to be cultured to an acceptable density before inducing gene expression, thereby promoting higher product yields.
[0271] Various signal sequences can be used according to the present invention. Signal sequences homologous to biologically active polypeptide coding sequences can be used. Alternatively, signal sequences that have been selected or designed to be effectively secreted and processed in expression hosts can also be used. For example, suitable signal sequence / host cell pairs include the subtilis sacB signal sequence for secretion in bacillus subtilis, and the α-pairing factor of saccharomyces cerevisiae or the pichia acid phosphatase phoI signal sequence for secretion of pichia pastoris. The signal sequence can be directly connected to the protein coding sequence by the sequence encoding the signal peptidase cleavage site, or directly connected by a short nucleotide bridge composed of usually less than 10 codons, wherein the bridge ensures the correct reading frame of the downstream TCR sequence.
[0272] Elements for enhancing transcription and translation have been identified for eukaryotic protein expression systems. For example, positioning the cauliflower mosaic virus (CaMV) promoter 1,000 bp on either side of a heterologous promoter can increase transcription levels by 10 to 400 times in plant cells. The expression construct should also include a suitable translation initiation sequence. Modifying the expression construct to include a Kozak consensus sequence for appropriate translation initiation can increase translation levels by 10 times.
[0273] A selectable marker is often used, which can be part of the expression construct or separate from it (e.g., carried by an expression vector) so that the marker can integrate at a different site from the gene of interest. Examples include conferring antibiotic resistance (e.g., bla confers ampicillin resistance for E. coli host cells; nptII confers kanamycin resistance for a variety of prokaryotic and eukaryotic cells) or allowing the host to grow on minimal media (e.g., HIS4 for Pichia pastoris or His - cerevisiae grows in the absence of histidine). Selectable markers have their own transcriptional and translational initiation and termination regulatory regions to allow independent expression of the marker. If antibiotic resistance is used as a marker, the concentration of the antibiotic used for selection will vary depending on the antibiotic, typically ranging from 10 to 600 μg antibiotic / mL culture medium.
[0274] Expression constructs are assembled by using known recombinant DNA techniques (Sambrook et al., 1989; Ausubel et al., 1999). Restriction enzyme digestion and connection are basic steps for connecting two fragments of DNA. The ends of the DNA fragments may need to be modified before connection, and this can be achieved by the following: filling the overhangs, making the end portions of one or more fragments missing with nucleases (e.g., ExoIII), site-directed mutagenesis, or adding new base pairs by PCR. Polymer linkers and adapters can be used to promote the connection of selected fragments. Expression constructs are usually assembled in the stage of using multiple rounds of restriction, connection and E. coli transformation. Many cloning vectors suitable for constructing expression constructs are known in the art (λZAP and pBLUESCRIPT SK-1, Stratagene, La Jolla, CA, pET, Novagen Inc., Madison, Wisconsin, cited in Ausubel et al., 1999) and specific selection is not important for the present invention. The selection of cloning vectors will be affected by the selected gene transfer system for introducing expression constructs into host cells. At the end of each stage, the resulting constructs can be analyzed by restriction, DNA sequence, hybridization, and PCR analysis.
[0275] The expression construct can be transformed into the host as a cloning vector construct (which can be linear or circular), or can be removed from the cloning vector and used as is or introduced into a delivery vector. The delivery vector helps to introduce and maintain the expression construct in the selected host cell type. The expression construct is introduced into the host cell by any of many known gene transfer systems (e.g., natural competence, chemically mediated transformation, protoplast transformation, electroporation, biolistic transformation, transfection or conjugation) (Ausubel et al., 1999; Sambrook et al., 1989). The gene transfer system is selected depending on the host cell and vector system used.
[0276] For example, expression constructs can be introduced into Saccharomyces cerevisiae cells by protoplast transformation or electroporation. Electroporation of Saccharomyces cerevisiae is easily accomplished and produces transformation efficiencies comparable to spheroplast transformation.
[0277] The present invention further provides a production method for separating the target fusion protein. In the process, a host cell (for example, yeast, fungi, insect, bacterium or zooblast) wherein the nucleic acid encoding the target protein operably connected with the regulating sequence has been introduced is grown in a substratum on a production scale to stimulate the transcription of the nucleotide sequence encoding the target fusion protein. Subsequently, the target fusion protein is separated from the host cell of the harvest or from the substratum. Standard protein purification techniques can be used to separate the target protein from the substratum or from the cells of the harvest. In particular, purification techniques can be used to express and purify the desired fusion protein (that is, with at least milligrams of amount) on a large scale from various implementation devices (including rotating bottles, revolving flasks, tissue culture plates, bioreactors, or fermentation tanks).
[0278] The expressed protein fusion complex can be separated and purified by known methods. The culture medium is usually centrifuged or filtered, and the supernatant is then purified by affinity chromatography or immunoaffinity chromatography (e.g., protein-A or protein-G affinity chromatography or immunoaffinity schemes including the use of monoclonal antibodies that bind to the expressed fusion complex). The fusion protein of the present invention can be separated and purified by an appropriate combination of known techniques. These methods include, for example, methods utilizing solubility (e.g., salt precipitation and solvent precipitation); methods utilizing molecular weight differences (e.g., dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis); methods utilizing charge differences (e.g., ion exchange column chromatography); methods utilizing specific affinity (e.g., affinity chromatography); methods utilizing hydrophobicity differences (e.g., reversed-phase high performance liquid chromatography); and methods utilizing isoelectric point differences (e.g., isoelectric focusing electrophoresis), metal affinity columns (e.g., Ni-NTA). For disclosures related to these methods, see Sambrook et al. and Ausubel et al., supra.
[0279] Preferably, the fusion protein of the present invention is substantially pure. In other words, the fusion protein has been separated from the cell replacement that naturally accompanies it, so that these fusion proteins are preferably present with at least 80% or 90% to 95% homogeneity (w / w). Fusion proteins with at least 98% to 99% homogeneity (w / w) are most preferred for many pharmaceutical, clinical and research applications. Once substantially purified, the fusion protein should be substantially free of pollutants for therapeutic applications. Once partially purified or reaching basic purity, the soluble fusion protein can be used for treatment, or for performing in vitro or in vivo determinations disclosed herein. Basic purity can be determined by a variety of standard techniques (such as chromatography and gel electrophoresis).
[0280] The fusion protein complexes of the present invention are suitable for use in vitro or in vivo with a variety of cells that are cancer cells or are infected or may be infected with one or more diseases.
[0281] Human interleukin-15 (huIL-15) is trans-presented to immune effector cells through the human IL-15 receptor α chain (huIL-15Rα) expressed on antigen presenting cells. IL-15Rα binds huIL-15 with high affinity (38pM) primarily through the extracellular sushi domain (huIL-15RαSu). As described herein, huIL-15 and huIL-15RαSu domains can be used as scaffolds for constructing multi-domain fusion complexes.
[0282] IgG domains, particularly the Fc fragment, have been successfully used as dimer scaffolds for many therapeutic molecules, including approved biologic drugs. For example, etanercept is a dimer of the soluble human p75 tumor necrosis factor-α (TNF-α) receptor (sTNFR) linked to the Fc domain of human IgG1. This dimerization renders etanercept 1,000-fold more potent than monomeric sTNFR in inhibiting TNF-α activity and provides the fusion with a serum half-life that is five-fold longer than the monomeric form. Thus, etanercept is effective in neutralizing the proinflammatory activity of TNF-α in vivo and in improving patient outcomes for a number of different autoimmune indications.
[0283] In addition to its dimerization activity, by complement activation and interaction with Fcγ receptors displayed on natural killer (NK) cells, neutrophils, phagocytes and dendritic cells, the Fc fragment also provides cytotoxic effector functions. In the context of anticancer therapeutic antibodies and other antibody domain-Fc fusion proteins, these activities may play an important role in the efficacy observed in animal tumor models and cancer patients. However, these cytotoxic effector responses may be insufficient in many therapeutic applications. Therefore, considerable interest has been generated to improve and amplify the effector activity of the Fc domain and to develop other ways of raising cytolytic immune responses (including T cell activity) to the disease site via targeted therapeutic molecules. IgG domains have been used as scaffolds to form bispecific antibodies, to improve the quality and quantity of the products produced by traditional hybridoma fusion technology. Although these methods bypass the shortcomings of other scaffolds, it is difficult to produce bispecific antibodies at a level sufficient to support clinical development and use in mammalian cells.
[0284] In an attempt to develop a human-derived immunostimulatory polymer scaffold, human IL-15 (huIL-15) and the IL-15 receptor domain were used. huIL-15 is a member of the small four-α-helical bundle family of cytokines that binds to the cytokine receptor with high binding affinity (equilibrium dissociation constant (KD) of approximately 10 -11M) is associated with the huIL-15 receptor α-chain (huIL-15Rα). The resulting complex is then trans-presented to the human IL-2 / 15 receptor β / co-γ chain (huIL-15RβγC) complex displayed on the surface of T cells and NK cells. This cytokine / receptor interaction leads to the expansion and activation of effector T cells and NK cells, which play an important role in eradicating viral infections and malignant cells. Typically, huIL-15 and huIL-15Rα are co-produced in dendritic cells to form complexes within the cell, which are then secreted and displayed as heterodimeric molecules on the cell surface. Therefore, the characteristics of the interaction between huIL-15 and huIL-15Rα indicate that these interchain binding domains can be used as human-derived immunostimulatory scaffolds to prepare soluble dimer molecules capable of target-specific binding.
[0285] As described in detail below, a huIL-15:huIL-15RαSu-based scaffold was used to generate PD-L1 / TGFβRII / TxM. The dimeric fusion protein complexes retained the immunostimulatory and target-specific biological activities of their huIL-15 domains and binding domains, indicating that the addition of huIL-15 and huIL-15Rα did not significantly change the spatial arrangement of the fusion domains and provided a sufficient degree of conformational flexibility without affecting cytokine activity. Therefore, this scaffold can be used to form multivalent fusion complexes, such as PD-L1 TxM, thereby increasing the overall binding affinity of the molecule. Soluble fusion proteins were produced at high levels in recombinant CHO cell cultures (mg / liter in cell culture supernatant without extensive cell line screening or optimization) and can be easily purified from cell culture supernatants.
[0286] The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are well within the scope of those skilled in the art. Such techniques are fully explained in, for example, "Molecular Cloning: A Laboratory Manual," 2nd edition (Sambrook, 1989); "Oligonucleotide Synthesis" (Gait, 1984); "Animal Cell Culture" (Freshney, 1987); "Methods in Enzymology" and "Handbook of Experimental Immunology" (Weir, 1996); "Gene Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Current Protocols in Molecular Biology" (Ausubel, 1987); "PCR: The Polymerase Chain Reaction," (Mullis, 1994); "Current Protocols in Immunology (Coligan, 1991). These techniques are applicable to the production of polynucleotides and polypeptides of the present invention, and as such, can be considered for use in making and practicing the present invention. Techniques that are particularly useful for specific embodiments are discussed in the following sections.
[0287] Lymphoma
[0288] Lymphoma is a type of blood cancer that develops when B or T lymphocytes divide faster than normal cells or live longer than expected. For example, B-cell lymphomas include both types of Hodgkin's lymphoma and most non-Hodgkin's lymphomas. B-cell lymphomas express CD20.
[0289] Lymphomas can develop in the lymph nodes, spleen, bone marrow, blood, or other organs. These malignant cells usually originate in the lymph nodes and appear as an enlargement of the lymph nodes, which are solid tumors of lymphoid cells. Lymph node biopsy, which is the removal of part or all of a lymph node, is examined under a microscope. This examination can reveal histopathological features that indicate lymphoma. Treatment may involve chemotherapy, radiation therapy, and / or a bone marrow transplant.
[0290] The following examples are presented so as to provide one of ordinary skill in the art with a complete disclosure and description of how to make and use the assays, screening and treatment methods of the invention and are not intended to limit the scope of what the inventors regard as their invention.
[0291] Example
[0292] Example 1: Generation and characterization of fusion protein complexes containing IL-15, anti-PDL1, and TGFβRII domains
[0293] Important therapeutic methods for treating cancer or infectious diseases rely on enhancing the activity of immune cells against disease cells. The strategy includes ex vivo stimulation of immune cells, then adoptive transfer and / or directly increasing the level or activity of immune cells in the patient. The immune cells involved in these methods can be immune cells of the innate (i.e., NK cells) or adaptive (i.e., T cells) immune system.
[0294] One method for enhancing immune activity is to provide immune stimulatory cytokines to immune cells. Such cytokines are known in the art and can be used alone or in combination with other cytokines or agents. As described in detail below, we have produced a fusion protein complex comprising: fused to an antibody (Ab) or antibody binding fragment that can bind to immune checkpoint protein programmed death ligand 1 (PD-L1): IL-15N72D:IL-15RαSu / Fc scaffold, and a TGFβRII domain capable of binding to TGFβ. These fusion protein complexes have advantages in binding to NK cells and signaling cell responses via cytokine receptors. The Fc region of the Ig molecule forms a dimer to provide a soluble multiple polypeptide complex, which can bind to protein A for purification purposes and can interact with Fcγ receptors on NK cells and macrophages that can mediate ADCC and ADCP. Additionally, the interaction between IL-15N72D and IL-15RαSu domains provides a means to link IL-15N72D, TGFβRII, and anti-PDL1 antibody (Ab) domains (and potentially other protein domains or agents) into a single immunostimulatory fusion protein complex.
[0295] Specifically, a TGFβRII monomer or dimer or single-chain anti-PDL1 Ab is connected to IL-15N72D and IL-15RαSu / Fc chain to prepare a construct. In the case of a TGFβRII dimer, the polypeptide consists of two TGFβRIIs, which can be connected via a flexible linker sequence to produce an active single-chain form. In some cases, the TGFβRII dimer and / or anti-PDL1 Ab are connected to the N-terminus of the IL-15N72D and / or IL-15RαSu / Fc chain by genetically engineered fusion. In other cases, the TGFβRII polypeptide is connected to the C-terminus of the IL-15RαSu / Fc chain with or without a linker. A specific fusion protein complex is described below, comprising: an IL-15N72D:IL-15RαSu / Fc scaffold fused to a TGFβRII and anti-PDL1 binding domain.
[0296] A: αPDL1 / TGFβRII / TXM (N-810C): A fusion protein complex was generated, which contained TGFβRII dimer / IL-15RαSu / Fc and anti-PDL1-IL15N72D fusion protein.
[0297] A1: TGFβRII / IL-15RαSu / Fc: The human TGFβRII coding sequence was obtained from the UniProt website and optimized for transfection of CHO cell lines. Specifically, the coding sequence of TGFβRII was linked to another TGFβRII with a linker to generate a sequence encoding a TGFβRII dimer, and this sequence was then directly linked to a sequence encoding the N-terminus of the IL-15RαSu / Fc chain to prepare a gene construct. The DNA sequence of the construct was synthesized by Genewiz Inc and used for molecular cloning into an expression vector.
[0298] The nucleic acid sequence of the TGFβRII / IL-15RαSu / Fc construct (including the signal peptide sequence) is as follows (SEQ ID NO: 1):
[0299] (Signal peptide)
[0300] atgaagtgggtgaccttcatcagcctgctgttcctgttctccagcgcctactcc
[0301] (Human TGFβRII)
[0302] atccccccccatgtgcaaaagagcgtgaacaacgatatgatcgtgaccgacaacaacggcgccgtgaagtttccccagctctgcaagttctgcgatgtcaggttcagcacctgcgataatcagaagtcctgcatgtccaactgcagcatcacctccatctgcgagaagccccaagaagtgtgcgtggccgtgtggcggaaaaatgacgagaacatcaccctggagaccgtgtgtcacgaccccaagctcccttatcacgacttcattctggaggacgctgcctcccccaaatgcatcatgaaggagaagaagaagcccggagagaccttctttatgtgttcctgtagcagcgacgagtgtaacgacaacatcatcttcagcgaagagtacaacaccagcaaccctgat
[0303] (Adapter)
[0304] ggaggtggcggatccggaggtggaggttctggtggaggtgggagt
[0305] (Human TGFβRII)
[0306] attcctccccacgtgcagaagagcgtgaataatgacatgatcgtgaccgataacaatggcgccgtgaaatttccccagctgtgcaaattctgcgatgtgaggttttccacctgcgacaaccagaagtcctgtatgagcaactgctccatcacctccatctgtgagaagcctcaggaggtgtgcgtggctgtctggcggaagaatgacgagaatatcaccctggaaaccgtctgccacgatcccaagctgccctaccacgatttcatcctggaagacgccgccagccctaagtgcatcatgaaagagaaaaagaagcctggcgagacctttttcatgtgctcctgcagcagcgacgaatgcaacgacaatatcatctttagcgaggaatacaataccagcaaccccgac
[0307] (Human IL-15Rα sushi domain)
[0308] atcacgtgtcctcctcctatgtccgtggaacacgcagacatctgggtcaagagctacagcttgtactccagggagcggtacatttgtaactctggtttcaagcgtaaagccggcacgtccagcctgacggagtgcgtgttgaacaaggccacgaatgtcgcccactggacaacccccagtctcaaatgcattaga
[0309] (Human IgG1 CH2-CH3 (Fc) domain)
[0310] gagccgaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctcctggtaaa
[0311] The amino acid sequence (including the signal peptide sequence) of the TGFβRII / IL-15RαSu / Fc fusion protein (SEQ ID NO: 2) is as follows:
[0312] (Signal peptide)
[0313] MKWVTFISLLFLFSSAYS
[0314] (Human TGFβRII)
[0315] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0316] (Connector)
[0317] GGGGSGGGGSGGGGS
[0318] (Human TGFβRII)
[0319] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0320] (Human IL-15Rαsushi domain)
[0321] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIR
[0322] (Human IgG1 CH2-CH3 (Fc) domain)
[0323] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0324] In some cases, a leader peptide is cleaved from the intact polypeptide to produce a soluble or secreted mature form.
[0325] A2: Anti-PDL1-15N72D: Also via overlapping PCR, by connecting the synthesized single-chain anti-PDL1 antibody nucleotide sequence to the N-terminal coding region of IL-15N72D, anti-PDL1-15N72D is produced to prepare a construct. Specifically, the light chain and heavy chain variable domain sequences of the anti-PDL1 Ab are connected with a sequence encoding a flexible linker to form a single-chain anti-PDL1 antibody construct, and then the single-chain anti-PD-L1 sequence is connected to the sequence encoding the N-terminus of IL-15N72D. The sequence of the single-chain anti-PDL1 Ab was synthesized by Genewiz Inc, and then connected to the N-terminal coding region of IL-15N72D via overlapping PCR. The nucleic acid and protein sequences of the construct are shown below, and the construct comprises a single-chain anti-PDL1 Ab connected to the N-terminus of IL15N72D.
[0326] The nucleic acid sequence of the anti-PDL1 / IL-15N72D construct (including the leader sequence) is as follows (SEQ ID NO: 3):
[0327] (Signal peptide)
[0328] atgaagtgggtgaccttcatcagcctgctgttcctgttctccagcgcctactcc
[0329] (anti-PDL1 single chain)
[0330] (Anti-PDL1 light chain variable domain)
[0331] aacatccagatgacccagtcccctagctccgtgtccgcctccgtgggagatcgggtgaccatcacctgtagggcctcccaggacatctccaggtggctggcctggtaccagcagaagcccggcaaggcccccaagctgctgatctacgccgcctcctccctgca gtccggagtgcctagcaggttctccggctccggatccggcacagacttcgccctgaccatctcctccctgcagcccgaggacttcgccacctactgccagcaggccgactccaggttctccatcaccttcggccagggcaccaggctggagatcaagaggg
[0332] (Connector)
[0333] ggaggtggcggatccggaggtggaggttctggtggaggtgggagt
[0334] (Variable domain of anti-PDL1 heavy chain)
[0335] gaggtgcagctggtgcagtccggaggaggactggtgcagcctggcggatccctgaggctgtcctgtgccgcttccggcttcaccttcagctcctactccatgaactgggtgaggcaggcccctggaaagggcctggagtgggtgtcctacatctccagctcctcctccaccatccagtacgccgactccgtgaagggcaggttcaccatctccagggacaacgccaagaactccctgtacctgcagatgaacagcctgagggacgaggacaccgccgtgtactactgcgccaggggcgactattactacggcatggacgtgtggggccagggaaccaccgtgaccgtgtcctcc
[0336] (Human IL-15 N72D)
[0337] aactgggttaacgtaataagtgatttgaaaaaaattgaagatcttattcaatctatgcatattgatgctactttatatacggaaagtgatgttcaccccagttgcaaagtaacagcaatgaagtgctttctcttggagttacaagttatttcacttgagtccggagatgcaagtattcatgatacagtagaaaatctgatcatcctagcaaacgacagtttgtcttctaatgggaatgtaacagaatctggatgcaaagaatgtgaggaactggaggaaaaaaatattaaagaatttttgcagagttttgtacatattgtccaaatgttcatcaacacttct
[0338] The amino acid sequence of the anti-PDL1 / IL-15 N72D fusion protein (including the leader sequence) is as follows (SEQ ID NO:4):
[0339] (Signal peptide)
[0340] MKWVTFISLLFLFSSAYS
[0341] (anti-PDL1 single chain)
[0342] (Anti-PDL1 light chain variable domain)
[0343] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0344] (Connector)
[0345] GGGGSGGGGSGGGGS
[0346] (Anti-PDL1 Heavy Chain Variable Domain)
[0347] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0348] (Human IL-15N72D)
[0349] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0350] In some cases, a leader peptide is cleaved from the intact polypeptide to produce a soluble or secreted mature form.
[0351] Co-transfection and protein purification. The TGFβRII / IL-15RαSu / Fc and anti-PDL1-IL15N72D constructs were cloned into expression vectors as previously described (U.S. Patent No. 8,507,222, Example 1, incorporated herein by reference), and the expression vectors were transfected into CHO cells. Co-expression of the two constructs in CHO cells allowed the formation and secretion of a soluble anti-PDL1-IL15N72D:TGFβRII / IL-15RαSu / Fc fusion protein complex (referred to as anti-PDL1 / TGFβRII / TxM). The anti-PDL1 / TGFβRII / TxM protein was purified from the CHO cell culture supernatant by protein A affinity chromatography and size exclusion chromatography to produce a soluble (non-aggregated) fusion protein complex consisting of a TGFβRII / IL-15RαSu / Fc dimer and an anti-PDL1-IL15N72D fusion protein ( Figure 2 ).
[0352] Reducing SDS-PAGE analysis of protein A-purified anti-PDL1-IL15N72D:TGFβRII / IL-15RαSu / Fc fusion protein complexes was shown in Figure 3 The bands corresponding to the soluble anti-PDL1-IL15N72D:TGFβRII / IL-15RαSu / Fc fusion protein were observed at approximately 40 kDa and approximately 70 kDa ( Figure 3 and 8 ).
[0353] B: TGFβRII / αPDL1 / TXM(N-810B)
[0354] For the second approach, a similar fusion protein complex was generated containing TGFβRII-IL15N72D:anti-PDL1-15RαSu / Fc fusion protein.
[0355] B1: Anti-PDL1-15RαSu / Fc: Anti-PDL1-15RαSu / Fc gene construct was generated by linking the synthetic single-chain anti-PDL1 Ab nucleotide sequence to the N-terminal coding region of IL-15RαSu / Fc via overlapping PCR. The nucleic acid and protein sequences of the construct are shown below, and the construct comprises an anti-PDL1 Ab linked to the N-terminus of IL-15RαSu / Fc.
[0356] The nucleic acid sequence of the anti-PDL1 / IL-15RαSu / Fc construct (including the signal peptide sequence) is as follows (SEQ ID NO: 5):
[0357] (Signal peptide)
[0358] atgaagtgggtgaccttcatcagcctgctgttcctgttctccagcgcctactcc
[0359] (Single-chain anti-PDL1)
[0360] (Variable light domain of anti-PDL1)
[0361] aacatccagatgacccagtcccctagctccgtgtccgcctccgtgggagatcgggtgaccatcacctgtagggcctcccaggacatctccaggtggctggcctggtaccagcagaagcccggcaaggcccccaagctgctgatctacgccgcctcctccctgcagtccggagtgcctagcaggttctccggctccggatccggcacagacttcgccctgaccatctcctccctgcagcccgaggacttcgccacctactactgccagcaggccgactccaggttctccatcaccttcggccagggcaccaggctggagatcaagagg
[0362] (Linker)
[0363] ggaggtggcggatccggaggtggaggttctggtggaggtgggagt
[0364] (Variable heavy domain of anti-PDL1)
[0365] gaggtgcagctggtgcagtccggaggaggactggtgcagcctggcggatccctgaggctgtcctgtgccgcttccggcttcaccttcagctcctactccatgaactgggtgaggcaggcccctggaaagggcctggagtgggtgtcctacatctccagctcctcctccaccatccagtacgccgactccgtgaagggcaggttcaccatctccagggacaacgccaagaactccctgtacctgcagatgaacagcctgagggacgaggacaccgccgtgtactactgcgccaggggcgactattactacggcatggacgtgtggggccagggaaccaccgtgaccgtgtcctcc
[0366] (Human IL-15Rα sushi domain)
[0367] atcacgtgtcctcctcctatgtccgtggaacacgcagacatctgggtcaagagctacagcttgtactccagggagcggtacatttgtaactctggtttcaagcgtaaagccggcacgtccagcctgacggagtgcgtgttgaacaaggccacgaatgtcgcccactggacaacccccagtctcaaatgcattaga
[0368] (Human IgG1 CH2-CH3 (Fc) domain)
[0369] gagccgaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctcctggtaaa
[0370] The amino acid sequence of the anti-PDL1 / IL-15RαSu / Fc fusion protein (including the signal peptide sequence) (SEQ ID NO: 6) is as follows:
[0371] (Signal peptide)
[0372] MKWVTFISLLFLFSSAYS
[0373] (Anti-PDL1 single chain)
[0374] (Variable domain of anti-PDL1 light chain)
[0375] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0376] (Connector)
[0377] GGGGSGGGGSGGGGS
[0378] (Anti-PDL1 Heavy Chain Variable Domain)
[0379] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0380] (Human IL-15Rαsushi domain)
[0381] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIR
[0382] (Human IgG1 CH2-CH3 (Fc) domain)
[0383] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0384] In some cases, a leader peptide is cleaved from the intact polypeptide to produce a soluble or secreted mature form.
[0385] B2: TGFβRII-IL15N72D: Specifically, a TGFβRII was linked to another TGFβRII using a linker to generate a TGFβRII dimer, and then the TGFβRII dimer sequence was directly linked to a sequence at the N-terminus of IL15N72D to prepare the construct. The DNA fragment encoding TGFβRII-IL15N72D was synthesized by GENEWIZ.
[0386] The nucleic acid sequence of the TGFβRII-IL15N72D construct (including the signal peptide sequence) is as follows (SEQ ID NO: 7):
[0387] (Signal peptide)
[0388] atgaagtgggtgaccttcatcagcctgctgttcctgttctccagcgcctactcc
[0389] (Human TGFβRII)
[0390] atcccccccccatgtgcaaaagagcgtgaacaacgatatgatcgtgaccgacaacaacggcgccgtgaagtttccccagctctgcaagttctgcgatgtcagg ttcagcacctgcgataatcagaagtcctgcatgtccaactgcagcatcacctccatctgcgagaagccccaagaagtgtgcgtggccgtgtggcggaaaaat gacgagaacatcaccctggagaccgtgtgtcacgaccccaagctcccttatcacgacttcattctggaggacgctgcctcccccaaatgcatcatgaaggag aagaagaagcccggagagaccttctttatgtgttcctgtagcagcgacgagtgtaacgacaacatcatcttcagcgaagagtacaacaccagcaaccctgat
[0391] (Connector)
[0392] ggaggtggcggatccggaggtggaggttctggtggaggtgggagt
[0393] (Human TGFβRII)
[0394] attcctccccacgtgcagaagagcgtgaataatgacatgatcgtgaccgataacaatggcgccgtgaaatttccccagctgtgcaaattctgcgatgtgaggttttccacctgcgacaaccagaagtcctgtatgagcaactgctccatcacctccatctgtgagaagcctcaggaggtgtgcgtggctgtctggcggaagaatgacgagaatatcaccctggaaaccgtctgccacgatcccaagctgccctaccacgatttcatcctggaagacgccgccagccctaagtgcatcatgaaagagaaaaagaagcctggcgagacctttttcatgtgctcctgcagcagcgacgaatgcaacgacaatatcatctttagcgaggaatacaataccagcaaccccgac
[0395] (Human IL-15 N72D)
[0396] aactgggttaacgtaataagtgatttgaaaaaaattgaagatcttattcaatctatgcatattgatgctactttatatacggaaagtgatgttcaccccagttgcaaagtaacagcaatgaagtgctttctcttggagttacaagttatttcacttgagtccggagatgcaagtattcatgatacagtagaaaatctgatcatcctagcaaacgacagtttgtcttctaatgggaatgtaacagaatctggatgcaaagaatgtgaggaactggaggaaaaaaatattaaagaatttttgcagagttttgtacatattgtccaaatgttcatcaacacttct
[0397] The amino acid sequence of the TGFβRII-IL15N72D fusion protein (including the leader sequence) is as follows (SEQ ID NO:8):
[0398] (Signal peptide)
[0399] MKWVTFISLLFLFSSAYS
[0400] (Human TGFβRII)
[0401] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0402] (Connector)
[0403] GGGGSGGGGSGGGGS
[0404] (Human TGFβRII)
[0405] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0406] (Human IL-15N72D)
[0407] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0408] In some cases, a leader peptide is cleaved from the intact polypeptide to produce a soluble or secreted mature form.
[0409] Co-transfection and protein purification: TGFβRII dimer / IL-15N72D and αPDL1 / IL-15RαSu / Fc constructs were cloned into expression vectors as previously described (U.S. Pat. No. 8,507,222, Example 1, incorporated herein by reference), and the expression vectors were transfected into CHO cells. Co-expression of the two constructs in CHO cells allowed the formation and secretion of a soluble TGFβRII / IL-15N72D:αPDL1 / IL-15RαSu / Fc fusion protein complex (referred to as TGFβRII / αPDL1 / TxM).
[0410] TGFβRII / anti-PDL1 / TxM protein was purified from CHO cell culture supernatant by protein A affinity chromatography and size exclusion chromatography to generate a soluble (non-aggregated) fusion protein complex ( Figure 5 ).
[0411] Reducing SDS-PAGE analysis of protein A-purified TGFβRII / anti-PDL1 / TxM fusion protein complexes was shown in Figure 6 The bands corresponding to the soluble anti-PDL1-IL15N72D:TGFβRII / IL-15RαSu / Fc fusion protein were observed at approximately 50 kDa and approximately 60 kDa ( Figure 6 and 8 ).
[0412] C: αPDL1 / TXM / TGFβRII(N-810A)
[0413] Similar fusion protein complexes were also generated containing IL15N72D and anti-PDL1 / IL-15RαSu / Fc / TGFβRII. In these constructs, TGFβRII was fused to the C-terminus of anti-PDL1-IL-15RαSu / Fc with or without a linker ( Figure 7 ).
[0414] C1 : IL15N72D: The IL15N72D construct was prepared as previously described (U.S. Patent No. 8,507,222, in Example 1, incorporated herein by reference).
[0415] The nucleic acid sequence of the IL15N72D construct (including the signal peptide sequence) is as follows (SEQ ID NO: 9):
[0416] (Signal peptide)
[0417] atgaagtgggtgaccttcatcagcctgctgttcctgttctccagcgcctactcc
[0418] (Human IL-15N72D)
[0419] aactgggttaacgtaataagtgatttgaaaaaaattgaagatcttattcaatctatgcatattgatgctactttatatacggaaagtgatgttcaccccagttgcaaagtaacagcaatgaagtgctttctcttggagttacaagttatttcacttgagtccggagatgca agtattcatgatacagtagaaaatctgatcatcctagcaaacgacagtttgtcttctaatgggaatgtaacagaatctggatgcaaagaatgtgaggaactggaggaaaaaaatattaaagaatttttgcagagttttgtacatattgtccaaatgttcatcaacacttct
[0420] The amino acid sequence of the IL15N72D protein (including the leader sequence) is as follows (SEQ ID NO: 10):
[0421] (Signal peptide)
[0422] MKWVTFISLLFLFSSAYS
[0423] (Human IL-15N72D)
[0424] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0425] In some cases, a leader peptide is cleaved from the intact polypeptide to produce a soluble or secreted mature form.
[0426] C2: Anti-PDL1 / IL-15RαSu / Fc / TGFβRII: Two constructs were prepared for this fusion protein ( Figure 7). In the first construct, TGFβRII was fused directly to the C-terminus of anti-PDL1 / IL-15RαSu / Fc. In the second construct, a linker was added between TGFβRII and anti-PDL1 / IL-15RαSu / Fc to increase flexibility. Both constructs were synthesized by Genewiz, encoding the nucleic acid sequence of anti-PDL1 / IL-15RαSu / Fc / TGFβRII. A nucleic acid mutation (G to T) was made at position 27 of the TGFβRII sequence, thereby generating a Hap1 restriction endonuclease cleavage site at that position, however, there was no amino acid sequence change.
[0427] C2A: anti-PDL1 / IL-15RαSu / Fc / TGFβRII-without linker: The nucleic acid sequence (including the signal peptide sequence) of the anti-PDL1 / IL-15RαSu / Fc / TGFβRII construct without a linker is as follows (SEQ ID NO: 11):
[0428] (Signal peptide)
[0429] atgaagtgggtgaccttcatcagcctgctgttcctgttctccagcgcctactcc
[0430] (Signal peptide)
[0431] atgaagtgggtgaccttcatcagcctgctgttcctgttctccagcgcctactcc
[0432] (anti-PDL1 single chain)
[0433] (Anti-PDL1 light chain variable domain)
[0434] aacatccagatgacccagtcccctagctccgtgtccgcctccgtgggagatcgggtgaccatcacctgtagggcctcccaggacatctccaggtggctggcctggtaccagcagaagcccggcaaggcccccaagctgctgatctacgccgcctcctccctgc agtccggagtgcctagcaggttctccggctccggatccggcacagacttcgccctgaccatctcctccctgcagcccgaggacttcgccacctactgccagcaggccgactccaggttctccatcaccttcggccagggcaccaggctggagatcaagagg
[0435] (Adapter)
[0436] ggaggtggcggatccggaggtggaggttctggtggaggtgggagt
[0437] (Anti-PDL1 heavy chain variable domain)
[0438] gaggtgcagctggtgcagtccggaggaggactggtgcagcctggcggatccctgaggctgtcctgtgccgcttccggcttcaccttcagctcctactccatgaactgggtgaggcaggcccctggaaagggcctggagtgggtgtcctacatctccagctcctcctccaccatccagtacgccgactccgtgaagggcaggttcaccatctccagggacaacgccaagaactccctgtacctgcagatgaacagcctgagggacgaggacaccgccgtgtactactgcgccaggggcgactattactacggcatggacgtgtggggccagggaaccaccgtgaccgtgtcctcc
[0439] (Human IL-15Rα sushi domain)
[0440] atcacgtgtcctcctcctatgtccgtggaacacgcagacatctgggtcaagagctacagcttgtactccagggagcggtacatttgtaactctggtttcaagcgtaaagccggcacgtccagcctgacggagtgcgtgttgaacaaggccacgaatgtcgcccactggacaacccccagtctcaaatgcattaga
[0441] (Human IgG1 CH2-CH3 (Fc) domain)
[0442] gagccgaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctcctggtaaa
[0443] (Human TGFβRII)
[0444] atccccccccacgtgcagaagtcc gttaacaacgacatgatcgtgaccgacaacaacggcgccgtgaagttcccccagctgtgcaagttctgcgacgtgaggttctccacctgcgacaaccaga agtcctgcatgtccaactgctccatcacctccatctgcgagaagcctcaggaggtgtgcgtggctgtgtggcggaagaacgacgagaacatcacc ctggagaccgtgtgccacgaccccaagctgccctaccacgacttcatcctggaggacgccgcctcccccaagtgcatgaaggagaagaagcccggcgagaccttctttatgtgctcctgctccagcgacgagtgcaacgacaacatcatcttctccgaggagtacaacacctccaaccccgac
[0445] The amino acid sequence of the anti-PDL1 / IL-15RαSu / Fc / TGFβRII fusion protein (including the signal peptide sequence) (SEQ ID NO: 12) is as follows:
[0446] (Signal peptide)
[0447] MKWVTFISLLFLFSSAYS
[0448] (anti-PDL1 single chain)
[0449] (Anti-PDL1 light chain variable domain)
[0450] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0451] (Connector)
[0452] GGGGSGGGGSGGGGS
[0453] (Anti-PDL1 Heavy Chain Variable Domain)
[0454] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0455] (Human IL-15Rαsushi domain)
[0456] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIR
[0457] (Human IgG1 CH2-CH3 (Fc) domain)
[0458] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0459] (Human TGFβRII)
[0460] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0461] C2B: Anti-PDL1 / IL-15RαSu / Fc / TGFβRII with a linker: The nucleic acid sequence (including the signal peptide sequence) of the anti-PDL1 / IL-15RαSu / Fc / TGFβRII construct with a linker is as follows (SEQ ID NO: 13):
[0462] (Signal peptide)
[0463] atgaagtgggtgaccttcatcagcctgctgttcctgttctccagcgcctactcc
[0464] Anti-PDL1 single chain
[0465] (Variable domain of anti-PDL1 light chain)
[0466] aacatccagatgacccagtcccctagctccgtgtccgcctccgtgggagatcgggtgaccatcacctgtagggcctcccaggacatctccaggtggctggcctggtaccagcagaagcccggcaaggcccccaagctgctgatctacgccgcctcctccctgcagtccggagtgcctagcaggttctccggctccggatccggcacagacttcgccctgaccatctcctccctgcagcccgaggacttcgccacctactactgccagcaggccgactccaggttctccatcaccttcggccagggcaccaggctggagatcaagagg
[0467] (Linker)
[0468] ggaggtggcggatccggaggtggaggttctggtggaggtgggagt
[0469] (Variable domain of anti-PDL1 heavy chain)
[0470] gaggtgcagctggtgcagtccggaggaggactggtgcagcctggcggatccctgaggctgtcctgtgccgcttccggcttcaccttcagctcctactccatgaactgggtgaggcaggcccctggaaagggcctggagtgggtgtcctacatctccagctcctcctccaccatccagtacgccgactccgtgaagggcaggttcaccatctccagggacaacgccaagaactccctgtacctgcagatgaacagcctgagggacgaggacaccgccgtgtactactgcgccaggggcgactattactacggcatggacgtgtggggccagggaaccaccgtgaccgtgtcctcc
[0471] (Human IL-15Rα sushi domain) atcacgtgtcctcctcctatgtccgtggaacacgcagacatctgggtcaagagctacagcttgtactccagggagcggtacatttgtaactctggtttcaagcgtaaagccggcacgtccagcctgacggagtgcgtgttgaacaaggccacgaatgtcgcccactggacaacccccagtctcaaatgcattaga
[0472] (Human IgG1 CH2-CH3 (Fc) domain)
[0473] gagccgaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctcctggtaaa
[0474] (Connector)
[0475] ggaggaggtggctccggaggcggtggctccggtggaggtggctccggaggtggcggttccggt
[0476] (Human TGFβRII)
[0477] atccccccccacgtgcagaagtcc gttaac aacgacatgatcgtgaccgacaacaacggcgccgtgaagttcccccagctgtgcaagttctgcgacgtgaggttctccacctgcgacaaccaga agtcctgcatgtccaactgctccatcacctccatctgcgagaagcctcaggaggtgtgcgtggctgtgtggcggaagaacgacgagaacatcacc ctggagaccgtgtgccacgaccccaagctgccctaccacgacttcatcctggaggacgccgcctcccccaagtgcatgaaggagaagaagcccggcgagaccttctttatgtgctcctgctccagcgacgagtgcaacgacaacatcatcttctccgaggagtacaacacctccaaccccgac
[0478] The amino acid sequence of anti-PDL1 / IL-15RαSu / Fc / TGFβRII with linker fusion protein (including signal peptide sequence) (SEQ ID NO: 14) is as follows:
[0479] (Signal peptide)
[0480] MKWVTFISLLFLFSSAYS
[0481] (anti-PDL1 single chain)
[0482] (Anti-PDL1 light chain variable domain)
[0483] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0484] (Connector)
[0485] GGGGSGGGGSGGGGS
[0486] (Anti-PDL1 heavy chain variable domain)
[0487] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0488] (Human IL-15Rα sushi domain)
[0489] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIR
[0490] (Human IgG1 CH2-CH3 (Fc) domain) EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0491] (Linker)
[0492] GGGGSGGGGSGGGGSGGGGSG
[0493] (Human TGFβRII)
[0494] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0495] Co-transfection and protein purification: IL-15N72D and αPDL1 / IL-15RαSu / Fc / TGFβRII constructs were cloned into expression vectors as previously described (U.S. Pat. No. 8,507,222, Example 1, incorporated herein by reference), and the expression vectors were transfected into CHO cells. Co-expression of the two constructs in CHO cells allowed the formation and secretion of a soluble IL-15N72D:αPDL1 / IL-15RαSu / Fc / TGFβRII fusion protein complex (referred to as αPDL1 / TxM / TGFβRII), which could be purified by protein A affinity and chromatography methods and analyzed by SDS-PAGE and SEC to confirm purity and appropriate banding patterns (Figure 22).
[0496] In some cases, a leader peptide is cleaved from the intact polypeptide to produce a soluble or secreted mature form.
[0497] Other sequences of the invention include:
[0498] 2x-TGFβRII-IL15(N72D)(SEQ ID NO:15):
[0499]
[0500]
[0501] TGFβRII-Dimer-IL15RaSu-IgG1-Fc (SEQ ID NO: 17):
[0502]
[0503] IL15(N72D)(SEQ ID NO:18):
[0504] Aactgggtgaatgtaataagtgatttgaaaaaaattgaagatcttatccagtccatgcacatcgacgccaccctgtacaccgagagcgacgtgcacccctcctgcaaggtgaccgccatgaagtgcttcctgctggagctgcaggtgatctccctggagtccggcgacgcctccatccacgacaccgtggagaacctgatcatcctggccaacgactccctgtcctccaacggcaacgtgaccgagtccggctgcaaggagtgcgaggagctggaggagaagaacatcaaggagttcctgcagtccttcgtgcacatcgtccaaatgttcatcaacacttct
[0505] αPD-L1 / SuFc / TGF-β(SEQ ID NO:19):
[0506]
[0507] In addition, the above fusion protein may also contain a sequence of wild-type IL-15 instead of the IL-15N72D variant. For example, the nucleic acid sequence encoding the IL-15N72D domain above may be replaced with a nucleic acid sequence encoding wild-type IL-15. The sequences of the present invention may be native sequences, or those sequences optimized for expression in host cells, i.e., codon-optimized sequences.
[0508] The amino acid sequence of the wild-type IL15 protein domain is as follows (SEQ ID NO: 20):
[0509] (Human IL-15)
[0510] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0511] N-810A
[0512] The amino acid sequence of N-810A (αPD-L1 light chain Fv / linker / αPD-L1 heavy chain Fv / linker / IL15RαSuFc / linker / TGFβRII) protein is as follows (SEQ ID NO: 21):
[0513] (IL-15(N72D))
[0514] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0515] (αPD-L1 light chain Fv)
[0516] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0517] (Connector)
[0518] GGGGSGGGGSGGGGS
[0519] (αPD-L1 heavy chain Fv)
[0520] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0521] (IL15RαSuFc)
[0522] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0523] (Linker)
[0524] GGGGSGGGGSGGGGSGGGGSG
[0525] (TGFβRII)
[0526] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM Q NCPITSICEKPQEVCVAVWRK Q DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEY Q TSNPD。
[0527] The amino acids of the unglycosylated TGFβRII* (αPD-L1 light chain Fv / Linker / αPD-L1 heavy chain Fv / Linker / IL15RαSuFc / Linker / TGFβRII) of N-810A (SEQ ID NO:22) are as follows:
[0528] (IL-15(N72D))
[0529] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0530] (αPD-L1 light chain Fv)
[0531] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0532] (Linker)
[0533] GGGGSGGGGSGGGGS
[0534] (αPD-L1 heavy chain Fv)
[0535] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0536] (IL15RαSuFc)
[0537] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0538] (Linker)
[0539] GGGGSGGGGSGGGGSGGGGSG
[0540] (TGFβRII)
[0541] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCM Q NCPITSICEKPQEVCVAVWRK Q DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEY Q TSNPD.
[0542] The amino acids of N-810A unglycosylated TGFβRII+Δ free cysteine*(αPD-L1 light chain Fv / linker / αPD-L1 heavy chain Fv / linker / IL15RαSuFc / linker / TGFβRII) (SEQ ID NO: 23) are as follows:
[0543] ((IL-15(N72D))
[0544] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0545] (αPD-L1 light chain Fv)
[0546] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0547] (Connector)
[0548] GGGGSGGGGSGGGGS
[0549] (αPD-L1 heavy chain Fv)
[0550] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0551] (IL15RαSuFc)
[0552] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKS S DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0553] (Linker)
[0554] GGGGSGGGGSGGGGSGGGGSG
[0555] (TGFβRII)
[0556] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM Q NCPITSICEKPQEVCVAVWRK Q DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEY Q TSNPD。
[0557] The amino acids of N-810AΔ hinge **(αPD-L1 light chain Fv / Linker / αPD-L1 heavy chain Fv / Linker / IL15RαSuFc / Linker / TGFβRII) (SEQ ID NO:24) are as follows:
[0558] ((IL-15(N72D))
[0559] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0560] (αPD-L1 light chain Fv)
[0561] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0562] (Linker)
[0563] GGGGSGGGGSGGGGS
[0564] (αPD-L1 heavy chain Fv)
[0565] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0566] (IL15RαSuFc)
[0567] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0568] (Linker)
[0569] GGGGSGGGGSGGGGSGGGGSG
[0570] (TGFβRII)
[0571] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMNNCPITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD。
[0572] The amino acids of N-810A+(IL15-K41Q, L45S, I67T, N79Y, E93A)*(αPD-L1 light chain Fv / linker / αPD-L1 heavy chain Fv / linker / IL15RαSuFc / linker / TGFβRII) (SEQ ID NO: 25) are as follows:
[0573] (IL-15-K41Q,L45S,I67T,N79Y,E93A)
[0574] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAM Q CFL S ELQVISLESGDASIHDTVENL T ILANDSLSSNG Y VTESGCKECEELE A KNIKEFLQSFVHIVQMFINTS
[0575] (αPD-L1 light chain Fv)
[0576] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0577] (Connector)
[0578] GGGGSGGGGSGGGGS
[0579] (αPD-L1 heavy chain Fv)
[0580] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0581] (IL15RαSuFc)
[0582] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0583] (Linker)
[0584] GGGGSGGGGSGGGGSGGGGSG
[0585] (TGFβRII)
[0586] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCPITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD。
[0587] The amino acids of N-810A+(IL15-L45S)*(αPD-L1 light chain Fv / Linker / αPD-L1 heavy chain Fv / Linker / IL15RαSuFc / Linker / TGFβRII) (SEQ ID NO:26) are as follows:
[0588] (IL15-L45S)
[0589] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFL S ELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0590] (αPD-L1 light chain Fv)
[0591] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0592] (Linker)
[0593] GGGGSGGGGSGGGGS
[0594] (αPD-L1 heavy chain Fv)
[0595] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0596] (IL15RαSuFc)
[0597] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0598] (Linker)GGGGSGGGGSGGGGSGGGGSG
[0599] (TGFβRII)
[0600] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCPITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0601] N-810D
[0602] αPD-L1 light chain Fv / linker / αPD-L1 heavy chain Fv / IL-15(N72D) (SEQ ID NO:27):
[0603] (αPD-L1 light chain Fv)
[0604] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0605] (linker)
[0606] GGGGSGGGGSGGGGS
[0607] (αPD-L1 heavy chain Fv)
[0608] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0609] ((IL-15(N72D))
[0610] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0611] IL15RαSuFc / linker / TGFβRII (SEQ ID NO:28):
[0612] (IL15RαSuFc)
[0613] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0614] (Linker)
[0615] GGGGSGGGGSGGGGSGGGGSG
[0616] (TGFβRII)
[0617] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCPITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0618] N-810D Unglycosylated TGFβRII*
[0619] The αPD-L1 light chain Fv / Linker / αPD-L1 heavy chain Fv / IL-15 (N72D) (SEQ ID NO:29) is as follows:
[0620] (αPD-L1 light chain Fv) NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0621] (Linker)
[0622] GGGGSGGGGSGGGGS
[0623] (αPD-L1 heavy chain Fv)
[0624] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0625] ((IL-15(N72D))
[0626] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0627] IL15RαSuFc / Linker / TGFβRII (SEQ ID NO:30):
[0628] (IL15RαSuFc)
[0629] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0630] (Linker)
[0631] GGGGSGGGGSGGGGSGGGGSG
[0632] (TGFβRII)
[0633] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM Q NCPITSICEKPQEVCVAVWRK QDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEY Q TSNPD
[0634] N-810E
[0635] αPD-L1 light chain Fv / Linker / αPD-L1 heavy chain Fv / IL-15(N72D) (SEQ ID NO:31):
[0636] (αPD-L1 light chain Fv)
[0637] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0638] (Linker)
[0639] GGGGSGGGGSGGGGS
[0640] (αPD-L1 heavy chain Fv)
[0641] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0642] ((IL-15(N72D))
[0643] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0644] TGFβRII / IL15RαSuFc (SEQ ID NO:32):
[0645] (TGFβRII)
[0646] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0647] (IL15RαSuFc)
[0648] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0649] N-810E Unglycosylated TGFβRII*
[0650] αPD-L1 light chain Fv / linker / αPD-L1 heavy chain Fv / IL-15(N72D) (SEQ ID NO 33)
[0651] (αPD-L1 light chain Fv)
[0652] NIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCQQADSRFSITFGQGTRLEIKR
[0653] (linker)
[0654] GGGGSGGGGSGGGGS
[0655] (αPD-L1 heavy chain Fv)
[0656] EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIQYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMDVWGQGTTVTVSS
[0657] (IL-15(N72D))
[0658] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0659] TGFβRII / IL15RαSuFc(SEQ ID NO:34):
[0660] (TGFβRII)
[0661] IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM Q NCPITSICEKPQEVCVAVWRK Q DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEY Q TSNPD
[0662] (IL15RαSuFc)
[0663] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIREPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
[0664] CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
[0665] VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
[0666] HYTQKSLSLSPGK
[0667] *Within underlined residues, new point mutations are annotated.
[0668] ** Deletions are indicated by strikethrough. The final sequence did not include these residues.
[0669] Note: All unglycosylated versions, mutated free cysteine and / or hinge deletion versions can also be combined with IL15-K41Q, L45S, I67T, N79Y, E93A.
[0670] Example 2. Biological activity of fusion protein complexes comprising IL-15, anti-PDL1, and TGFβRII domains. Various methods were used to characterize the biological activity of the complexes of the present invention ( Fig. 9 )
[0671] IL-15 immunostimulatory activity: The IL-15 immunostimulatory activity of αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, and αPDL1 / TGFβRII / TXM fusion protein complexes was evaluated based on the proliferation of IL-15-dependent 32Dβ cells (mouse hematopoietic cell line). Increasing levels of αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, or αPDL1 / TGFβRII / TXM were added to 32Dβ cells (10 μL) in 200 μL RPMI:10% FBS medium. 4 Cells were plated in 4% paraformaldehyde (PNA) flasks (100 μL / well) and incubated at 37°C for 3 days. PrestoBlue cell viability reagent (20 μL / well) was then added. After 4 hours, absorbance was measured at 570 nm (with a 600 nm reference wavelength for normalization) to determine cell proliferation by metabolically active cells based on the reduction of PrestoBlue (a resazurin-based solution). The half-maximal effective concentration (EC) for IL-15 bioactivity against αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, and αPDL1 / TGFβRII / TXM was then determined based on the relationship between absorbance and protein concentration. 50 ). The biological activity of ALT-803 was evaluated as a positive control.
[0672] like Fig.10 , 13 As shown in Figures 14A and 14B, αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, and αPDL1 / TGFβRII / TXM fusion protein complexes were able to stimulate the growth of 32Dβ cells, demonstrating that these proteins retain the IL-15 immunostimulatory activity.
[0673] Binding to PD-L1: A flow cytometry-based assay was used to evaluate the binding of αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, and αPDL1 / TGFβRII / TXM to PD-L1 in vitro. Specifically, serial dilutions of αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, αPDL1 / TGFβRII / TXM, and anti-PD-L1 antibody control were incubated on ice in the dark with human H441 tumor cells expressing PD-L1 (2.5 × 10 5 Cells were incubated with 4% paraformaldehyde (40% paraformaldehyde) for 2 hours. The cells were then washed, resuspended, and stained with APC anti-human IgG Fc antibody (clone HP6017) for 30 minutes at 4°C in the dark. After washing twice, the cells were resuspended in 250 μl FACS buffer (1% BSA and 0.05% NaN3 in phosphate buffer) and kept on ice until analyzed on a BD FCSVerse flow cytometer with BD FD FCS kit V1.0.6. For each protein concentration, the mean fluorescence intensity (MFI) was quantified.
[0674] like Fig.12 , 13 , 15A and 15B, αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM fusion protein complexes are able to bind to PDL1 expressed on human tumor cells. Similarly, FIG. 22 shows the binding of the αPDL1 / TxM / TGFβRII complex to PD-L1 as determined by surface plasmon resonance (SPR).
[0675] Inhibition of TGFβ activity: TGFβ protein binds to receptors on the cell surface, initiating a signaling cascade that leads to phosphorylation and activation of SMAD2 and SMAD3 (which then form a complex with SMAD4). The SMAD complex translocates into the nucleus and binds to SMAD binding elements (SBEs) in the nucleus, leading to transcription and expression of TGF-β / SMAD response genes. The ability of αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, and αPDL1 / TGFβRII / TXM fusion protein complexes to inhibit TGF-β-induced Smad2 / 3 signaling was evaluated.
[0676] 5 × 10 cells / mL in 100 μl of MEM medium 4HEK293 carrying the TGFβ / SMAD signaling pathway SEB reporter (BPS Bioscience, #60653) were plated in white clear bottom 96-well microplates (Corning 3610) at a density of 10 cells / well and incubated overnight at 37°C and 5% CO2. After 24 hours, the wells were changed to 80 μl of fresh assay medium and incubated for 4 hours at 37°C and 5% CO2. 10 μl of serially diluted αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, αPDL1 / TGFβRII / TXM or TGFβRII-Fc control was then added to each well and incubated for 1 hour, followed by the addition of 10 μl of recombinant TGF-β1 or TGF-β3 (R&D Systems, 100 ng / mL) to each well to a total volume of 100 μl. After overnight incubation, 100 μl of ONE-Step TM Luciferase reagent (BPSBioscience, #60690), and the plate was incubated at room temperature for at least 5 minutes. The luminescence based on TGF-β-induced Smad2 / 3 signaling was measured using a GloMax Explorer microplate reader (Promega). Graphpad Prism7 software was then used to determine the half-maximal inhibitory concentration (EC) of TGF-β-induced Smad2 / 3 signaling of αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, and αPDL1 / TGFβRII / TXM based on the relationship between absorbance and protein concentration. 50 ).
[0677] like Fig.11 , 13 , 16A, 16B, 17A and 17B, αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM fusion protein complexes can inhibit TGF-β1-induced Smad2 / 3 signaling. Similarly, TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM fusion protein complexes can also inhibit TGF-β3-induced Smad2 / 3 signaling ( Fig.17A , 17B). Therefore, these complexes act as TGF-β trap molecules and are expected to block the activity of TGF-β proteins. Notably, both TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM fusion protein complexes showed greater inhibitory activity against TGF-β1 and TGF-β3 compared to the positive control TGFβRII-Fc protein.
[0678] Previously, proteins containing the TGF-β trap domain have been shown to resist TGF-β1-induced mesenchymalization in tumor cells (David et al., 2017, OncoImmunology 6:10, e1349589). αPDL1 / TxM / TGFβRII, TGFβRII / αPDL1 / TXM, and αPDL1 / TGFβRII / TXM fusion protein complexes are expected to retain this biological activity. As provided by David et al., this can be assessed based on inhibition of TGF-β1-mediated changes in tumor cell mesenchymal marker expression (i.e., vimentin, fibronectin), proliferation inhibition, and chemotherapy resistance in vitro or in vivo.
[0679] Evaluation of proteins bound to TGFβ protein: The ELISA method was used to evaluate the binding of TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM fusion protein complexes to TGFβ1 and TGFβ3. Specifically, 96-well ELISA plates were coated with TGFβ1 and TGFβ3 in PBS with 10% CSF overnight at 4°C. The next day, the plates were washed three times with wash buffer (PBS, 0.05% Tween-20) and blocked with 1% bovine serum albumin in PBS for 1 hour at room temperature. The plates were then incubated with serially diluted TGFβRII / αPDL1 / TXM, αPDL1 / TGFβRII / TXM or TGFβRII-Fc for 1 hour at room temperature. After the washing step, protein binding was detected using anti-hIgG horseradish peroxidase (HRP) (Jackson Immuno Research, 1:4,000 dilution) for 30 minutes at room temperature. Then, after the substrate was developed, the absorbance was read at 405 nm using a BioTek microplate reader.
[0680] like Fig.18A , 18B , 19A, and 19B, both TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM fusion protein complexes were able to bind to TGFβ1 and TGFβ3, consistent with the ability of TXM protein to block the biological activities mediated by TGFβ1 and TGFβ3.
[0681] Similarly, Fig.23 Binding of the αPDL1 / TxM / TGFβRII complex to TGFβ1, TGFβ2, and TGFβ3 as measured by surface plasmon resonance (SPR) is shown.
[0682] Antibody-dependent cellular cytotoxicity against PD-L1-positive tumor cells: TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM can be effective against tumors by inducing natural killer and CD8 T cell effector responses, blocking the immunosuppressive effects of TFG-β proteins or PD-1 checkpoint inhibitors, and / or targeting immune responses against tumor cells expressing PD-L1. To evaluate the ability of these proteins to mediate antibody-dependent cellular cytotoxicity against PD-L1-positive tumor cells, Celltrace-labeled PD-L1-positive human H441 lung tumor cells (2x10 5 Cells) and NK effector cells. After 20 hours of incubation, cells were harvested and resuspended in PI solution (2 μg / ml) to mark dead cells. The percentage of dead Celltrace-positive PI-positive H441 tumor cells was then measured by flow cytometry.
[0683] like Fig. 20 and 21 As shown, both TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM fusion protein complexes are able to mediate ADCC against tumor cells expressing PD-L1. In fact, TGFβRII / αPDL1 / TXM showed greater ADCC than equivalent molar concentrations of anti-PD-L1 IgG1 antibodies. Similar results were observed using PD-L1-positive human HCC4006 lung cancer cells, CaSki cervical cancer cells, and MDA-MB-231 breast cancer cells. In addition, the αPDL1 / TXM / TGFβRII complex showed ADCC activity against PD-L1-positive human cancer cells (Figure 22).
[0684] Inhibition of PD-L1 activity: In addition to evaluating PD-L1 binding activity and ADCC activity against PD-L1-positive tumor cells, we evaluated the ability of TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM complexes to inhibit the immunosuppressive (checkpoint) activity of PD-L1 on PD-1-positive effector cells. In a standardized assay, artificial antigen-presenting cells (aAPCs) expressing human PD-L1 and an engineered cell surface protein designed to activate the cognate TCR in an antigen-independent manner were mixed with Jurkat T cells expressing human PD-1 and a luciferase reporter driven by an NFAT response element. When the two cell types were co-cultured, the PD-1 / PD-L1 interaction inhibited TCR signaling and NFAT-RE-mediated luminescence. Addition of anti-PD-1 or anti-PD-L1 antibody domains that block the PD-1 / PD-L1 interaction released the inhibitory signal and resulted in TCR activation and NFAT-RE-mediated luminescence ( Fig.23 In this assay, the activity of TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM complexes was assessed using standard procedures ( Fig.24 ). Anti-PD-L1 antibody and PD-L1 / TxM protein complex (similar to TGFβRII / αPDL1 / TXM and αPDL1 / TGFβRII / TXM complexes, but lacking the TGFβRII domain) were used as positive controls.
[0685] like Fig.25A and 25B As shown, αPDL1 / TGFβRII / TXM, TGFβRII / αPDL1 / TXM, and αPDL1 / TXM / TGFβRII complexes were able to induce NFAT-RE-mediated luminescence in a dose-dependent manner with activity similar to that of the anti-PD-L1 Ab control. These results confirm that αPDL1 / TGFβRII / TXM, TGFβRII / αPDL1 / TXM, and αPDL1 / TXM / TGFβRII complexes retain immune checkpoint blockade activity.
[0686] N-810: Fig.26A and 26B Demonstrated that the expression of αPDL1 / TxM in vitro was comparable to that in vivo with the parental control molecule (αPDL1 / TxM, Fig.26B ) compared to the activity against N-810( Fig.26A), human TGFβ specific blocking activity. A stable cell-based luciferase reporter system (HEK-293T-luc2P / SBE) was used to evaluate specific TGFβ blocking activity. Cultured cells were stimulated with 0.0175nM recombinant human TGFβ1 for 20 hours in the presence or absence of a blocker. The response to hTGFβ1 was expressed as relative luminescence units (RLU) ± SD.
[0687] N-810Sorrento-Fc: Fig.27A and 27B Proven to be comparable to the parental control molecule αPDL1 / TxM ( Fig.27B ) compared to the activity against N-810Sorrento-Fc( Fig.27A ), specific hTGFβ1 blocking activity. A stable cell-based luciferase reporter system (HEK-293T-luc2P / SBE) was used to evaluate specific TGFβ blocking activity. Cultured cells were stimulated with 0.0175nM recombinant human TGFβ1 for 20 hours in the presence or absence of a blocker. The response to hTGFβ1 was expressed as relative luminescence units (RLU) ± SD.
[0688] N-810ΔC: Fig.28A and 28B Proven to be comparable to the parental control molecule αPDL1 / TxM ( Fig.28B ) compared to the activity against N-810ΔC ( Fig.28A ), specific hTGFβ1 blocking activity. A stable cell-based luciferase reporter system (HEK-293T-luc2P / SBE) was used to evaluate specific TGFβ blocking activity. Cultured cells were stimulated with 0.0175nM recombinant human TGFβ1 for 20 hours in the presence or absence of a blocker. The response to hTGFβ1 was expressed as relative luminescence units (RLU) ± SD.
[0689] N-810D: Fig.29A and 29B It was demonstrated that the expression of αPDL1 / TxM in the parental control molecule (αPDL1 / TxM) Fig.29B ) compared to the activity against N-810D ( Fig.29A ), a graph of specific hTGFβ1 blocking activity. A stable cell-based luciferase reporter system (HEK-293T-luc2P / SBE) was used to assess specific TGFβ blocking activity. Cultured cells were stimulated with 0.0175 nM recombinant human TGFβ1 for 20 hours in the presence or absence of a blocker. The response to hTGFβ1 is expressed as relative luminescence units (RLU) ± SD.
[0690] Antibody-dependent cellular cytotoxicity (ADCC) of TxM constructs: Fig.30 The antibody-dependent cellular cytotoxicity (ADCC) of TxM constructs was demonstrated in breast adenocarcinoma cells (MDA-MB-231). Antibody-dependent cellular cytotoxicity (ADCC) was used to determine specific αPD-L1 activity. Effector cells: haNK (NK-92 derivative).
[0691] TxM constructs: Figures 31A-31H is a schematic representation showing different constructs. Fig.31A :N-810A. Fig.31B : Unglycosylated N-810A. Fig.31C : Unglycosylated N-810A, Δ free cysteine. Fig.31D :N-810AΔ Hinge. Fig.31E : N-810A (IL15-K41Q, L45S, I67T, N79Y, E93A). Mutations in IL15 enhance the solubility and expression of the molecule. Fig.31F : N-810A (IL15-L45S). Mutations in IL15 enhance the solubility and expression of the molecule. Figure 31G :N-810D. Fig.31H :N-810E.
[0692] Fig.32 Table 1 demonstrates that IL15 mutations increase protein production and reduce aggregation. The N-810D mutation also increases production and reduces aggregation.
[0693]
[0694] Other Implementations
[0695] Although the invention has been described in conjunction with its detailed description, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.
[0696] The patents and scientific literature mentioned herein establish the knowledge available to those skilled in the art. All U.S. patents and published or unpublished U.S. patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. The Genbank and NCBI submissions indicated by the accession numbers cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.
[0697] While the invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention as encompassed by the appended claims.
[0698]
[0699]
[0700]
[0701]
[0702]
[0703]
[0704]
[0705]
[0706]
[0707]
[0708]
[0709]
[0710]
[0711]
[0712]
[0713]
[0714]
[0715]
[0716]
[0717]
[0718]
[0719]
[0720]
[0721]
[0722]
[0723]
[0724]
[0725]
[0726]
[0727]
[0728]
[0729]
[0730]
[0731]
[0732]
[0733]
[0734]
[0735]
[0736]
[0737]
[0738]
[0739]
[0740]
[0741]
[0742]
[0743]
[0744]
[0745]
[0746]
[0747]
[0748]
[0749]
[0750]
[0751]
[0752]
[0753]
[0754]
[0755]
[0756]
[0757]
[0758]
[0759]
[0760]
[0761]
[0762]
[0763]
[0764]
[0765]
[0766]
[0767]
[0768]
[0769]
[0770]
[0771]
[0772]
[0773]
[0774]
[0775]
[0776]
Claims
1. A separated soluble fusion protein complex, the separated soluble fusion protein complex comprising a first fusion protein and a second fusion protein, wherein the first fusion protein comprises an interleukin-15 (IL-15) polypeptide domain and consists of the amino acid sequence of SEQ ID NO: 4, and the second fusion protein comprises an IL-15 receptor alpha sushi-binding domain (IL-15RαSu) fused to an immunoglobulin Fc domain, wherein the immunoglobulin Fc domain is fused to or linked to a transforming growth factor-beta receptor type 2 (TGFβRII) domain, and wherein the second fusion protein consists of the amino acid sequence of SEQ ID NO: 2; The first fusion protein comprises a binding domain that specifically binds to PD-L1, and The IL-15 domain of the first fusion protein binds to the IL-15RαSu domain of the second fusion protein, thereby forming the isolated soluble fusion protein complex.
2. A soluble fusion protein complex, wherein a first separated soluble fusion protein complex is covalently linked to a second separated soluble fusion protein complex via a disulfide bond, wherein the disulfide bond links the Fc domain of the first separated soluble fusion protein complex to the Fc domain of the second separated soluble fusion protein complex to form the soluble fusion protein complex, wherein the first separated soluble fusion protein complex and the second separated soluble fusion protein complex are separated soluble fusion protein complexes according to claim 1.
3. An isolated soluble fusion protein complex, comprising a first fusion protein and a second fusion protein, wherein: The first fusion protein comprises a transforming growth factor-β receptor type 2 (TGFβRII) dimer fused to an interleukin-15 (IL-15) polypeptide domain, wherein the first fusion protein consists of the amino acid sequence of SEQ ID NO: 8; Furthermore, the second fusion protein comprises a soluble IL-15 receptor αsushi-binding domain (IL-15RαSu) fused to an immunoglobulin Fc domain; wherein the second fusion protein further comprises a PD-L1 binding domain, and wherein the second fusion protein consists of the amino acid sequence of SEQ ID NO: 6; The IL-15 domain of the first fusion protein binds to the IL-15RαSu domain of the second fusion protein, thereby forming the separated soluble fusion protein complex.
4. A soluble fusion protein complex, wherein a first separated soluble fusion protein complex is covalently linked to a second separated soluble fusion protein complex via a disulfide bond, wherein the disulfide bond links the Fc domain of the first separated soluble fusion protein complex to the Fc domain of the second separated soluble fusion protein complex to form the soluble fusion protein complex, wherein the first separated soluble fusion protein complex and the second separated soluble fusion protein complex are separated soluble fusion protein complexes according to claim 3.
5. A separated soluble fusion protein complex, the separated soluble fusion protein complex comprising two soluble proteins, wherein The first soluble protein comprises an interleukin-15 (IL-15) polypeptide domain and consists of the amino acid sequence of SEQ ID NO: 10, and the second soluble protein comprises a soluble IL-15 receptor alpha sushi-binding domain (IL-15RαSu) fused to an immunoglobulin Fc domain, wherein the immunoglobulin Fc (IgG Fc) domain is fused to or linked to a transforming growth factor-beta receptor type 2 (TGFβRII) domain, wherein the second soluble protein consists of the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 14; and wherein The second soluble protein further comprises a PD-L1 binding domain that specifically binds to PD-L1, and wherein The IL-15 domain of the first soluble protein binds to the IL-15RαSu domain of the second soluble protein, thereby forming the isolated soluble fusion protein complex.
6. A soluble fusion protein complex, wherein a first separated soluble fusion protein complex is covalently linked to a second separated soluble fusion protein complex via a disulfide bond, wherein the disulfide bond links the Fc domain of the first separated soluble fusion protein complex to the Fc domain of the second separated soluble fusion protein complex to form the soluble fusion protein complex, wherein the first separated soluble fusion protein complex and the second separated soluble fusion protein complex are separated soluble fusion protein complexes according to claim 5.
